U.S. patent application number 15/157686 was filed with the patent office on 2016-10-06 for markers associated with human double minute 2 inhibitors.
This patent application is currently assigned to Novartis AG. The applicant listed for this patent is Swann Gaulis, Sebastien Jeay. Invention is credited to Swann Gaulis, Sebastien Jeay.
Application Number | 20160289770 15/157686 |
Document ID | / |
Family ID | 49304035 |
Filed Date | 2016-10-06 |
United States Patent
Application |
20160289770 |
Kind Code |
A1 |
Gaulis; Swann ; et
al. |
October 6, 2016 |
MARKERS ASSOCIATED WITH HUMAN DOUBLE MINUTE 2 INHIBITORS
Abstract
The invention provides methods of monitoring differential gene
expression of biomarkers to determine patient sensitivity to Human
Double Minute inhibitors (MDM2i), methods of determining the
sensitivity of a cell to an MDM2i by measuring biomarkers and
methods of screening for candidate MDM2i.
Inventors: |
Gaulis; Swann; (Basel,
CH) ; Jeay; Sebastien; (Niffer, FR) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Gaulis; Swann
Jeay; Sebastien |
Basel
Niffer |
|
CH
FR |
|
|
Assignee: |
Novartis AG
Basel
CH
|
Family ID: |
49304035 |
Appl. No.: |
15/157686 |
Filed: |
May 18, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13950881 |
Jul 25, 2013 |
9371568 |
|
|
15157686 |
|
|
|
|
61677859 |
Jul 31, 2012 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 35/00 20180101;
G01N 33/57496 20130101; C12Q 1/6883 20130101; C12Q 1/6886 20130101;
G01N 2333/4748 20130101; G01N 33/6875 20130101; C12Q 2600/106
20130101; A61K 31/496 20130101; G01N 2333/4704 20130101; C07D
401/12 20130101; C12Q 2600/136 20130101; C12Q 2600/158 20130101;
C12Q 2600/156 20130101; C12Y 603/02019 20130101; G01N 33/5011
20130101; G01N 2800/52 20130101; G01N 33/5748 20130101; G01N 33/574
20130101; G01N 2333/9015 20130101 |
International
Class: |
C12Q 1/68 20060101
C12Q001/68; G01N 33/574 20060101 G01N033/574 |
Claims
1. A method of predicting the sensitivity of a cancer patient for
treatment with a Human Double Minute 2 inhibitor (MDM2i), the
method comprising: a) measuring differential gene expression of at
least one biomarker selected from Table 2 in a cancer sample
obtained from the patient; and b) comparing the differential gene
expression of the at least one biomarker with gene expression of
said biomarker in a control sample, wherein the increase or
decrease in gene expression comparison indicates that the patient
is sensitive to treatment with an MDM2i.
2. The method of claim 1, wherein more than one biomarker is
selected from Table 2.
3. The method of claim 1, comprising the biomarkers MDM2, CDKN1A,
ZMAT3, DDB2, FDXR, RPS27L, BAX, RRM2B, SESN1, CCNG1, XPC, TNFRSF10B
and AEN.
4. The method of claim 1, wherein comparing the differential gene
expression of the at least one biomarker with gene expression of a
control sample indicates a functional p53 gene pathway.
5. The method of claim 1, wherein the cancer sample is selected
from the group consisting of breast, lung, pancreas, ovary, central
nervous system (CNS), endometrium, stomach, large intestine, colon,
esophagus, bone, urinary tract, hematopoietic, lymphoid, liver,
skin, melanoma, kidney, soft tissue sarcoma and pleura.
6. The method of claim 1, wherein a nucleic acid or protein of at
least one biomarker is measured.
7. The method of claim 1, wherein the expression of the at least
one biomarker is increased in the cancer sample when compared to a
control sample.
8. The method of claim 1, wherein the MDM2i is selected from Table
1.
9.-16. (canceled)
17. A method of predicting the sensitivity of a cancer cell to a
Human Double Minute 2 inhibitor (MDM2i), the method comprising: a)
obtaining a cancer sample from a cancer patient, b) measuring
differential gene expression of at least two biomarkers selected
from Table 2 in the cell; and c) comparing the differential gene
expression of the at least two biomarkers selected from Table 2
with gene expression of the at least two biomarkers from a normal
or control cell.
18. The method of claim 17, wherein the MDM2i is selected from
Table 1.
19. The method of claim 17, wherein more than three biomarkers are
selected from Table 2.
20. The method of claim 17, comprising the biomarkers MDM2, CDKN1A,
ZMAT3, DDB2, FDXR, RPS27L, BAX, RRM2B, SESN1, CCNG1, XPC, TNFRSF10B
and AEN.
21. The method of claim 17, wherein comparing the differential gene
expression of the at least two biomarkers with gene expression of a
control sample indicates a functional p53 gene pathway.
22. The method of claim 17, wherein the cancer sample is selected
from the group consisting of breast, lung, pancreas, ovary, central
nervous system (CNS), endometrium, stomach, large intestine, colon,
esophagus, bone, urinary tract, hematopoietic, lymphoid, liver,
skin, melanoma, kidney, soft tissue sarcoma and pleura.
23. The method of claim 17, wherein a nucleic acid or protein of at
least two biomarkers is measured.
24. The method of claim 17, wherein the gene expression of the at
least two biomarkers is increased in the cancer cell.
25.-48. (canceled)
Description
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit of priority to U.S.
provisional application Ser. No. 61/677,859, filed Jul. 31, 2012,
which is herein incorporated by reference.
FIELD OF THE INVENTION
[0002] The present invention relates to the field of
pharmacogenomics, and the use of biomarkers useful in determining
patient sensitivity prior to treatment, following patient response
after treatment, cancer sensitivity and screening of compounds.
BACKGROUND
[0003] p53, also known as tumor protein 53, is a tumor suppressor
gene involved in the prevention of cancer, often referred to as the
gatekeeper or guardian of the genome (Levine, Cell 1997,
88:323-331). The p53 gene encodes for a transcription factor that
is normally quiescent, and becoming activated when the cell is
stressed or damaged, such as when DNA damage incurred from a
mutagen. If the cell is stressed or damaged, p53 acts to limit the
damage, or barring that, trigger the apoptotic pathway so the
damaged cell is eliminated and no longer a threat to the organism
(Vogelstein et al., Nature 2000, 408:307-310). An analysis of
different cancers showed that p53 is mutated in about 50% of human
cancers (Hollstein et al., Nucleic Acids Res. 1994, 22:3551-3555:
Hollstein et al., Science 1991, 253(5015): 49-53). Humans who are
heterozygous for p53, with only a single functional copy, will
develop tumors early in adulthood, a disorder known as Li-Fraumeni
syndrome (Varley et al., Hum. Mutat. 2003, 21(3):313-320). However,
as much as p53 regulates the cell's fate, p53 is regulated by
another protein known as MDM2.
[0004] Double minute 2 protein (MDM2) was discovered as a negative
regulator of p53 (Fakharzadeh et al., EMBO J. 1991,
10(6):1565-1565). MDM2 encodes an E3 ligase containing a p53
binding domain and a nuclear export signal sequence, and upon
complexing with p53, removes it from the nucleus and
ubiquitinylates it, which promotes the degradation of the p53
protein via the ubiquitin-proteosome pathway (Haupt et al., Nature
1997, 387(6630):296-299; Piette et al., Oncogene 1997
15(9):1001-1010). In addition, MDM2 directly inhibits the activity
of p53 by binding to the p53 transactivation domain, also
preventing p53 mediated gene expression (Wu et a., Genes Dev. 1993,
7:1126-1132). Thus, MDM2 regulates p53 in multiple ways.
[0005] MDM2 is overexpressed in a number of cancers, for example,
liposarcoma, glioblastoma, and leukemia (Momand et al., Nucleic
Acids Res. 1998, 26(15):3453-3459). Overexpression of MDM2 can
interfere with the activities of p53, preventing apoptosis and
growth arrest of the tumor (de Rozieres et al., Oncogene 2000,
19(13):1691-1697). Overexpression of MDM2 correlates with poor
prognosis in glioma, and acute lympocytic leukemia (Onel et al.,
Mol. Cancer Res. 2004, 2(1):1-8).
[0006] As MDM2 is an inhibitor of p53, therapeutics which prevent
the binding of MDM2 to p53 would prevent the degradation of p53,
allowing free p53 to bind and mediate gene expression in cancer
cells, resulting in cell cycle arrest and apoptosis. There are
previous reports of small molecule inhibitors of the p53-MDM2
interaction (Vassilev et al., Science, 2004, 303(5659):844-888;
Zhang et al., Anticancer drugs, 2009 20(6):416-424; Vu et al.,
Curr. Topics Microbiol. Immuno., 2011, 348:151-172). The mode of
binding of these compounds and a crystal structure of the human
MDM2--Nutlin complex as well as a scaffold and pockets of the p53
binding site on MDM2 are also known (Vassilev, supra). The first of
these MDM2 inhibitors, known as the Nutlins, bind MDM2 and occupy
the p53 binding pocket, preventing the formation of the MDM2-p53
complex. This leads to less degradation of the p53 protein, and
expression of p53 target genes. Cancer cell lines treated with
Nutlins showed growth arrest and increased apoptosis. For example,
the SJSA-1 osteosarcoma line contains amplified copies of the MDM2
gene. Treatment of this line with Nutlin-3 reduced proliferation
and increased apoptosis (Vassilev et al., Science, 2004,
303(5659):844-888). The SJSA-1 cell line was used in creating
xenographs in mouse. Administration of Nutlin-3 reduced xenograft
growth by 90%. To investigate the effect the Nutlin compounds had
on non-cancerous cells, human and mouse normal fibroblasts were
treated with Nutlin-3 and while the proliferation of the cells was
slowed, they retained their viability (Vassilev, supra).
[0007] Finding biomarkers which indicate which patient should
receive a therapeutic is useful, especially with regard to cancer.
This allows for more timely and aggressive treatment as opposed to
a trial and error approach. In addition, the discovery of
biomarkers which indicate that cells continue to be sensitive to
the therapy after administration is also useful. These biomarkers
can be used to monitor the response of those patients receiving the
therapeutic. If biomarkers indicate that the patient has become
insensitive to the treatment, then the dosage administered can be
increased, decreased, completely discontinued or an additional
therapeutic administered. As such, there is a need to develop
biomarkers associated with MDM2 inhibitors. This approach ensures
that the correct patients receive the appropriate treatment and
during the course of the treatment the patient can be monitored for
continued MDM2 inhibitor sensitivity.
[0008] In the development of MDM2 inhibitors, specific biomarkers
will aid in understanding the mechanism of action upon
administration. The mechanism of action may involve a complex
cascade of regulatory mechanisms in the cell cycle and differential
gene expression. This analysis is done at the pre-clinical stage of
drug development in order to determine the particular sensitivity
of cancer cells to the MDM2 inhibitor candidate and the activity of
the candidate. Of particular interest in the pharmacodynamic
investigation is the identification of specific markers of
sensitivity and activity, such as the ones disclosed herein.
SUMMARY OF THE INVENTION
[0009] The invention relates to the analysis that a number of genes
identified in Table 2 act as specific biomarkers in determining the
sensitivity of cells to MDM2 inhibitors (henceforth "MDM2i"). The
invention relates to the analysis that at least one of the
biomarkers in Table 2 provides a "gene signature" for MDM2i that
has increased accuracy and specificity in predicting which cancer
cells are sensitive to MDM2i. The method analyzes the gene
expression or protein level of at least one of the biomarkers in
Table 2 in a cancer sample taken from a patient and compared to a
baseline control predicts the sensitivity of the cancer sample to
an MDM2i. The pattern of expression level changes may be indicative
of a favorable response or an unfavorable one. In addition, the
gene signature provided in Table 2 has increased predictive value
because it also indicates that the p53 pathway is functional. This
is an unexpected result as many tumors contain a mutated p53 and a
non-functional pathway which provides the tumor with a growth
advantage. The invention is an example of "personalized medicine"
wherein patients are treated based on a functional genomic
signature that is specific to that individual.
[0010] The predictive value of at least one biomarker in Table 2
can also be used after treatment with an MDM2i to determine if the
patient remains sensitive to the treatment. Once the MDM2i
therapeutic has been administered, the biomarkers are used to
monitor the continued sensitivity of the patient to MDM2i
treatment. The disclosure alsorelates to the up or down regulation
of the expression of the identified genes after MDM2i treatment.
This is useful in determining that patients receive the correct
course of treatment. The invention comprises a method of predicting
and monitoring the sensitivity of a patient to MDM2i treatment. The
method includes the step of administration of an MDM2i to the
patient and measurement of biomarker gene expression on a
biological sample obtained from the patient. The response of the
patient is evaluated based on the detection of gene expression of
at least one biomarker from Table 2. Detection and/or alteration in
the level of expression of at least one biomarker compared to
baseline is indicative of the sensitivity of the patient to the
treatment. The pattern of expression level changes can be
indicative of a favorable patient response or an unfavorable
one.
DESCRIPTION OF THE DRAWINGS
[0011] FIG. 1A shows the in vitro potency of the MDM2i in
disrupting p53-MDM2 interaction. FIG. 1B shows the in vitro potency
of the MDM2i on the proliferation of cancer cells.
[0012] FIG. 2 shows the p53 status (mutant or wild type) and the
sensitivity of the cancer cells to MDM2i(2). The X axis is the
crossing point for sensitivity and the Y axis is the Amax
value.
[0013] FIG. 3 are biomarkers showing the fold change in expression
and the statistical significance of the overexpression value.
[0014] FIG. 4 is a Western blot of sensitive and insensitive
representative cells treated with an MDM2i(1) for 4 hours at
various concentrations and then probed for selected p53 target
genes as pharmacodynamic biomarker representatives.
[0015] FIG. 5 is a graph demonstrating the increase in predictive
value of the gene signature as opposed to a larger set of
biomarkers.
[0016] FIG. 6 is a list of cell lines, each analyzed for the gene
signature and the prediction of whether the cell line is sensitive
or insensitive and the IC50 when treated with an MDM2i.
[0017] FIG. 7A-C shows the dose-dependent inhibition of tumor
growth in the SJSA-1 xenograft model (predicted to be sensitive by
the gene signature) following treatment with MDM2i(1), and the
concomitant induction of p21(CDKN1A) expression as a representative
pharmacodynamic biomarker.
[0018] FIG. 8 shows the expression of p21(CDKN1A) at the protein
level after treatment of MDM2i(1) sensitive cells at efficacious
doses.
[0019] FIG. 9 is a model of tumor samples predicted to be sensitive
using the gene signature in the OncExpress database and the Primary
Tumor Bank.
[0020] FIG. 10 represents the Positive Predictive Values (PPV)
achieved by the MDM2i(2) sensitivity predictive models, built from
multiple combinations of biomarkers described in Table 2.
[0021] FIG. 11 represents the Specificities achieved by the MDM2i
sensitivity predictive models, built from multiple combinations of
biomarkers described in Table 2.
[0022] FIG. 12 represents the Sensitivities achieved by the MDM2i
sensitivity predictive models, built from multiple combinations of
biomarkers described in Table 2.
[0023] FIG. 13 represents the PPV achieved by the MDM2i sensitivity
predictive models, built from multiple combinations of biomarkers
described in Table 2, together with p53 mutation status.
[0024] FIG. 14 represents the Specificities achieved by the MDM2i
sensitivity predictive models, built from multiple combinations of
biomarkers described in Table 2, together with p53 mutation
status.
[0025] FIG. 15 represents the Sensitivities achieved by the MDM2i
sensitivity predictive models, built from multiple combinations of
biomarkers described in Table 2, together with p53 mutation
status.
DESCRIPTION OF THE INVENTION
[0026] The aspects, features and embodiments of the present
invention are summarized in the following items and can be used
respectively alone or in combination:
[0027] 1. A method of predicting the sensitivity of a cancer
patient for treatment with a Human Double Minute 2 inhibitor
(MDM2i), the method comprising: a) measuring differential gene
expression of at least one biomarker selected from Table 2 in a
cancer sample obtained from the patient; and b) comparing the
differential gene expression of the at least one biomarker with
gene expression of said biomarker in a control sample, wherein the
increase or decrease in gene expression comparison indicates that
the patient is sensitive to treatment with an MDM2i.
[0028] 2. A method of treating a cancer patient comprising: a)
measuring differential gene expression of at least one biomarker
selected from Table 2 in a cancer sample obtained from the patient;
b) comparing the differential gene expression of the at least one
biomarker with gene expression of the biomarker in a control
sample; c) determining sensitivity of the patient to an MDM2i; and
d) administering to the patient an MDM2i.
[0029] 3. A method of predicting the sensitivity of a cancer cell
to a Human Double Minute 2 inhibitor (MDM2i), the method
comprising: a) measuring differential gene expression of at least
one biomarker selected from Table 2 in the cell; b) comparing the
differential gene expression of the at least one biomarker selected
from Table 2 with gene expression from a normal or control
cell.
[0030] 4. A method of determining the sensitivity of a cancer cell
to a Human Double Minute 2 inhibitor (MDM2i), the method
comprising: a) contacting a cancer cell with at least one MDM2i; b)
measuring differential gene expression of at least one biomarker
selected from Table 2 in the cell contacted with the MDM2i; c)
comparing the differential gene expression of the at least one
biomarker with gene expression of the biomarker from an untreated
or placebo treated control cell; d) wherein there is an increase in
the expression of at the least one biomarker when compared with the
expression of the at least one biomarker from the untreated or
placebo treated control cell.
[0031] 5. The method of any one of items 1 to 3, wherein more than
one biomarker is selected from Table 2.
[0032] 6. The method of item 1 or 4, wherein at least two, at least
three, at least four, at least five, at least six, at least seven,
at least eight, at least nine, at least ten, at least eleven, at
least twelve or all thirteen biomarkers are selected from Table
2.
[0033] 7. The method of any one of items 1 to 5, wherein p53 is
selected as a biomarker in addition to any biomarker selected from
Table 2.
[0034] 8. The method of any one of items 1 to 6, comprising the
biomarkers MDM2, CDKN1A, ZMAT3, DDB2, FDXR, RPS27L, BAX, RRM2B,
SESN1, CCNG1, XPC, TNFRSF10B and/or AEN.
[0035] 9. The method of any one of items 1 to 7, wherein comparing
the differential gene expression of the at least one biomarker with
gene expression of a control sample indicates a functional p53 gene
pathway.
[0036] 10. The method of any one of items 1 to 8, wherein the
cancer sample is selected from the group consisting of breast,
lung, pancreas, ovary, central nervous system (CNS), endometrium,
stomach, large intestine, colon, esophagus, bone, urinary tract,
hematopoietic, lymphoid, liver, skin, melanoma, kidney, soft tissue
sarcoma and pleura.
[0037] 11. The method of any one of items 1 to 9, wherein a nucleic
acid or protein of at least one biomarker is measured.
[0038] 12. The method of any one of items 1, 2 or 5 to 11, wherein
the expression of the at least one biomarker is increased in the
cancer sample when compared to a control sample.
[0039] 13. The method of any one of items 1 to 11, wherein the
MDM2i is selected from Table 1.
[0040] 14. The method of any one of items 1 to 12, wherein the
MDM2i is a compound that binds to a p53 binding pocket of MDM2.
[0041] 15. The method of any one of items 1 to 13, wherein the
MDM2i is a compound that binds to substantially the same p53
binding pocket of MDM2 as Nutlin-3a or the MDM2i from the Table
1.
[0042] 16. The method of any one of items 1 to 14, wherein the
MDM2i is a compound that prevents the protein-protein interaction
between p53 and MDM2.
[0043] 17. The method of any one of items 1 to 15, wherein the
MDM2i is a compound that inhibits cell proliferation by inducing
the p53 pathway activity.
[0044] 18. The method of any one of items 2 to 16 further
comprising obtaining a biological sample from the patient prior to
the administration of the MDM2i.
[0045] 19. The method of any one of items 2 to 17, wherein the
MDM2i is administered in a therapeutically effective amount.
[0046] 20. The method of any one of items 3 to 11, or 13 to 19,
wherein the gene expression of the at least one biomarker is
increased in the cancer cell.
[0047] 21. The method of any one of items 4 to 11, or 13 to 20,
wherein the IC50 of the cancer cell contacted with at least one
MDM2i is less than 1 .mu.M
[0048] 22. The method of any one of items 4 to 11, or 13 to 21,
wherein the cell is contacted by the MDM2i at least at two
different time points.
[0049] 23. The method of any one of items 4 to 11, or 13 to 22,
wherein the cell is contacted by two different MDM2i at step
a).
[0050] 24. The method of item 23, wherein the cell is contacted by
the two different MDM2i at the same time.
[0051] 25. The method of item 23, wherein the cell is contacted by
two different MDM2i at different time points.
[0052] 26. The method of any one of items 4 to 11, or 13 to 25,
wherein the steps b) and c) are repeated at a time points selected
from the group consisting of: 4 hours, 8 hours, 16 hours, 24 hours,
48 hours, 3 days, 1 week, 1 month and several months after
administration of each dose of MDM2i.
[0053] 27. A method of screening for MDM2i candidates the method
comprising: a) contacting a cell with a MDM2i candidate; b)
measuring gene expression of at least one biomarker selected from
Table 2 in the cell contacted with the MDM2i candidate; and c)
comparing the gene expression of the at least one biomarker
selected from Table 2 from the cell contacted with the MDM2i
candidate with gene expression of the at least one biomarker
selected from Table 2 from a cell contacted with an MDM2i taken
from Table 1 and the gene expression of at least one biomarker of
an untreated or placebo treated cell.
[0054] 28. The method of item 27, wherein the differential gene
expression of the MDM2i candidate is compared with the differential
gene expression of an MDM2i selected from Table 1.
[0055] 29. The method of item 27 or 28, wherein the MDM2i candidate
increases gene expression of at least one, at least two, at least
three, at least four, at least five, at least six, at least seven,
at least eight, at least nine, at least ten, at least eleven, at
least twelve or all thirteen biomarkers from Table 2.
[0056] 30. The method of any one of items 27 to 29, wherein the
cell is a cancer cell selected from the group consisting of breast,
lung, pancreas, ovary, central nervous system (CNS), endometrium,
stomach, large intestine, colon, esophagus, bone, urinary tract,
hematopoietic, lymphoid, liver, skin, melanoma, kidney, soft tissue
sarcoma and pleura.
[0057] 31. The method of any one of items 27 to 30, wherein the
expression of nucleic acid or protein of at least one biomarker of
Table 2 is measured.
[0058] 32. The method of any one of items 27 to 31, comprising the
biomarkers MDM2, CDKN1A, ZMAT3, DDB2, FDXR, RPS27L, BAX, RRM2B,
SESN1, CCNG1, XPC, TNFRSF10B and AEN.
[0059] 33. Composition comprising an MDM2i for use in treatment of
cancer in a selected cancer patient population, wherein the cancer
patient population is selected on the basis of showing an increased
gene expression rate of at least one biomarker selected from Table
2 in a cancer cell sample obtained from said patients compared to a
normal control cell sample.
[0060] 34. The composition of item 33, wherein at least two, at
least three, at least four, at least five, at least six, at least
seven, at least eight, at least nine, at least ten, at least
eleven, at least twelve or all thirteen biomarkers are selected
from Table 2.
[0061] 35. The composition of items 33 or 34, wherein p53 is
selected as a biomarker in addition to any biomarker selected from
Table 2.
[0062] 36. The composition of any one of items 33 to 35, wherein
the biomarker is MDM2, CDKN1A, ZMAT3, DDB2, FDXR, RPS27L, BAX,
RRM2B, SESN1, CCNG1, XPC, TNFRSF10B and/or AEN.
[0063] 37. The composition of any one of items 33 to 36, wherein
the MDM2i is selected from Table 1.
[0064] 38. The composition of any one of items 33 to 37, wherein
the MDM2i is a compound that binds to a p53 binding pocket of
MDM2.
[0065] 39. The composition of any one of items 33 to 38, wherein
the MDM2i is a compound that binds to substantially the same p53
binding pocket of MDM2 as Nutlin-3a or the MDM2i from the Table
1.
[0066] 40. The composition of any one of items 33 to 39, wherein
the MDM2i is a compound that prevents the protein-protein
interaction between p53 and MDM2.
[0067] 41. The composition of any one of items 33 to 40, wherein
the MDM2i is a compound that inhibits cell proliferation by
inducing the p53 pathway activity.
[0068] 42. The composition of any one of items 33 to 41, wherein
the cancer cell sample is selected from the group consisting of
breast, lung, pancreas, ovary, central nervous system (CNS),
endometrium, stomach, large intestine, colon, esophagus, bone,
urinary tract, hematopoietic, lymphoid, liver, skin, melanoma,
kidney, soft tissue sarcoma and pleura.
[0069] 43. The composition of any one of items 33 to 42, wherein
the patients are selected on the basis of an increased gene
expression of the biomarkers MDM2, CDKN1A, ZMAT3, DDB2, FDXR,
RPS27L, BAX, RRM2B, SESN1, CCNG1, XPC, TNFRSF10B and AEN.
[0070] 44. A kit for predicting the sensitivity of a cancer patient
for treatment with a Human Double Minute 2 inhibitor (MDM2i)
comprising: i) means for detecting the expression of any one of the
biomarkers from the table 2, preferably more than one, particularly
at least two, at least three, at least four, at least five, at
least six, at least seven, at least eight, at least nine, at least
ten, at least eleven, at least twelve or all thirteen biomarkers
selected from Table 2; and ii) instructions how to use said
kit.
[0071] 45. The kit of item 44, wherein the biomarkers are MDM2,
CDKN1A, ZMAT3, DDB2, FDXR, RPS27L, BAX, RRM2B, SESN1, CCNG1, XPC,
TNFRSF10B or/and AEN.
[0072] 46. The kit of item 45 further comprising means for
detecting the expression of p53.
[0073] 47. Use of the kit according to item 45 or 46 for any of the
methods of items 1 to 32.
[0074] Further aspects describe the invention:
[0075] In one aspect, a disclosed invention relates to methods of
analyzing at least one of the biomarkers identified in Table 2 in a
sample containing cancer cells wherein increased or decreased
expression of at least one biomarker when compared to a baseline
indicates if the cancer cell will be sensitive to MDM2i treatment.
The pattern of expression level changes can be indicative of a
favorable patient response or of an unfavorable one and patients
can be selected or rejected based on the increased or decreased
expression of at least one biomarker from Table 2. Alternatively,
all of the biomarkers in Table 2 can be assayed for as a single
set.
[0076] After treatment with an MDM2i, the invention relates to
methods of analyzing at least one of the biomarkers identified in
Table 2 in a sample containing cancer cells wherein increased or
decreased expression of the biomarker when compared to a baseline
control after MDM2i treatment indicates that the patient is still
sensitive to MDM2i treatment. Detection and/or alteration in the
level of expression of at least one biomarker compared to a
baseline is indicative of the MDM2i sensitivity, and this
correlates with a response of the patient to the treatment.
Alternatively, all of the biomarkers in Table 2 can be assayed for
as a single set. The pattern of expression level changes can be
indicative of a favorable patient response or of an unfavorable
one.
[0077] Accordingly, the invention provides for a method of
predicting the sensitivity of a cancer patient for treatment with a
Human Double Minute 2 inhibitor (MDM2i), the method comprising: a)
measuring differential gene expression of at least one biomarker
selected from Table 2 in a cancer sample obtained from the patient;
and b) comparing the differential gene expression of the at least
one biomarker with gene expression of a control sample, wherein the
increase or decrease in gene expression comparison indicates that
the patient is sensitive to treatment with an MDM2i.
[0078] The method wherein more than one biomarker is selected from
Table 2.
[0079] The method comprising the biomarkers MDM2, CDKN1A, ZMAT3,
DDB2, FDXR, RPS27L, BAX, RRM2B, SESN1, CCNG1, XPC, TNFRSF10B and
AEN.
[0080] The method wherein comparing the differential gene
expression of the at least one biomarker with gene expression of a
control sample indicates a functional p53 gene pathway.
[0081] The method wherein the cancer sample is selected from the
group consisting of: breast, lung, pancreas, ovary, central nervous
system (CNS), endometrium, stomach, large intestine, colon,
esophagus, bone, urinary tract, hematopoietic, lymphoid, liver,
skin, melanoma, kidney, soft tissue sarcoma and pleura.
[0082] The method wherein a nucleic acid or protein of at least one
biomarker is measured.
[0083] The method wherein the gene expression of the at least one
biomarker is increased.
[0084] The method wherein the MDM2i is selected from Table 1.
[0085] The method wherein the MDM2i is administered in a
therapeutically effective amount.
[0086] A method of treating a cancer patient comprising: a)
measuring differential gene expression of at least one biomarker
selected from Table 2 in a cancer sample obtained from the patient;
b) comparing the differential gene expression of the at least one
biomarker with gene expression of a control sample; c) determining
sensitivity of the patient to an MDM2i; and d) administering to the
patient an MDM2i.
[0087] The method wherein more than one biomarker is selected from
Table 2.
[0088] The method of comprising the biomarkers MDM2, CDKN1A, ZMAT3,
DDB2, FDXR, RPS27L, BAX, RRM2B, SESN1, CCNG1, XPC, TNFRSF10B and
AEN.
[0089] The method wherein the at least one biomarker indicates a
functional p53 gene pathway.
[0090] The method further comprising obtaining a biological sample
from the patient prior to the administration of the MDM2i.
[0091] The method wherein the cancer sample is selected from the
group consisting of: breast, lung, pancreas, ovary, central nervous
system (CNS), endometrium, stomach, large intestine, colon,
esophagus, bone, urinary tract, hematopoietic, lymphoid, liver,
skin, melanoma, kidney, soft tissue sarcoma and pleura.
[0092] The method wherein the MDM2i is selected from Table 1.
[0093] The method wherein the MDM2i is administered in a
therapeutically effective amount.
[0094] A method of predicting the sensitivity of a cancer cell to a
Human Double Minute 2 inhibitor (MDM2i), the method comprising: a)
measuring differential gene expression of at least one biomarker
selected from Table 2 in the cell b) comparing the differential
gene expression of the at least on biomarker selected from Table 2
with gene expression from a normal or control cell.
[0095] The method wherein the MDM2i is selected from Table 1.
[0096] The method wherein more than one biomarker is selected from
Table 2.
[0097] The method comprising the biomarkers MDM2, CDKN1A, ZMAT3,
DDB2, FDXR, RPS27L, BAX, RRM2B, SESN1, CCNG1, XPC, TNFRSF10B and
AEN.
[0098] The method wherein comparing the differential gene
expression of the at least one biomarker with gene expression of a
control sample indicates a functional p53 gene pathway.
[0099] The method wherein the cancer sample is selected from the
group consisting of: breast, lung, pancreas, ovary, central nervous
system (CNS), endometrium, stomach, large intestine, colon,
esophagus, bone, urinary tract, hematopoietic, lymphoid, liver,
skin, melanoma, kidney, soft tissue sarcoma and pleura.
[0100] The method wherein a nucleic acid or protein of at least one
biomarker is measured.
[0101] The method wherein the gene expression of the at least one
biomarker is increased.
[0102] The method wherein the MDM2i is selected from Table 1.
[0103] The method wherein the MDM2i is administered in a
therapeutically effective amount.
[0104] A method of assaying for the sensitivity of a cancer cell to
a Human Double Minute 2 inhibitor (MDM2i), the method comprising:
a) contacting a cancer cell with at least one MDM2i; b) measuring
differential gene expression of at least one biomarker selected
from Table 2 in the cancer cell contacted with the MDM2i; c)
comparing the differential gene expression with gene expression
from an untreated or placebo treated control cell; d) wherein the
IC50 of the cancer cell contacted with at least one MDM2i is less
than 3 .mu.M.
[0105] The method wherein the cancer cell is contacted by the MDM2i
at least two different time points.
[0106] The method wherein the cancer cell is contacted by two
different MDM2i at step a).
[0107] The method wherein the cancer cell is contacted by the two
different MDM2i at the same time.
[0108] The method wherein the cancer cell is contacted by two
different MDM2i at different time points.
[0109] The method wherein the cancer cell is selected from the
group consisting of breast, lung, pancreas, ovary, central nervous
system (CNS), endometrium, stomach, large intestine, colon,
esophagus, bone, urinary tract, hematopoietic, lymphoid, liver,
skin, melanoma, kidney, soft tissue sarcoma and pleura.
[0110] The method wherein a nucleic acid or protein of at least one
biomarker is measured.
[0111] The method wherein the gene expression of the at least one
biomarker is increased.
[0112] The method comprising the biomarkers: MDM2, CDKN1A, ZMAT3,
DDB2, FDXR, RPS27L, BAX, RRM2B, SESN1, CCNG1, XPC, TNFRSF10B and
AEN.
[0113] The method wherein the steps b) and c) are repeated at time
points of: 4 hours, 8 hours, 16 hours, 24 hours, 48 hours, 3 days,
1 week, 1 month and 2 months after contact with an MDM2i.
[0114] A method of screening for MDM2i candidates the method
comprising: a) contacting a cell with a MDM2i candidate; b)
measuring differential gene expression of at least one biomarker
selected from Table 2 in the cell contacted with the MDM2i
candidate; and c) comparing the differential gene expression of at
least one biomarker selected from Table 2 from the cell contacted
with the MDM2i candidate with differential gene expression of at
least one biomarker selected from Table 2 from a cell contacted
with an MDM2i taken from Table 1 and the differential gene
expression of at least one biomarker of an untreated or placebo
treated cell.
[0115] The method wherein the differential gene expression of the
MDM2i candidate is compared with the differential gene expression
of an MDM2i selected from Table 1. The method wherein the MDM2i
candidate increases gene expression of at least one biomarker of
Table 2.
[0116] The method wherein the cancer cell is selected from the
group consisting of breast, lung, pancreas, ovary, central nervous
system (CNS), endometrium, stomach, large intestine, colon,
esophagus, bone, urinary tract, hematopoietic, lymphoid, liver,
skin, melanoma, kidney, soft tissue sarcoma and pleura.
[0117] The method wherein the expression of nucleic acid or protein
of at least one biomarker of Table 2 is measured.
[0118] The method comprising the biomarkers MDM2, CDKN1A, ZMAT3,
DDB2, FDXR, RPS27L, BAX, RRM2B, SESN1, CCNG1, XPC, TNFRSF10B and
AEN.
[0119] Composition comprising an MDM2i for use in treatment of
cancer in a selected cancer patient population, wherein the cancer
patient population is selected on the basis of showing an increased
gene expression rate of at least one biomarker selected from Table
2 in a cancer cell sample obtained from said patients compared to a
normal control cell sample. The composition wherein the cancer
sample is selected from the group consisting of breast, lung,
pancreas, ovary, central nervous system (CNS), endometrium,
stomach, large intestine, colon, esophagus, bone, urinary tract,
hematopoietic, lymphoid, liver, skin, melanoma, kidney, soft tissue
sarcoma and pleura.
[0120] The composition wherein the patients are selected on the
basis of an increased gene expression of the biomarkers MDM2,
CDKN1A, ZMAT3, DDB2, FDXR, RPS27L, BAX, RRM2B, SESN1, CCNG1, XPC,
TNFRSF10B and AEN.
[0121] A kit for predicting the sensitivity of a cancer patient for
treatment with a Human Double Minute 2 inhibitor (MDM2i)
comprising: i) means for detecting the expression of the biomarkers
MDM2, CDKN1A, ZMAT3, DDB2, FDXR, RPS27L, BAX, RRM2B, SESN1, CCNG1,
XPC, TNFRSF10B and AEN; and ii) instructions how to use said
kit.
DEFINITIONS
[0122] As used in the specification and claims, the singular form
"a", "an" and "the" include plural references unless the context
clearly dictates otherwise. For example, the term "a cell" includes
a plurality of cells, including mixtures thereof.
[0123] All numerical designations, e.g., pH, temperature, time,
concentration, and molecular weight, including ranges, are
approximations which are varied (+) or (-) by increments of 0.1. It
is to be understood, although not always explicitly stated that all
numerical designations are preceded by the term "about." It also is
to be understood, although not always explicitly stated, that the
reagents described herein are merely exemplary and that equivalents
of such are known in the art.
[0124] The terms "marker" or "biomarker" are used interchangeably
herein. A biomarker is a nucleic acid or polypeptide and the
presence, absence or differential expression of the nucleic acid or
polypeptide is used to determine sensitivity to any MDM2i. For
example, CDKN1A is a biomarker and the mRNA expression of CDKN1A in
a cancer cell is increased when compared to CDKN1A expression in
normal (non-cancerous) tissue or control tissue.
[0125] "MDM2" refers to an E3 ubiquitin-protein ligase that
mediates the ubiquitination of p53, permits the nuclear export of
p53 and triggers p53 degradation. Unless specifically stated
otherwise, MDM2 as used herein, refers to human MDM2-accession
numbers NM_002392/NP_002383 (SEQ ID NO. 1/SEQ ID NO. 2).
[0126] A cell is "sensitive" or displays "sensitivity" for
inhibition with an MDM2i when at least one of the biomarkers
disclosed in Table 2 is differentially expressed. Alternatively, a
cell is "sensitive" for inhibition with an MDM2i when all of the
biomarkers disclosed in Table 2 as a set are differentially
expressed.
[0127] A "control cell" or "normal cell" refers to non-cancerous
tissue or cell.
[0128] A "control tissue" or "normal tissue" refers to
non-cancerous tissue or cell.
[0129] A "control sample" or "normal sample" refers to
non-cancerous tissue or cell.
[0130] The terms "nucleic acid" and "polynucleotide" are used
interchangeably and refer to a polymeric form of nucleotides of any
length, either deoxyribonucleotides or ribonucleotides or analogs
thereof. Polynucleotides can have any three-dimensional structure
and may perform any function. The following are non-limiting
examples of polynucleotides: a gene or gene fragment (for example,
a probe, primer, EST or SAGE tag), exons, introns, messenger RNA
(mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant
polynucleotides, branched polynucleotides, plasmids, vectors,
isolated DNA of any sequence, isolated RNA of any sequence, nucleic
acid probes, and primers. A polynucleotide can comprise modified
nucleotides, such as methylated nucleotides and nucleotide analogs.
If present, modifications to the nucleotide structure can be
imparted before or after assembly of the polymer. The sequence of
nucleotides can be interrupted by non-nucleotide components. A
polynucleotide can be further modified after polymerization, such
as by conjugation with a labeling component. The term also refers
to both double- and single-stranded molecules. Unless otherwise
specified or required, any embodiment of this invention that is a
polynucleotide encompasses both the double-stranded form and each
of two complementary single-stranded forms known or predicted to
make up the double-stranded form.
[0131] A "gene" refers to a polynucleotide containing at least one
open reading frame (ORF) that is capable of encoding a particular
polypeptide or protein after being transcribed and translated. A
polynucleotide sequence can be used to identify larger fragments or
full-length coding sequences of the gene with which they are
associated. Methods of isolating larger fragment sequences are
known to those of skill in the art.
[0132] "Gene expression" or alternatively a "gene product" refers
to the nucleic acids or amino acids (e.g., peptide or polypeptide)
generated when a gene is transcribed and translated.
[0133] The term "polypeptide" is used interchangeably with the term
"protein" and in its broadest sense refers to a compound of two or
more subunit amino acids, amino acid analogs, or peptidomimetics.
The subunits can be linked by peptide bonds. In another embodiment,
the subunit may be linked by other bonds, e.g., ester, ether,
etc.
[0134] As used herein the term "amino acid" refers to either
natural and/or unnatural or synthetic amino acids, and both the D
and L optical isomers, amino acid analogs, and peptidomimetics. A
peptide of three or more amino acids is commonly called an
oligopeptide if the peptide chain is short. If the peptide chain is
long, the peptide is commonly called a polypeptide or a
protein.
[0135] The term "isolated" means separated from constituents,
cellular and otherwise, in which the polynucleotide, peptide,
polypeptide, protein, antibody or fragment(s) thereof, are normally
associated with in nature. For example, an isolated polynucleotide
is separated from the 3' and 5' contiguous nucleotides with which
it is normally associated within its native or natural environment,
e.g., on the chromosome. As is apparent to those of skill in the
art, a non-naturally occurring polynucleotide, peptide,
polypeptide, protein, antibody, or fragment(s) thereof, does not
require "isolation" to distinguish it from its naturally occurring
counterpart. In addition, a "concentrated," "separated" or
"diluted" polynucleotide, peptide, polypeptide, protein, antibody
or fragment(s) thereof, is distinguishable from its naturally
occurring counterpart in that the concentration or number of
molecules per volume is greater in a "concentrated" version or less
than in a "separated" version than that of its naturally occurring
counterpart. A polynucleotide, peptide, polypeptide, protein,
antibody, or fragment(s) thereof, which differs from the naturally
occurring counterpart in its primary sequence or, for example, by
its glycosylation pattern, need not be present in its isolated form
since it is distinguishable from its naturally occurring
counterpart by its primary sequence or, alternatively, by another
characteristic such as glycosylation pattern. Thus, a non-naturally
occurring polynucleotide is provided as a separate embodiment from
the isolated naturally occurring polynucleotide. A protein produced
in a bacterial cell is provided as a separate embodiment from the
naturally occurring protein isolated from a eukaryotic cell in
which it is produced in nature.
[0136] A "probe" when used in the context of polynucleotide
manipulation refers to an oligonucleotide that is provided as a
reagent to detect a target potentially present in a sample of
interest by hybridizing with the target. Usually, a probe will
comprise a label or a means by which a label can be attached,
either before or subsequent to the hybridization reaction. Suitable
labels include, but are not limited to radioisotopes,
fluorochromes, chemiluminescent compounds, dyes, and proteins,
including enzymes.
[0137] A "primer" is a short polynucleotide, generally with a free
3'--OH group that binds to a target or "template" potentially
present in a sample of interest by hybridizing with the target, and
thereafter promoting polymerization of a polynucleotide
complementary to the target. A "polymerase chain reaction" ("PCR")
is a reaction in which replicate copies are made of a target
polynucleotide using a "pair of primers" or a "set of primers"
consisting of an "upstream" and a "downstream" primer, and a
catalyst of polymerization, such as a DNA polymerase, and typically
a thermally-stable polymerase enzyme. Methods for PCR are well
known in the art, and taught, for example in PCR: A Practical
Approach, M. MacPherson et al., IRL Press at Oxford University
Press (1991). All processes of producing replicate copies of a
polynucleotide, such as PCR or gene cloning, are collectively
referred to herein as "replication." A primer can also be used as a
probe in hybridization reactions, such as Southern or Northern blot
analyses (Sambrook et al., Molecular Cloning: A Laboratory Manual,
2nd edition (1989)).
[0138] As used herein, "expression" refers to the process by which
DNA is transcribed into mRNA and/or the process by which the
transcribed mRNA is subsequently translated into peptides,
polypeptides or proteins. If the polynucleotide is derived from
genomic DNA, expression may include splicing of the mRNA in a
eukaryotic cell.
[0139] "Differentially expressed" as applied to a gene, refers to
the differential production of the mRNA transcribed and/or
translated from the gene or the protein product encoded by the
gene. A differentially expressed gene may be overexpressed or
underexpressed as compared to the expression level of a normal or
control cell. However, as used herein, overexpression is an
increase in gene expression and generally is at least 1.25 fold or,
alternatively, at least 1.5 fold or, alternatively, at least 2
fold, or alternatively, at least 3 fold or alternatively, at least
4 fold expression over that detected in a normal or control
counterpart cell or tissue. As used herein, underexpression, is a
reduction of gene expression and generally is at least 1.25 fold,
or alternatively, at least 1.5 fold, or alternatively, at least 2
fold or alternatively, at least 3 fold or alternatively, at least 4
fold expression under that detected in a normal or control
counterpart cell or tissue. The term "differentially expressed"
also refers to where expression in a cancer cell or cancerous
tissue is detected but expression in a control cell or normal
tissue (e.g. non-cancerous cell or tissue) is undetectable.
[0140] A high expression level of the gene may occur because of
over expression of the gene or an increase in gene copy number. The
gene may also be translated into increased protein levels because
of deregulation or absence of a negative regulator.
[0141] A "gene expression profile" refers to a pattern of
expression of at least one biomarker that recurs in multiple
samples and reflects a property shared by those samples, such as
tissue type, response to a particular treatment, or activation of a
particular biological process or pathway in the cells. Furthermore,
a gene expression profile differentiates between samples that share
that common property and those that do not with better accuracy
than would likely be achieved by assigning the samples to the two
groups at random. A gene expression profile may be used to predict
whether samples of unknown status share that common property or
not. Some variation between the levels of at least one biomarker
and the typical profile is to be expected, but the overall
similarity of the expression levels to the typical profile is such
that it is statistically unlikely that the similarity would be
observed by chance in samples not sharing the common property that
the expression profile reflects.
[0142] The term "cDNA" refers to complementary DNA, i.e. mRNA
molecules present in a cell or organism made into cDNA with an
enzyme such as reverse transcriptase. A "cDNA library" is a
collection of all of the mRNA molecules present in a cell or
organism, all turned into cDNA molecules with the enzyme reverse
transcriptase, then inserted into "vectors" (other DNA molecules
that can continue to replicate after addition of foreign DNA).
Exemplary vectors for libraries include bacteriophage (also known
as "phage"), viruses that infect bacteria, for example, lambda
phage. The library can then be probed for the specific cDNA (and
thus mRNA) of interest.
[0143] As used herein, "solid phase support" or "solid support",
used interchangeably, is not limited to a specific type of support.
Rather a large number of supports are available and are known to
one of ordinary skill in the art. Solid phase supports include
silica gels, resins, derivatized plastic films, glass beads,
plastic beads, alumina gels, microarrays, and chips. As used
herein, "solid support" also includes synthetic antigen-presenting
matrices, cells, and liposomes. A suitable solid phase support may
be selected on the basis of desired end use and suitability for
various protocols. For example, for peptide synthesis, solid phase
support may refer to resins such as polystyrene (e.g., PAM-resin
obtained from Bachem Inc., Peninsula Laboratories), polyHIPE(R).TM.
resin (obtained from Aminotech, Canada), polyamide resin (obtained
from Peninsula Laboratories), polystyrene resin grafted with
polyethylene glycol (TentaGelR.TM., Rapp Polymere, Tubingen,
Germany), or polydimethylacrylamide resin (obtained from
Milligen/Biosearch, California).
[0144] A polynucleotide also can be attached to a solid support for
use in high throughput screening assays. PCT WO 97/10365, for
example, discloses the construction of high density oligonucleotide
chips. See also, U.S. Pat. Nos. 5,405,783; 5,412,087 and 5,445,934.
Using this method, the probes are synthesized on a derivatized
glass surface to form chip arrays. Photoprotected nucleoside
phosphoramidites are coupled to the glass surface, selectively
deprotected by photolysis through a photolithographic mask and
reacted with a second protected nucleoside phosphoramidite. The
coupling/deprotection process is repeated until the desired probe
is complete.
[0145] As an example, transcriptional activity can be assessed by
measuring levels of messenger RNA using a gene chip such as the
Affymetrix.RTM. HG-U133-Plus-2 GeneChips. High-throughput,
real-time quantitation of RNA of a large number of genes of
interest thus becomes possible in a reproducible system.
[0146] The terms "stringent hybridization conditions" refers to
conditions under which a nucleic acid probe will specifically
hybridize to its target subsequence, and to no other sequences. The
conditions determining the stringency of hybridization include:
temperature, ionic strength, and the concentration of denaturing
agents such as formamide. Varying one of these factors may
influence another factor and one of skill in the art will
appreciate changes in the conditions to maintain the desired level
of stringency. An example of a highly stringent hybridization is:
0.015M sodium chloride, 0.0015M sodium citrate at 65-68.degree. C.
or 0.015M sodium chloride, 0.0015M sodium citrate, and 50%
formamide at 42.degree. C. (see Sambrook, supra). An example of a
"moderately stringent" hybridization is the conditions of: 0.015M
sodium chloride, 0.0015M sodium citrate at 50-65.degree. C. or
0.015M sodium chloride, 0.0015M sodium citrate, and 20% formamide
at 37-50.degree. C. The moderately stringent conditions are used
when a moderate amount of nucleic acid mismatch is desired. One of
skill in the art will appreciate that washing is part of the
hybridization conditions. For example, washing conditions can
include 02.X-0.1 X SSC/0.1% SDS and temperatures from 42-68.degree.
C., wherein increasing temperature increases the stringency of the
wash conditions.
[0147] When hybridization occurs in an antiparallel configuration
between two single-stranded polynucleotides, the reaction is called
"annealing" and those polynucleotides are described as
"complementary." A double-stranded polynucleotide can be
"complementary" or "homologous" to another polynucleotide, if
hybridization can occur between one of the strands of the first
polynucleotide and the second. "Complementarity" or "homology" (the
degree that one polynucleotide is complementary with another) is
quantifiable in terms of the proportion of bases in opposing
strands that are expected to form hydrogen bonding with each other,
according to generally accepted base-pairing rules.
[0148] A polynucleotide or polynucleotide region (or a polypeptide
or polypeptide region) has a certain percentage (for example, 80%,
85%, 90%, 95%, 98% or 99%) of "sequence identity" to another
sequence means that, when aligned, that percentage of bases (or
amino acids) are the same in comparing the two sequences. This
alignment and the percent homology or sequence identity can be
determined using software programs known in the art, for example
those described in Current Protocols in Molecular Biology, Ausubel
et al., eds., (1987) Supplement 30, section 7.7.18, Table 7.7.1.
Preferably, default parameters are used for alignment. A preferred
alignment program is BLAST, using default parameters. In
particular, preferred programs are BLASTN and BLASTP, using the
following default parameters: Genetic code=standard; filter=none;
strand=both; cutoff=60; expect=10; Matrix=BLOSUM62; Descriptions=50
sequences; sort by=HIGH SCORE; Databases=non-redundant.
[0149] The term "cell proliferative disorders" shall include
dysregulation of normal physiological function characterized by
abnormal cell growth and/or division or loss of function. Examples
of "cell proliferative disorders" include but are not limited to
hyperplasia, neoplasia, metaplasia, and various autoimmune
disorders, e.g., those characterized by the dysregulation of T cell
apoptosis.
[0150] As used herein, the terms "neoplastic cells," "neoplastic
disease," "neoplasia," "tumor," "tumor cells," "cancer," and
"cancer cells," (used interchangeably) refer to cells which exhibit
relatively autonomous growth, so that they exhibit an aberrant
growth phenotype characterized by a significant loss of control of
cell proliferation (i.e., de-regulated cell division). Neoplastic
cells can be malignant or benign. A metastatic cell or tissue means
that the cell can invade and destroy neighboring body
structures.
[0151] The term "cancer" refers to cancer diseases including, for
example, breast, lung, pancreas, ovary, central nervous system
(CNS), endometrium, stomach, large intestine, colon, esophagus,
bone, urinary tract, hematopoietic, lymphoid, liver, skin,
melanoma, kidney, soft tissue sarcoma and pleura.
[0152] The term "PBMC" refers to peripheral blood mononuclear cells
and includes "PBL"--peripheral blood lymphocytes.
[0153] "Suppressing" tumor growth indicates a reduction in tumor
cell growth when contacted with an MDM2i compared to tumor growth
without contact with an MDM2i compound. Tumor cell growth can be
assessed by any means known in the art, including, but not limited
to, measuring tumor size, determining whether tumor cells are
proliferating using a 3H-thymidine incorporation assay, measuring
glucose uptake by FDG-PET (fluorodeoxyglucose positron emission
tomography) imaging, or counting tumor cells. "Suppressing" tumor
cell growth means any or all of the following states: slowing,
delaying and stopping tumor growth, as well as tumor shrinkage.
[0154] A "composition" is a combination of active agent and another
carrier, e.g., compound or composition, inert (for example, a
detectable agent or label) or active, such as an adjuvant, diluent,
binder, stabilizer, buffers, salts, lipophilic solvents,
preservative, adjuvant or the like. Carriers also include
pharmaceutical excipients and additives, for example; proteins,
peptides, amino acids, lipids, and carbohydrates (e.g., sugars,
including monosaccharides and oligosaccharides; derivatized sugars
such as alditols, aldonic acids, esterified sugars and the like;
and polysaccharides or sugar polymers), which can be present singly
or in combination, comprising alone or in combination 1-99.99% by
weight or volume. Carbohydrate excipients include, for example;
monosaccharides such as fructose, maltose, galactose, glucose,
D-mannose, sorbose, and the like; disaccharides, such as lactose,
sucrose, trehalose, cellobiose, and the like; polysaccharides, such
as raffinose, melezitose, maltodextrins, dextrans, starches, and
the like; and alditols, such as mannitol, xylitol, maltitol,
lactitol, xylitol sorbitol (glucitol) and myoinositol.
[0155] Exemplary protein excipients include serum albumin such as
human serum albumin (HSA), recombinant human albumin (rHA),
gelatin, casein, and the like. Representative amino acid/antibody
components, which can also function in a buffering capacity,
include alanine, glycine, arginine, betaine, histidine, glutamic
acid, aspartic acid, cysteine, lysine, leucine, isoleucine, valine,
methionine, phenylalanine, aspartame, and the like.
[0156] The term "carrier" further includes a buffer or a pH
adjusting agent; typically, the buffer is a salt prepared from an
organic acid or base. Representative buffers include organic acid
salts such as salts of citric acid, ascorbic acid, gluconic acid,
carbonic acid, tartaric acid, succinic acid, acetic acid, or
phthalic acid; Tris, tromethamine hydrochloride, or phosphate
buffers. Additional carriers include polymeric excipients/additives
such as polyvinylpyrrolidones, ficolls (a polymeric sugar),
dextrates (e.g., cyclodextrins, such as
2-hydroxypropyl-quadrature-cyclodextrin), polyethylene glycols,
flavoring agents, antimicrobial agents, sweeteners, antioxidants,
antistatic agents, surfactants (e.g., polysorbates such as TWEEN
20.TM. and TWEEN 80.TM.), lipids (e.g., phospholipids, fatty
acids), steroids (e.g., cholesterol), and chelating agents (e.g.,
EDTA).
[0157] As used herein, the term "pharmaceutically acceptable
carrier" encompasses any of the standard pharmaceutical carriers,
such as a phosphate buffered saline solution, water, and emulsions,
such as an oil/water or water/oil emulsion, and various types of
wetting agents. The compositions also can include stabilizers and
preservatives and any of the above noted carriers with the
additional provisio that they be acceptable for use in vivo. For
examples of carriers, stabilizers and adjuvants, see Remington's
Pharmaceutical Science., 15th Ed. (Mack Publ. Co., Easton (1975)
and in the Physician's Desk Reference, 52nd ed., Medical Economics,
Montvale, N.J. (1998).
[0158] An "effective amount" is an amount sufficient to effect
beneficial or desired results. An effective amount can be
administered in one or more administrations, applications or
dosages.
[0159] A "subject," "individual" or "patient" is used
interchangeably herein, which refers to a vertebrate, preferably a
mammal, more preferably a human. Mammals include, but are not
limited to, mice, simians, humans, farm animals, sport animals, and
pets.
[0160] An "inhibitor" of MDM2 as used herein reduces the
association of p53 and MDM2. This inhibition may include, for
example, reducing the association of p53 and MDM2 before they are
bound together, or reducing the association of p53 and MDM2 after
they are bound together, thus freeing both molecules.
[0161] A number of genes have now been identified as biomarkers for
MDM2i. The decrease or increase of gene expression of one or more
of the biomarkers identified herein and in Table 2 can be used to
determine patient sensitivity to any MDM2i, for example, the
increase or overexpression of a biomarker indicates that a cancer
patient is sensitive to and would favorably respond to
administration of an MDM2i. As another example, after treatment
with a MDM2i, a patient sample can be obtained and the sample
assayed for sensitivity to discover if the patient is still
sensitive to the MDM2i treatment. Alternatively, all of the
biomarkers in Table 2 can be assayed for as a single set.
[0162] MDM2 inhibitors (MDM2i) are compounds which are inhibitors
of the p53-MDM2 association, and are useful in conjunction with the
methods or uses of the invention. MDM2i are useful in
pharmaceutical compositions for human or veterinary use where
inhibition of the p53-MDM2 association is indicated, e.g., in the
treatment of tumors and/or cancerous cell growth. In particular,
such compounds are useful in the treatment of human cancer, since
the progression of these cancers may be at least partially
dependent upon overriding the "gatekeeper" function of p53, for
example the overexpression of MDM2. MDM2i compounds are useful in
treating, for example, carcinomas (e.g., breast, lung, pancreas,
ovary, central nervous system (CNS), endometrium, stomach, large
intestine, colon, esophagus, bone, urinary tract, hematopoietic,
lymphoid, liver, skin, melanoma, kidney, soft tissue sarcoma and
pleura A listing of exemplary MDM2i compounds is found in Table 1
(see WO 2011076786). Other MDM2i that bind to a p53 binding pocket
of MDM2, particularly to substantially the same p53 binding pocket
of MDM2 as Nutlin-3a or substantially where the exemplary MDM2i
from the Table 1 binds, can also be applied in the methods or uses
of the invention. MDM2i used according to present embodiments can
be structurally related to the one described in Table 1 (i.e.
MDM2i(1) and MDM2i(2)) or to Nutlin 3a, such as, for example,
substituted isoquinolinones, or quinazolinones. The methods
included herein can also be used with other compounds such as the
spiro-oxindoles, imidazolyl indole and cis-imidazoline (see
Shangary et al., Mol. Cancer Ther. 2008 7(6): 1533-1542: Furet et
al., BioOrg. Med. Chem. Let. 2012 22:3498-3502 and Carol et al.,
Pediatr. Blood Cancer 2012 pages 1-9, published online Jul. 2,
2012, prior to inclusion into journal). MDM2i as used herein
prevents the protein-protein interaction between p53 and MDM2 or
inhibits cell proliferation by inducing the p53 pathway
activity.
TABLE-US-00001 TABLE 1 MDM2i compounds ##STR00001## MDM2i(1)
##STR00002## MDM2i(2)
[0163] Measurement of Gene Expression
[0164] Detection of gene expression can be by any appropriate
method, including for example, detecting the quantity of mRNA
transcribed from the gene or the quantity of cDNA produced from the
reverse transcription of the mRNA transcribed from the gene or the
quantity of the polypeptide or protein encoded by the gene. These
methods can be performed on a sample by sample basis or modified
for high throughput analysis. For example, using Affymetrix.TM.
U133 microarray chips.
[0165] In one aspect, gene expression is detected and quantitated
by hybridization to a probe that specifically hybridizes to the
appropriate probe for that biomarker. The probes also can be
attached to a solid support for use in high throughput screening
assays using methods known in the art. WO 97/10365 and U.S. Pat.
Nos. 5,405,783, 5,412,087 and 5,445,934, for example, disclose the
construction of high density oligonucleotide chips which can
contain one or more of the sequences disclosed herein. Using the
methods disclosed in U.S. Pat. Nos. 5,405,783, 5,412,087 and
5,445,934, the probes of this invention are synthesized on a
derivatized glass surface. Photoprotected nucleoside
phosphoramidites are coupled to the glass surface, selectively
deprotected by photolysis through a photolithographic mask, and
reacted with a second protected nucleoside phosphoramidite. The
coupling/deprotection process is repeated until the desired probe
is complete.
[0166] In one aspect, the expression level of a gene is determined
through exposure of a nucleic acid sample to the probe-modified
chip. Extracted nucleic acid is labeled, for example, with a
fluorescent tag, preferably during an amplification step.
Hybridization of the labeled sample is performed at an appropriate
stringency level. The degree of probe-nucleic acid hybridization is
quantitatively measured using a detection device. See U.S. Pat.
Nos. 5,578,832 and 5,631,734.
[0167] Alternatively any one of gene copy number, transcription, or
translation can be determined using known techniques. For example,
an amplification method such as PCR may be useful. General
procedures for PCR are taught in MacPherson et al., PCR: A
Practical Approach, (IRL Press at Oxford University Press (1991)).
However, PCR conditions used for each application reaction are
empirically determined. A number of parameters influence the
success of a reaction. Among them are annealing temperature and
time, extension time, Mg 2+ and/or ATP concentration, pH, and the
relative concentration of primers, templates, and
deoxyribonucleotides. After amplification, the resulting DNA
fragments can be detected by agarose gel electrophoresis followed
by visualization with ethidium bromide staining and ultraviolet
illumination.
[0168] In one embodiment, the hybridized nucleic acids are detected
by detecting one or more labels attached to the sample nucleic
acids. The labels can be incorporated by any of a number of means
well known to those of skill in the art. However, in one aspect,
the label is simultaneously incorporated during the amplification
step in the preparation of the sample nucleic acid. Thus, for
example, polymerase chain reaction (PCR) with labeled primers or
labeled nucleotides will provide a labeled amplification product.
In a separate embodiment, transcription amplification, as described
above, using a labeled nucleotide (e.g. fluorescein-labeled UTP
and/or CTP) incorporates a label in to the transcribed nucleic
acids.
[0169] Alternatively, a label may be added directly to the original
nucleic acid sample (e.g., mRNA, polyA, mRNA, cDNA, etc.) or to the
amplification product after the amplification is completed. Means
of attaching labels to nucleic acids are well known to those of
skill in the art and include, for example nick translation or
end-labeling (e.g. with a labeled RNA) by kinasing of the nucleic
acid and subsequent attachment (ligation) of a nucleic acid linker
joining the sample nucleic acid to a label (e.g., a
fluorophore).
[0170] Detectable labels suitable for use in the present invention
include any composition detectable by spectroscopic, photochemical,
biochemical, immunochemical, electrical, optical or chemical means.
Useful labels in the present invention include biotin for staining
with labeled streptavidin conjugate, magnetic beads (e.g.,
Dynabeads.TM.), fluorescent dyes (e.g., fluorescein, texas red,
rhodamine, green fluorescent protein, and the like), radiolabels
(e.g., 3H, 125I, 35S, 14C, or 32P) enzymes (e.g., horse radish
peroxidase, alkaline phosphatase and others commonly used in an
ELISA), and calorimetric labels such as colloidal gold or colored
glass or plastic (e.g., polystyrene, polypropylene, latex, etc.)
beads. Patents teaching the use of such labels include U.S. Pat.
Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437;
4,275,149; and 4,366,241.
[0171] Detection of labels is well known to those of skill in the
art. Thus, for example, radiolabels may be detected using
photographic film or scintillation counters, fluorescent markers
may be detected using a photodetector to detect emitted light.
Enzymatic labels are typically detected by providing the enzyme
with a substrate and detecting the reaction product produced by the
action of the enzyme on the substrate, and calorimetric labels are
detected by simply visualizing the colored label.
[0172] The detectable label may be added to the target (sample)
nucleic acid(s) prior to, or after the hybridization, such as
described in WO 97/10365. These detectable labels are directly
attached to or incorporated into the target (sample) nucleic acid
prior to hybridization. In contrast, "indirect labels" are joined
to the hybrid duplex after hybridization. Generally, the indirect
label is attached to a binding moiety that has been attached to the
target nucleic acid prior to the hybridization. For example, the
target nucleic acid may be biotinylated before the hybridization.
After hybridization, an avidin-conjugated fluorophore will bind the
biotin bearing hybrid duplexes providing a label that is easily
detected. For a detailed review of methods of labeling nucleic
acids and detecting labeled hybridized nucleic acids see Laboratory
Techniques in Biochemistry and Molecular Biology, Vol. 24:
Hybridization with Nucleic Acid Probes, P. Tijssen, ed. Elsevier,
N.Y. (1993).
[0173] Detection of Polypeptides
[0174] Expression level of the biomarker can also be determined by
examining protein expression or the protein product at least one of
the biomarkers listed in Table 2. Determining the protein level
involves measuring the amount of any immunospecific binding that
occurs between an antibody that selectively recognizes and binds to
the polypeptide of the biomarker in a sample obtained from a
patient and comparing this to the amount of immunospecific binding
of at least one biomarker in a control sample. The amount of
protein expression of the biomarker can be increased or reduced
when compared with control expression. Alternatively, all of the
biomarkers in Table 2 can be assayed for as a single set.
[0175] A variety of techniques are available in the art for protein
analysis. They include but are not limited to radioimmunoassays,
ELISA (enzyme linked immunosorbent assays), "sandwich"
immunoassays, immunoradiometric assays, in situ immunoassays (using
e.g., colloidal gold, enzyme or radioisotope labels), western blot
analysis, immunoprecipitation assays, immunofluorescent assays,
flow cytometry, immunohistochemistry, confocal microscopy,
enzymatic assays, surface plasmon resonance and PAGE-SDS.
[0176] Assaying for Biomarkers and MDM2i Treatment
[0177] Once a patient has been predicted to be sensitive to an
MDM2i, administration of any MDM2i to a patient can be effected in
one dose, continuously or intermittently throughout the course of
treatment. Methods of determining the most effective means and
dosage of administration are well known to those of skill in the
art and will vary with the composition used for therapy, the
purpose of the therapy, the target cell being treated, and the
subject being treated. Single or multiple administrations can be
carried out with the dose level and pattern being selected by the
treating physician. Suitable dosage formulations and methods of
administering the agents may be empirically adjusted.
[0178] At least one of the biomarkers provided in Table 2 can be
assayed for after MDM2i administration in order to determine if the
patient remains sensitive to the MDM2i treatment. In addition, at
least one biomarker can be assayed for in multiple time points
after a single MDM2i administration. For example, an initial bolus
of an MDM2i is administered, at least one biomarker from Table 2 is
assayed for at 1 hour, 2 hours, 3 hours, 4 hours, 8 hours, 16
hours, 24 hours, 48 hours, 3 days, 1 week or 1 month or several
months after the first treatment. Alternatively, all of the
biomarkers in Table 2 can be assayed for as a single set.
[0179] The at least one biomarker in Table 2 can be assayed for
after each MDM2i administration, so if there are multiple MDM2i
administrations, then at least one biomarker can be assayed for
after each administration to determine continued patient
sensitivity. The patient could undergo multiple MDM2i
administrations and the biomarkers then assayed at different time
points. For example, a course of treatment can require
administration of an initial dose of MDM2i, a second dose a
specified time period later, and still a third dose hours after the
second dose. At least one biomarker of Table 2 could be assayed for
at 1 hour, 2 hours, 3 hours, 4 hours, 8 hours, 16 hours, 24 hours,
48 hours, 3 days, 1 week or 1 month or several months after
administration of each dose of MDM2i. Alternatively, all of the
biomarkers in Table 2 can be assayed for as a single set.
[0180] It is also within the scope of the invention that different
biomarkers are assayed for at different time points. Without being
bound to any one theory, due to mechanism of action of the MDM2i or
of the biomarker, the response to the MDM2i is delayed and at least
one biomarker from Table 2 is assayed for at any time after
administration to determine if the patient remains sensitive to
MDM2i administration. An assay for at least one biomarker in Table
2 after each administration of MDM2i will provide guidance as to
the means, dosage and course of treatment. Alternatively, all of
the biomarkers in Table 2 can be assayed for as a single set.
[0181] Finally, there is administration of different MDM2 is and
followed by assaying for at least one biomarker in Table 2. In this
embodiment, more than one MDM2i is chosen and administered to the
patient. At least one biomarker from Table 2 can then be assayed
for after administration of each different MDM2i. This assay can
also be done at multiple time points after administration of the
different MDM2i. For example, a first MDM2i could be administered
to the patient and at least one biomarker assayed at 1 hour, 2
hours, 3 hours, 4 hours, 8 hours, 16 hours, 24 hours, 48 hours, 3
days, 1 week or 1 month or several months after administration. A
second MDM2i could then be administered and at least one biomarker
could be assayed for again at 1 hour, 2 hours, 3 hours, 4 hours, 8
hours, 16 hours, 24 hours, 48 hours, 3 days, 1 week or 1 month or
several months after administration of the second MDM2i. In each
case, all of the biomarkers in Table 2 can be assayed for as a
single set.
[0182] Another aspect of the invention provides for a method of
assessing for suitable dose levels of an MDM2i, comprising
monitoring the differential expression of at least one of the genes
identified in Table 2 after administration of the MDM2i. For
example, after administration of a first bolus of MDM2i, at least
one biomarker of Table 2 is analyzed and based on this result, an
increase or decrease in MDM2i dosage is recommended. After
administration of the adjusted dosage of MDM2i the analysis of at
least one biomarker will determine whether the patient is still
sensitive to the adjusted dose and that the adjusted dose is
providing the expected benefit, e.g., suppressing tumor growth.
Alternatively, all of the biomarkers in Table 2 can be assayed for
as a single set for assessing sensitivity to the dose of the
MDM2i.
[0183] Kits for assessing the activity of any MDM2i can be made.
For example, a kit comprising nucleic acid primers for PCR or for
microarray hybridization for the biomarkers listed in Table 2 can
be used for assessing MDM2i sensitivity. Alternatively, a kit
supplied with antibodies for at least one of the biomarkers listed
in Table 2 would be useful in assaying for MDM2i sensitivity.
[0184] It is well known in the art that cancers can become
resistant to chemotherapeutic treatment, especially when that
treatment is prolonged. Assaying for differential expression of at
least one of the biomarkers in Table 2 can be done after prolonged
treatment with any chemotherapeutic to determine if the cancer is
sensitive to the MDM2i. For example, kinase inhibitors such as
Gleevec.RTM. will strongly inhibit a specific kinase, but may also
weakly inhibit other kinases. There are also other MDM2i, for
example, the Nutlin family of compounds. If the patient has been
previously treated with another chemotherapeutic or another MDM2i,
it is useful information for the patient to assay for at least one
of the biomarkers in Table 2 to determine if the tumor is sensitive
to an MDM2i. This assay can be especially beneficial to the patient
if the cancer goes into remission and then re-grows or has
metastasized to a different site.
[0185] Screening for MDM2 Inhibitors
[0186] It is possible to assay for at least one biomarker listed in
Table 2 to screen for other MDM2i. This method comprises assaying a
cell with at least one biomarker from Table 2, which predicts if
the cell is sensitive to an MDM2i candidate inhibitor, the cell is
then contacted with the candidate MDM2i and the 1050 of the treated
cell is compared with a known MDM2i contacting a sensitive cell.
For example, for cells predicted to be sensitive to any MDM2i as
determined by the differential expression of at least one biomarker
in Table 2, the candidate MDM2i will have an IC50.ltoreq.3 .mu.M.
The measurement of at least one biomarker from Table 2 expression
can be done by methods described previously, for example, PCR or
microarray analysis. Alternatively, all of the biomarkers in Table
2 can be assayed for as a single set.
TABLE-US-00002 TABLE 2 SEQ ID NO. Gene Name Accession number
(nucleotide/protein) MDM2 NM_002392/NP_002383 SEQ ID NO. 1/SEQ ID
NO. 2 CDKN1A NM_000389/NP_000380 SEQ ID NO. 3/SEQ ID NO. 4 ZMAT3
NM_022470/NP_071915 SEQ ID NO. 5/SEQ ID NO. 6 DDB2
NM_000107/NP_000098 SEQ ID NO. 7/SEQ ID NO. 8 FDXR
NM_004110/NP_004101 SEQ ID NO. 9/SEQ ID NO. 10 RPS27L
NM_015920/NP_057004 SEQ ID NO. 11/SEQ ID NO. 12 BAX
NM_004324/NP_004315 SEQ ID NO. 13/SEQ ID NO. 14 RRM2B
NM_015713/NP_056528 SEQ ID NO. 15/SEQ ID NO. 16 SESN1
NM_014454/NP_055269 SEQ ID NO. 17/SEQ ID NO. 18 CCNG1
NM_004060/NP_004051 SEQ ID NO. 19/SEQ ID NO. 20 XPC
NM_004628/NP_004619 SEQ ID NO. 21/SEQ ID NO. 22 TNFRSF10B
NM_003842/NP_003833 SEQ ID NO. 23/SEQ ID NO. 24 AEN
NM_022767/NP_073604 SEQ ID NO. 25/SEQ ID NO. 26
EXAMPLES
Example 1
Both MDM2i(1) and MDM2i(2) are Equally Potent p53-MDM2 Inhibitors
in Biochemical and Cellular Assays
[0187] TR-FRET Assay for IC.sub.50 determination: standard assay
conditions consisted of 60 .mu.L total volume in white 384-well
plates (Greiner Bio-One: Frickenhausen, Germany), in PBS buffer
containing 125 mM NaCl, 0.001% Novexin, 0.01% Gelatin, 0.2%
Pluronic F-127, 1 mM DTT and 1.7% final DMSO). Both MDM2i(1) and
MDM2i(2) were added at different concentrations to 0.1 nM
biotinylated MDM2 (human MDM2 amino acids 2-188, internal
preparations), 0.1 nM Europium-labeled streptavidin (Perkin Elmer:
Waltham, Mass., USA) and 10 nM Cy5-p53 peptide (Cy5-p53 aa18-26,
internal preparation). After incubation at room temperature for 15
minutes, samples were measured on a GeniosPro reader (Tecan:
Mannedorf, Germany). FRET assay readout was calculated from the raw
data of the two distinct fluorescence signals measured in time
resolved mode (fluorescence 665 nm/fluorescence 620 nm.times.1000).
IC.sub.50 values are calculated by curve fitting using XLfit.RTM.
(Fit Model #205). This data is shown in FIG. 1A.
[0188] Determination of binding rate constants (K.sub.on,
K.sub.off): the rapid mixing tool of GeniosPro reader (Tecan:
Mannedorf, Germany) was used to study fast binding kinetics (single
well mode). Microplates containing the inhibitor and 20 nM
Cy5-labeled p53 peptide in 50 .mu.l assay buffer were placed in the
reader. After 10 min equilibration at 25.degree. C., binding
reactions were initiated by injecting 50 .mu.l of buffer containing
0.2 nM biotinylated MDM2 and 0.2 nM europium-streptavidin at 475
.mu.l/s. Fluorescence was measured at 665 nM and at various time
intervals, the first one 0.6 s after injection. In the absence of
inhibitor, Cy5 fluorescence was maximal already at 0.6 s and
remained stable for at least 15 min. In the presence of MDM2i(1)
and MDM2i(2) fluorescence decreased slowly and measurements were
made until steady-state was achieved. Control fluorescence was
taken as the difference between wells containing 1% DMSO and wells
containing 10 .mu.M Nutlin-3 as a control. The inhibitory effect at
each time point was calculated as percent of the corresponding
control. Progress curves obtained in the presence of different
concentrations of inhibitor were combined and fitted as a whole.
Nonlinear regression was performed with XLfit.RTM. using a novel
fit methodology that was designed to obtain precise K.sub.on and
K.sub.off values, based on the following respective equations:
Fit=[Imin+((Imax-(((Ki nH)*Imax)/((y nH)+(Ki
nH))))*(1-exp(((-1)*(koff+((y*koff)/Ki)))*X)))] and
Fit=[Imin+((Imax-(((Ki nH)*Imax)/((y nH)+(Ki
nH))))*(1-exp(((-1)*(kon*(Ki+y)))*X)))], where Ki represents the
constant of inhibition, Imin represents the minimum inhibition (in
%), Imax represents the maximum inhibition (in %), nH represents
the Hill coefficient, x represents the time and y represents the
inhibitor concentration). This data is shown in FIG. 1A.
[0189] Cell proliferation inhibition and GRIP p53 translocation
assay: Effects of MDM2i(1) and MDM2i(2) on cellular growth and loss
of viability is measured in both p53 wild-type (SJSA-1 and HCT116
p53.sup.wt/wt cells) and p53 mutant cell lines (SAOS2 and HCT116
p53.sup.-/- cells) using a standard proliferation assay based on
the DNA-interacting fluorescent dye YOPRO (Invitrogen: Lucern,
Switzerland). Briefly, cells are plated in 96-well plates overnight
at 37.degree. C. and are treated with increasing concentrations of
MDM2i(1) or MDM2i(2) for 72 hours. Cell concentration in each well
is then determined using the DNA-interacting fluorescent dye YOPRO
according to the manufacturer's instructions and the fluorescent
signal is measured using a Gemini-EM standard plate reader
(Molecular Devices:Sunnyvale, Calif., USA). IC.sub.50 values are
calculated by curve fitting using XLfit.RTM. (Fit Model #201) and
this data is shown in FIG. 1A.
[0190] The mechanistic p53-MDM2 Redistribution assay (GRIP assay)
is used to directly monitor in cells the ability of compounds to
modulate the p53-MDM2 protein-protein interaction. In this fully
engineered assay, the p53 protein is tagged with a fluorescent
GFP-label and is bound to MDM2 protein which is anchored in the
cytoplasm of the cells. The treatment of the cells with specific
compounds causes the dissociation of the interaction between the
two proteins and the translocation of the released p53-GFP protein
from the cytoplasm to the nuclei. This effect is detected and
quantified using a high content imaging platform using the
ArrayScan-VTi (Cellomics), following the fluorescent signal over
time (see FIG. 1B, GRIP p53 translocation assay).
[0191] Altogether, using both in vitro and cellular assays, the
results presented in FIGS. 1A and 1B show that both MDM2i(1) and
MDM2i(2) are comparable potent p53-MDM2 protein-protein interaction
inhibitors in vitro, inhibiting the p53-MDM2 protein-protein
interaction, hampering tumor cell proliferation in a p53-dependent
manner, and inducing p53 accumulation and translocation to the
nucleus. This data is shown in FIG. 1B; note that there are large
discrepancies in the IC50 between the cell lines. This is also an
indication that there are differences in the sensitivity between
the two cell lines to an MDM2i, and thus a determination of
sensitivity can be useful in determining which patients receive the
therapeutic.
Example 2
The p53 Mutational Status is Associated with MDM2i Chemical
Sensitivity in Cell Lines
[0192] The association of p53 mutation to MDM2i(2) chemical
sensitivity in a panel of cancer-relevant cell lines was tested by
Fisher's Exact test. The cell line panel is the one covered by the
Cancer Cell Line Encyclopedia (CCLE) initiative (Barretina J.,
Caponigro G., Stransky N., Venkatesan K., et al. The Cancer Cell
Line Encyclopedia enables predictive modeling of anticancer drug
sensitivity. Nature 483:603-7, 2012). A detailed genomic, genetic
and pharmacologic characterization was conducted on the CCLE cell
lines.
[0193] p53 mutation status in CCLE cell lines is taken from a data
source of gene-level genetic alterations, for example,
point-mutations, insertions, deletions and complex genetic
alterations, compiled from the Sanger center COSMIC data and
internal sources including Exome Capture Sequencing. This comprises
data from approximately 1,600 cancer-related genes over the CCLE
cell lines. Analysis of the CCLE panel revealed 244 cell lines
containing a mutant p53, and 112 cell lines that expressed wild
type p53.
[0194] The MDM2i(2) chemical sensitivity was determined from the
pharmacologic characterization of the CCLE cell lines. The cell
lines were separated in two groups according to MDM2i(2)
sensitivity. One group contains the cell lines sensitive to
MDM2i(2) compound, while the other group encompasses those being
chemically insensitive to the MDM2i(2) compound. Such
stratification resulted in two groups of 47 sensitive and 309
insensitive cell lines, respectively. From such in vitro chemical
sensitivity data, the prediction that a cell would be sensitive to
an MDM2i treatment was estimated to be 13%.
The statistical testing of the p53 mutation to sensitivity groups
association shows an association between p53 mutation (mt) and the
chemical sensitivity to MDM2i(2) (FIG. 2). The mt panel in FIG. 2
displays the MDM2i(2) sensitivity profiles for p53 mutated CCLE
cell lines, the wild type (wt) panel displays the MDM2i(2)
sensitivity profiles for p53 wild-type CCLE cell lines. Amax is
defined as the maximal effect level (the inhibition at the highest
tested MDM2i(2) concentration, calibrated to MG132, a proteaseome
inhibitor used as a reference, as described in the CCLE publication
referenced above, and IC50 is defined as of the .mu.M concentration
at which MDM2i(2) response reached an absolute inhibition of -50
with respect to the reference inhibitor. Cell line count broken
down by MDM2i(2) chemical sensitivity and p53 mutation status, and
associated statistics: Data is also displayed as a contingency
table with associated statistics.
[0195] This data indicates it is more likely for a cell line to
show sensitivity to MDM2i(2) if its p53 mutation status is wild
type. Indeed, the majority of p53 mutated cell lines are found
insensitive to the compound, whereas more than two-third of p53
wild type cell lines are sensitive.
[0196] From this data we can conclude a p53 wild type genotype is
the first indication of MDM2i sensitivity, and therefore it is the
first stratification biomarker to be considered for selecting
cancer patients responsive to an MDM2i.
Example 3
Prediction of Cell Line Chemical Sensitivity to MDM2i from Genomic
Data and Clinical Implication
[0197] The two cell line sensitivity groups, given by MDM2i(2)
treatment, are compared with the aim of identifying the biomarkers
differentiating the sensitive cell lines from the insensitive cell
lines, prior to any MDM2i treatment. Such biomarkers are used to
predict the sensitivity of any MDM2i treatment. The biomarkers
analyzed are the following types: 1) gene-level expression values
generated by the Affymetrix GeneChip.TM. technology with the
HG-U133 plus 2 array, summarized according to the RMA normalization
method; 2) gene-level chromosome copy number values, obtained with
the Affymetrix SNP6.0 technology (Affymetrix Santa Clara, Calif.,
USA) and processed using the Affymetrix apt software, and expressed
as log 2 transformed ratios to a collection of HapMap reference
normal samples; 3) gene-level genetic alterations or mutations, as
described above in Example 2; 4) pathway-level expression values,
summarizing pathway expression levels by a standardized average
approach over the genes contributing to the pathways, as referenced
in the GeneGo Metacore.RTM. knowledge base; 5) cell line lineage
(cell line tissue of origin); 6) gene-level Tumor suppressor
status, summarizing the activation status of a selection of tumor
suppressor genes, by integrating the genetic alteration, copy
number and expression information. Such genomic data was generated
in the context of the CCLE cell line genomic and genetic
characterization, and covers a total of about 45,000 genomic
features.
[0198] Wilcoxon signed-rank tests or Fisher's exact tests are used
to compare the two cell line group genomic features, depending on
the feature type. The features having continuous values (gene
expression and copy number, pathway expression features) are
subjected to Wilcoxon signed-ranked test, those having discrete
values (genetic alteration, tumor suppressor status and lineage
features), to Fisher's exact test, for differential profile
evaluation between sensitive and insensitive cell line groups. The
significant features, discriminating the sensitive cell line group
from the insensitive one, are the ones passing a false discovery
rate-controlled p-value cutoff. Irrespective of the p-value limit,
a minimum or maximum number of features per feature type are also
required. To minimize the impact of the high degree of correlation
among the features on the feature selection step, the feature data
is clustered before the statistical tests as a pre-processing step.
This step is performed at the feature type-level using the Frey's
and Dueck's Affinity Propagation method (Clustering by Passing
Messages Between Data Points. Frey B. and Dueck D. Science
315:972-6, 2007), and retrieves a set of features representing the
most variability.
[0199] The cell line sensitivity groups or classes are defined as
follows for this two-class comparison aiming at biomarker
identification: a sensitive group of 47 sensitive cell lines, and
an insensitive group of 204 insensitive cell lines. The 204 cell
lines making this insensitive group are the most insensitive ones
from the 309 insensitive cell line set mentioned in Example 2. This
feature selection step yielded a total of about 200 significant
features, having a significant differential profile to
differentiate the sensitive cell line group from the insensitive
one, and thus having the required properties to be considered as
markers to predict the chemical sensitivity of samples to an MDM2i.
As described above in Example 2, a relevant biomarker is the p53
mutation status itself. The statistics of the feature selection
step (p-value 1.17E-21) confirmed its role in predicting
sensitivity to an MDM2i. Furthermore, the odds-ratio associated
with p53 status (0.024) indicates p53 mutation is more represented
in MDM2i insensitive cell lines. Still noteworthy and still
according to the statistics of the feature selection step, most of
the predictive biomarkers are found to be a subset of p53
transcriptional target genes. These are shown in Table 2/FIG. 3.
Their fold-changes indicate the transcripts of these biomarkers are
more expressed in the MDM2i sensitive cell line population, as
shown in FIG. 3. This is likely indicative of a level of p53
functional activity pre-existing before any treatment in cell lines
that are sensitive to an MDM2i.
[0200] That the biomarkers in Table 2/FIG. 3 are reflective of a
functional p53 pathway in MDM2i sensitive cells is verified in FIG.
4. In FIG. 4, cells have been treated with increasing
concentrations of MDM2i(1) for 4 hours, prior to cell lysis. Whole
cell lysates were prepared using a cell lysis buffer containing 50
mM Tris-HCl pH 7.5, 120 mM NaCl, 1 mM EDTA, 6 mM EGTA pH 8.5, 1%
NP-40, 20 mM NaF, 1 mM PMSF and 0.5 mM Na-Vanadat, proteins were
separated on NuPAGE 4-12% Bis-Tris Gel (Invitrogen # NP0322BOX,
Lucerne; Switzerland), transferred onto Nitrocellulose Protran.RTM.
BA 85 membranes (Whatman #10 401 261: Piscataway, N.J., USA) at 1.5
mA/cm.sup.2 membrane for 2 h using a semi-dry blotting system, and
immunoblotted with either an anti-phospho-p53 (Ser.sup.15) (1/1000;
Cell Signaling Technology #9284: Beverly, Mass., USA) rabbit
polyclonal antibody, or an anti-p53 (Ab-6) (Pantropic, clone DO-1)
(1/1000; Calbiochem # OP43 San Diego, Calif., USA), an anti-MDM2
(Ab-1, clone IF2) (1/1000; Calbiochem # OP46), an
anti-p21.sup.wAF1(Ab-1, clone EA10) (1/500; Calbiochem # OP64: San
Diego, Calif., USA) or an anti-.alpha.-Tubulin (Sigma # T5168: St.
Louis, Mo., USA) mouse monoclonal antibodies, as indicated. As
shown in FIG. 4, increasing concentrations of MDM2i(1) induces
stabilization of p53 protein levels, with no significant increase
of phospho-p53 in both C3A and COLO 792 cells. Interestingly,
treatment with MDM2i(1) also induces a strong de novo expression of
both p53 target genes p21(CDKN1A) and MDM2 in C3A sensitive cells,
but not in COLO-792 insensitive cell line. Altogether, this data
indicates that sensitivity to an MDM2i inhibitor is directly
related to the presence of an intrinsic functional p53 pathway,
that the biomarkers in Table2/FIG. 3, taken together as a set or
alone, point directly to p53 pathway functionality before
treatment, and indicates these biomarkers have a strong ability to
predict patient sensitivity that correlates with the mechanism of
action of p53.
[0201] The significant genomics features are used as the basis
features for naive Bayes probabilistic modeling of the two MDM2i
chemical sensitivity groups, or classes. The goal of the modeling
step is to derive a classification scheme or classifier that
predicts the patient's response (either sensitive or insensitive)
of an unknown sample with a certain confidence. The predictive
model is defined by training a naive Bayes algorithm over the
entire chemically characterized COLE cell line population
stratified into the two above-mentioned sensitivity classes. The
performance of the classifier is evaluated through 5 repeats of
5-fold cross-validations of the data used to train the model. The
model performance is summarized with the following class-level
measures: sensitivity, specificity, positive predictive value, and
negative predictive value. The sensitive class is used as the
reference for the sensitivity and positive predicted value
calculations. The default output of the naive Bayes algorithm is a
score or probability, for each predicted sample to be assigned to
one class or the other. A probability threshold is defined to
transform the probability scores into a sensitive or insensitive
class-level prediction. The probability threshold is defined as the
probability maximizing the sensitivity and specificity calculated
over all predicted samples. The entire and nearly-identical
procedure is described in more details in the COLE publication
referenced in Example 2.
[0202] To demonstrate a better predictive power can be achieved
from at least one biomarker found in Table 2, and alternatively,
the biomarkers in Table 2 as a set, than from p53 mutation status
alone, or from the entire predictive feature set of about 200
genes, naive Bayes models from each of these feature sets were
trained, and their performance assessed by cross-validation, as
above mentioned, and compared (FIG. 5). FIG. 5 demonstrates the
selected biomarkers found in Table 2 outperform both the p53
mutation status and the larger group of about 200 significant
features, and provide a substantial improvement in predicting
patient responsiveness to an MDM2i. This is particularly striking
when performances are evaluated by positive predictive value
(PPV).
[0203] A positive predicted value (PPV) of 76% suggests that 76% of
the predicted sensitive cell lines will be sensitive to MDM2i
treatment. As an extrapolation to a clinical setting, a PPV of 76%
also suggests that 76% of cancer patients, predicted as sensitive
to MDM2i(2) from tumor biopsies, would show clinical response upon
MDM2i(2) treatment. This enrichment of clinical response by patient
stratification, using the biomarkers in Table 2 and associated with
the naive Bayes predictive model, was compared to the baseline
clinical response rate without prior patient stratification. The
baseline clinical response rate estimated from the chemical
sensitivity data is 19% Thus, in a clinical perspective; the
biomarkers of Table 2 have a clear increase of the clinical
response in the predicted sensitive patient population. This
increase in prediction is greater and more specific than assaying
for p53 status alone or all of the approximately 200 genomic
features initially selected. This can be seen in FIG. 5, where the
"All 200 biomarkers" feature bar is the PPV of the approximately
200 genomic features initially selected. The PPV reported for "All
200 biomarkers" feature is 59%. The PPV for using p53 alone is 56%
(FIG. 5). The PPV of the set of biomarkers disclosed in Table 2 is
76% ("Table 2 selected biomarkers"). This is a surprising result,
as in general, the larger data set of 200 genomic features would
provide more data points and more insight into prediction of MDM2i
sensitivity. However, this is not the case, as the biomarkers in
Table 2, when taken as a set, provide a 17% increase in predictive
value. This is important in the clinic, as now 17 additional
patients out of 100 would be predicted to receive the correct
treatment.
[0204] In order to test the predictive value of the biomarkers of
Table 2, 52 cell lines that were not previously examined in the
pharmacologic characterization as part of the COLE project, were
assayed for their sensitivity to MDM2i in proliferation assays.
Briefly, cells are plated in 96-well plates overnight at 37.degree.
C. and are treated with increasing concentrations of an MDM2i for
72 hours. Cell concentration in each well is then determined using
the CellTiter-Glo Luminescent Cell Viability Assay.RTM. (Promega
Cat. # G7571/2/3: Madison Wis., USA), according to the
manufacturer's instructions and the luminescent signal is measured
using a SYNERGY HT plate reader (BioTek: Winooski, Vt., USA).
IC.sub.50 values are calculated by curve fitting using XLfit.RTM.
(FIG. 6). Sensitivity of cell lines to an MDM2i is determined by
comparing the observed IC.sub.50 of all cells that were tested in
cell proliferation inhibition assay as described in Example 1. The
cut-off for sensitivity was determined at IC.sub.50.ltoreq.3 .mu.M
for both MDM2i(1) and MDM2i(2). Predictions of sensitivity for
every cell lines are performed using the predictive model as
described above, to confirm the values disclosed in FIG. 5. The
cell lines are from a variety of tumors. For example; melanoma
(COLO-829, COLO-849, IGR-1, MEL-JUSO,SK-MEL-1, SK-MEL-31, UACC-62,
UACC-257), leukemia (BV173, EOL-1, GDM-1,HuNS1, L-540,
MV-4-11,OCI-LY3, RS4:11, SUP-B15, HDLM2, JM1), breast cancer
(CAL51, EFM-192, HCC202), pancreatic cancer (DAN-G), hepatic cancer
(JHH-5) and lung cancer (RERF-LCK-KJ). This assay was done with the
all of the biomarkers disclosed in Table 2 as a single set.
Overall, 36/52 cell lines were predicted to be sensitive to an
MDM2i, and of these 36 cell lines 24 were sensitive, resulting in a
positive predictive value of 66%, again a significant increase in
predictive value (PPV) over assaying for p53 alone. With regard to
screening out the non-responding cells, 16/52 cell lines were
predicted to be insensitive to a p53-MDM2 inhibitor, and 13/16 were
found to indeed be insensitive, leading to a significant negative
predictive value (NPV) of 81%. Overall, these data are similar to
the predictive model performances described in FIG. 5. The actual
in vitro testing of unrelated cell lines allowed testing of the
MDM2i chemical sensitivity predictive model, hence validating the
biomarkers disclosed in Table 2.
Example 4
MDM2i Treatment Inhibits Tumor Growth Inhibition In Vivo which is
Correlated to a Dose-Dependent Increase of p21(CDKN1A) mRNA and
Protein Levels in Tumors
[0205] To further validate the predictive biomarkers disclosed in
FIG. 3, in vivo human xenograft models either from human primary
samples or from cell lines were directly injected and grown in
tumors subcutaneously in mice and then assessed for MDM2i
sensitivity. All the animals were allowed to adapt for 4 days and
housed in a pathogen-controlled environment (5 mice/Type III cage)
with access to food and water ad libitum. Animals were identified
with transponders. Studies were performed according to procedures
covered by permit number 1975 issued by the Kantonales Veterinaramt
Basel-Stadt and strictly adhered to the Eidgenossisches
Tierschutzgesetz and the Eidgenossische Tierschutzverordnung.
Subcutaneous tumors were induced by concentrating
3.0.times.10.sup.6 SJSA-1 osteosarcoma cells in 100 .mu.l of PBS
(without Ca.sup.2+ and Mg.sup.2+) and injecting in the right flank
of Harlan nude mice. The administration of MDM2i began 12-14 days
post cell injection. MDM2i was prepared immediately before each
administration. MDM2is were dissolved in 0.5% HPMC
(hydroxypropylmethylcellulose) and were injected daily (q24 h) at
25, 50 or 100 mg/kg. Tumor volumes (TVol), determined from caliper
measurements (using the formula l.times.w.times.h.times..pi./6)
were measured three times per week. Tumor response was quantified
by the change in tumor volume (endpoint minus starting value in
mm.sup.3) as the T/C, i.e.
( .DELTA. TVol drug .DELTA. TVol vehicle .times. 100 ) .
##EQU00001##
In the case of a tumor regression, the tumor response was
quantified by the percentage of regression of the starting TVol,
i.e.
( .DELTA. TVol drug .DELTA. TVol Day 0 .times. 100 ) .
##EQU00002##
The body-weight (BW) of the mice was measured three times per week
allowing calculation at any particular time-point relative to the
day of initiation of treatment (day 0) of both the percentage
change in BW (.DELTA.% BW). As shown in FIG. 7A, a 10-day treatment
of SJSA-1 xenografted tumors with MDM2i(1) led to a dose-dependent
tumor growth inhibition with a significant T/C of 50% at 25 mg/kg
q24 h and of 3% (stasis) at 50 mg/kg q24 h. At 100 mg/kg q24 h for
10 days, MDM2i(1) treatment induced a significant tumor regression
of 65% (FIG. 7B). All doses were well tolerated at q24 h schedule,
as indicated by the mean body weight curves over time.
[0206] Anti-tumor activity of MDM2i(1) was correlated with a
significant dose-dependent induction of p21(CDKN1A) mRNA levels in
tumors (FIG. 7C). Briefly, total RNA was purified from cell pellets
using the QIAshredder.RTM. (79654, Qiagen:Valencia Calif., USA) and
RNeasy Mini Kite (74106, Qiagen: Valencia Calif., USA) according to
the manufacturer's instructions, with the exception that no DNA
digestion was performed. Total RNA was eluted with 50 .mu.L of
RNase-free water. Total RNA was quantitated using the
spectrophotometer ND-1000 Nanodrop.RTM. (Wilmington Del., USA). The
qRT-PCR (Quantitative Reverse Transcriptase Polymerase Chain
Reaction) was set up in triplicate per sample using the One-Step RT
qPCR Master Mix Plus (RT-QPRT-032X, Eurogentec: Seraing, Belgium),
with either control primers and primers for human p21(CDKN1A)
(Hs00355782_m1, Applied Biosystems: Carlsbad Calif., USA) or mouse
p21(CDKN1A) (Mm00432448_m1, Applied Biosystems: Carlsbad Calif.,
USA), namely TaqMan Gene Expression kit assays (20.times. probe dye
FAM.TM. (or VIC)-TAMRA (or MGB); Applied Biosystems: Carlsbad
Calif., USA). More specifically, a master mix was prepared on ice
for a final concentration of: 1.times. Master Mix buffer, 1.times.
primer solution, and 1.times. Euroscript reverse transcriptase,
combined with H.sub.2O, total volume: 8 .mu.L/well. A MicroAmp
Optical 384-well Reaction Plate (4309849, Applied Biosystems) was
fixed on the bench, and 2 .mu.L of mRNA (concentration: 10 or 20
ng/.mu.l) (or water for negative control) were pipetted in
triplicate, followed by addition of 8 .mu.L/well of master mix. The
plate was then covered with a MicroAmp Optical Adhesive film kit
(4313663, Applied Biosystems: Carlsbad Calif., USA), centrifuged
for 5 min at 1000 rpm at 4.degree. C. and placed in a 7900 HT Fast
Real-Time PCR System (Applied Biosystems: Carlsbad Calif., USA).
The program was run with one cycle of 48.degree. C. for 30 min, one
cycle of 95.degree. C. for 10 min, and finally 40 cycles of
alternating 95.degree. C. for 15 sec and 60.degree. C. for 1 min.
The number of cycles (CT) was determined, 2.sup.-CT values were
calculated, and the value normalized by dividing with the 2.sup.-CT
value obtained from the Gapdh control. Fold increase over control
(i.e. DMSO- or vehicle-treated animals) was calculated and plotted
in the bar graph.
[0207] In addition, the anti-tumor activity of MDM2i(1) was
correlated with a significant dose-dependent induction of
p21(CDKN1A) protein levels in tumors, as judged by
immunohistochemistry (FIG. 8). SJSA-1 xenograft tumors were
collected and a 3-4 mm slice out of the middle of the tumor was
removed, transferred into pre-labelled histo-cassettes and
immersion-fixed in neutral buffered formalin (NBF) 10% (v/v) (pH
6.8-7.2) (J. T. Baker, Winter Garden, Fla., USA), pre-cooled at
4.degree. C. Tumors were then fixed at room temperature for 24
hours, followed by processing in the TPC 15Duo (Tissue Processing
Center, Medite) for paraffinization. Subsequently, the tumor slices
were embedded in paraffin and from each paraffin block several 3
.mu.m thick sections were cut on a rotary microtome (Mikrom
International AG, Switzerland), spread in a 48.degree. C.
water-bath, mounted on glass slides (SuperFrost Plus, Thermo
Scientific:Waltham Mass., USA), and dried in an oven either at
37.degree. C. overnight or at 60.degree. C. for 30 min. Dry tissue
section were processed for immunohistochemistry (IHC) staining.
p21(CDKN1A) immunohistochemistry has been performed using the mouse
monoclonal antibody clone SX118 from Dako (Cat. No. M7202 Dako:
Carpenteria Calif., USA) at a dilution of 1:50.
Immunohistochemistry has been performed on a Ventana Discovery XT
automated immunostainer using the N-Histofine Mousestain Kit
(Nichirei Bioscience Inc, Japan) in combination with the DABMap Kit
chromogen system, omitting the SA-HRP solution (Ventana/Roche
Diagnostics GmbH, Mannheim, Germany). Antigen retrieval was done by
using Cell Conditioning ULTRA.RTM. (Ventana/Roche Diagnostics GmbH,
Mannheim, Germany) at mild (95.degree. C. for 8 min+100.degree. C.
for 20 min) conditions. Mouse cross reactivities were blocked by
using Blocking Reagents A and B from the N-Histofine Mousestain
Kite (Nichirei Bioscience Inc, Japan) before and after primary
antibody incubation, following the manufacturer instructions. The
primary antibody was applied manually at the desired dilution in
Dako antibody diluent (AbD), followed by incubation for 1 hour at
ambient temperature. Corresponding negative controls were incubated
with AbD only. Sections were subsequently stained using the labeled
polymer system Simple Stain Mouse MAX PO (M) from the N-Histofine
Mousestain Kite (Nichirei) and DAB substrate from the DABMap Kit
(Ventana/Roche Diagnostics). Counterstaining of sections was done
using hematoxylin (Ventana/Roche Diagnostics). After the automated
staining run, slides were dehydrated in a graded series of ethanol,
cleared in xylene and mounted with Pertex.RTM. mounting medium.
Example 5
Prediction of MDM2i(2) Sensitivity in Human Primary Tumor Mouse
Xenograft Models and in Human Primary Tumors
[0208] The biomarkers in Table 2, were used in association with a
naive Bayes predictive model to predict MDM2i sensitivity in a
collection of human primary tumor samples and xenograft models, to
demonstrate whether the biomarkers, and their associated predictive
power, exists outside of in vitro cell line systems.
[0209] The gene-level expression values of all the biomarkers of
Table 2 were used as the feature basis for naive Bayes
probabilistic modeling. They were generated as described in Example
3, the only difference being in the RMA summarization step where
the normalization was targeted to a reference set of normal &
tumor samples. The naive Bayes modeling is conducted as described
in Example 3.
[0210] The human primary tumor samples and xenograft models
submitted for sensitivity prediction were a collection of about
18,000 and 503 samples, respectively, for which gene expression
profiles, generated with Affymetrix technology (Human Genome U133
plus 2.0 array), are available. The samples of the collection were
internally annotated with controlled vocabulary for sample ontology
including pathology, histology and primary site. The associated
gene chip data was gathered from both public and internal sources,
and normalized as described above to the same reference sample set
for consistency.
[0211] Ratios of MDM2i predicted sensitive samples from the
collection were compared to the proportions of sensitive cell
lines, as given by the MDM2i(2) chemical sensitivity data described
in Example 3 above. A good correlation is expected to demonstrate
the ability of the biomarkers disclosed in FIG. 3 to be predictive
for MDM2i sensitivity in human primary tumor samples. For clarity,
as well as to potentially identify lineages in which sensitive cell
line proportions are underestimated in the cell line chemical
sensitivity data, sensitive prediction ratio to sensitive cell line
ratio comparison is broken down by tissue of origin.
[0212] FIG. 9 (left panel) shows a correlation between predicted
sensitive human primary tumor samples from the collection and the
sensitive cell lines from MDM2i chemical sensitivity data. It
indicates the biomarkers disclosed in Table 2 and its use for
predicting sensitivity outside of in vitro cell line samples is
valid. It also indicates that the biomarkers disclosed in Table 2
can be used to predict MDM2i chemical sensitivity in human primary
tumor samples. It reveals new tumor indications which have not been
investigated previously and confirms results found in the current
study The new indications, for example, liver (hepatocellular
carcinoma) and kidney (renal cell carcinoma), represent potentially
new disease indications to be pre-clinically and clinically
evaluated with the biomarkers disclosed in Table 2 for treatment
with an MDM2i. FIG. 9A also indicates that the biomarkers disclosed
in Table 2 can be used to predict MDM2i chemical sensitivity in
primary melanoma tumors, consistent with the results found in the
current study.
[0213] FIG. 9 (right panel) shows a correlation between the
fractions of predicted sensitive human primary tumor samples and
the predicted sensitive ratios in the primary tumor xenograft
collection. The tumor samples/xenografts/cell lines are organized
by lineage. The dashed line in both panels is the identity line. It
shows the data generated from the in vivo mouse xenograft models,
in which the exemplified signature and associated predictive
classifier can be studied and validated, is in line with the data
from the rest of the in vivo collection samples. It confirms the
mouse xenograft models as a source of material to validate the p53
downstream target gene based classifier approach to predict
clinical outcome of cancer patients and diseases indications, in an
in vivo pre-clinical setting.
Example 6
Single Biomarkers and any Combinations of the Identified Thirteen
Biomarkers Predict Chemical Sensitivity to MDM2i
[0214] The thirteen biomarkers depicted in Table 2, when used in
association with a naive Bayes predictive modeling framework,
predict MDM2i sensitivity in both in vitro systems and in vivo, as
exemplified in Examples 3 and 5. To investigate whether subsets of
these thirteen biomarkers would also predict for MDM2i sensitivity,
single biomarkers and multiple combinations of them are employed as
feature basis for predictive modeling. Their prediction
performances are then compared to the ones achieved with either the
full thirteen biomarkers or with p53 mutation status when used as a
predictive feature for MDM2i sensitivity prediction.
[0215] Two instances of p53 mutation status are considered in
Example 6. These two instances are defined from the Exome Capture
Sequencing data of the CCLE cell lines, as mentioned in Example 2,
and are meant to be surrogates of clinical settings where the p53
gene is sequenced for stratification or clinical annotation of
patients.
[0216] The first instance of p53 mutation status is defined from
the mutations spanning exons 5 to 8 of p53. Exons 5 to 8 encompass
the DNA binding domain of p53, which contains the majority of
described p53 mutations, and are the p53 exons commonly targeted
for sequencing in clinical settings (for example, Rapid sequencing
of the p53 gene with a new automated DNA sequencer. Bharaj B.,
Angelopoulou K., and Diamandis E., Clinical Chemistry 44:7
1397-1403, 1998). The second instance considers the complete open
reading frame of the main p53 transcript, and is therefore defined
from all coding exon mutations.
[0217] Multiple biomarker combinations can be generated from the
list of 13 biomarkers disclosed in Table 2. All combination types
from 2 to 12 biomarkers are evaluated as feature basis for
predictive modeling of MDM2i chemical sensitivity. When more than
50 different combinations exist for a given combination type, the
number of evaluated combinations is restricted to 50. All 50
combinations in each combination type were randomly picked.
[0218] All predictive models associated to the above described
feature sets (single biomarkers, 2-to-12 biomarker combinations,
p53 mutation status instances) were trained and evaluated mostly as
described in Example 3. What differs from Example 3 is as follows:
The training data was slightly larger than the one used is Example
3 and encompasses 264 cell lines (47 from the sensitive class, and
217 from the insensitive class); A p-value threshold of 0.5 was
used upon the naive Bayes probabilistic modeling to call a cell
line either sensitive or insensitive in the 5-fold cross-validation
scheme. Moreover, all sample strata generated by the
cross-validation processes were randomly selected and independent
from one-another. The performances of the combinatorial predictive
models and their comparisons to the p53 mutation status instance
and 13 biomarker models are shown in FIGS. 10 to 12.
[0219] FIG. 10 depicts the positive predicted values (PPV) achieved
by the single biomarker, the combinatorial, the thirteen biomarker
and the p53 mutation models. The PPV is an estimate of the clinical
efficacy one would expect in a clinical trial upon patient
selection with the considered modeling process. For convenience,
the data is depicted as box-and-whisker plots when there are more
than five data points to plot per feature set.
[0220] FIG. 10 shows that combinations from as few as two and three
biomarkers outperform exon 5-to-8 p53 mutation ("ex5to8mt") and
all-exon p53 mutation features ("allExMt"), respectively. Indeed,
the upper and lower boundaries defined by the ends of the whiskers
encompass about 99% of the data points, assuming a normal
distribution of the data. Therefore, the majority of the evaluated
2- and 3-biomarker combinations show a higher PPV than the ones
achieved by the p53 mutation status instances. Moreover, even if
all single gene models do not outperform the two p53 mutations
instances, a majority of them (around 75%, the box plus the upper
whisker) outperforms the p53 all-exon mutations. Noteworthy, all
single gene models give rise to PPVs that are higher than the
sensitive cell line ratio (-18%) in the considered sample
population, indicating that MDM2i sensitivity prediction models,
built from as few as one biomarker, are capable of enriching the
selected samples in sensitive ones.
[0221] Additionally, under this modeling exercise, as plotted in
FIG. 10, the PPV given by the p53 exons 5-to-8 mutation status
model, averaged over the 5 cross-validation repeats, is 48%. It is
significantly lower than the p53 mutation PPV disclosed in Example
3 (56%). This indicates that, in a clinical setting where p53 exon
5-to-8 sequencing is employed for patient selection, which is
common practice, the exemplified 13 biomarker-based patient
selection has even higher added value than anticipated from Example
3.
[0222] FIG. 11 shows the specificities achieved by the several
evaluated models. As for PPV in FIG. 10, every combination made
from as few as 2 biomarkers is sufficient to achieve specificity
higher than the ones obtained from the mutations instances only.
All single biomarker models outperform the mutations, when
specificity is used to monitor the model performances.
[0223] FIG. 12 shows the sensitivities. Sensitivity is also called
recall, and is an estimate of the truly sensitive patient
population retained upon patient selection. Combinations of 9
biomarkers as the feature basis for MDM2i sensitivity prediction
models are sufficient to obtain sensitivities comparable to the one
achieved the full 13 biomarker list. However, only a few
9-biomarker combinations would achieve sensitivities higher than
the ones given by the 2 p53 mutation status predictive models. But
noteworthy, all evaluated combinations, from as few as 2
biomarkers, and a majority of single biomarker models, display
sensitivities higher than the one which is expected by chance upon
random classification (.about.18%).
[0224] In conclusion from FIGS. 10, 11 and 12, single biomarkers,
when used as feature basis in models predicting chemical
sensitivity to MDM2i, are sufficient to achieve sample sensitivity
predictions that would result in a significant enrichment of
potentially MDM2i responding patient in a clinical setting.
Furthermore, combinations made from any 2 biomarkers, or more,
increase the expected clinical efficacy with respect to the one
obtained with p53 mutation-based patient selection. Assembling 8
biomarkers, from any of the Table 2 thirteen ones, are sufficient
to achieve a patient recall equivalent to the one given by the 13
biomarker model. The predictive model performance metrics, obtained
for the 13 gene signature and associated combinations, can be
further optimized by optimizing the class assignment p-value
threshold used in the naive Bayes probabilistic step of the model,
as it was done in Example 3.
[0225] In a further embodiment, it is investigated whether the
biomarkers depicted in Table 2 could predict MDM2i chemical
sensitivity in collaboration with p53 mutation status. Single
biomarkers and combinations of 2 biomarkers and above are combined
with p53 mutation status in feature lists. The feature lists are
then utilized as basis for sensitivity predictive modeling, as
previously and described above. The performances of the multiple
resulting models are evaluated as described above.
[0226] The p53 mutation status instance which is used as an example
is the p53 exon 5-to-8 mutations. FIGS. 13, 14 and 15 depict the
PPVs, specificities and sensitivities of those models combining p53
mutation with biomarkers, respectively, and are compared to the
results given by mutation only models and the full 13-biomarker
model.
[0227] FIG. 13 shows that at least a single biomarker from the list
of 13, in collaboration with p53 mutation status, is sufficient to
achieve a PPV higher that the basal sensitivity rate (18%) in the
data. It also shows that a single biomarker at minimum, still in
combination with p53 mutation status, achieves a higher PPV than
the ones obtained with the two above mentioned p53 mutation status
instances, when employed as features in a predictive model. And
finally, any 5 biomarkers in combination with p53 mutation
recapitulate the PPV which is achieved by the 13 biomarker
model.
[0228] The same conclusions are drawn from FIGS. 14 and 15 when
specificities and sensitivities are taken into account as model
performance metrics. Noteworthy from FIG. 15, a high sensitivity
can be obtained from as few as one biomarker, when modeled along
with p53 mutation.
[0229] In conclusion, combining a single or multiple biomarkers
from Table 2 with p53 mutation status enables the prediction of
MDM2i sensitivity, and would result, when applied for patient
selection in a therapeutic or clinical setting, in a significant
enrichment with a limited loss of potential MDM2i responding
patients.
Sequence CWU 1
1
2617472DNAHomo sapiens 1gcaccgcggc gagcttggct gcttctgggg cctgtgtggc
cctgtgtgtc ggaaagatgg 60agcaagaagc cgagcccgag gggcggccgc gacccctctg
accgagatcc tgctgctttc 120gcagccagga gcaccgtccc tccccggatt
agtgcgtacg agcgcccagt gccctggccc 180ggagagtgga atgatccccg
aggcccaggg cgtcgtgctt ccgcgcgccc cgtgaaggaa 240actggggagt
cttgagggac ccccgactcc aagcgcgaaa accccggatg gtgaggagca
300ggcaaatgtg caataccaac atgtctgtac ctactgatgg tgctgtaacc
acctcacaga 360ttccagcttc ggaacaagag accctggtta gaccaaagcc
attgcttttg aagttattaa 420agtctgttgg tgcacaaaaa gacacttata
ctatgaaaga ggttcttttt tatcttggcc 480agtatattat gactaaacga
ttatatgatg agaagcaaca acatattgta tattgttcaa 540atgatcttct
aggagatttg tttggcgtgc caagcttctc tgtgaaagag cacaggaaaa
600tatataccat gatctacagg aacttggtag tagtcaatca gcaggaatca
tcggactcag 660gtacatctgt gagtgagaac aggtgtcacc ttgaaggtgg
gagtgatcaa aaggaccttg 720tacaagagct tcaggaagag aaaccttcat
cttcacattt ggtttctaga ccatctacct 780catctagaag gagagcaatt
agtgagacag aagaaaattc agatgaatta tctggtgaac 840gacaaagaaa
acgccacaaa tctgatagta tttccctttc ctttgatgaa agcctggctc
900tgtgtgtaat aagggagata tgttgtgaaa gaagcagtag cagtgaatct
acagggacgc 960catcgaatcc ggatcttgat gctggtgtaa gtgaacattc
aggtgattgg ttggatcagg 1020attcagtttc agatcagttt agtgtagaat
ttgaagttga atctctcgac tcagaagatt 1080atagccttag tgaagaagga
caagaactct cagatgaaga tgatgaggta tatcaagtta 1140ctgtgtatca
ggcaggggag agtgatacag attcatttga agaagatcct gaaatttcct
1200tagctgacta ttggaaatgc acttcatgca atgaaatgaa tccccccctt
ccatcacatt 1260gcaacagatg ttgggccctt cgtgagaatt ggcttcctga
agataaaggg aaagataaag 1320gggaaatctc tgagaaagcc aaactggaaa
actcaacaca agctgaagag ggctttgatg 1380ttcctgattg taaaaaaact
atagtgaatg attccagaga gtcatgtgtt gaggaaaatg 1440atgataaaat
tacacaagct tcacaatcac aagaaagtga agactattct cagccatcaa
1500cttctagtag cattatttat agcagccaag aagatgtgaa agagtttgaa
agggaagaaa 1560cccaagacaa agaagagagt gtggaatcta gtttgcccct
taatgccatt gaaccttgtg 1620tgatttgtca aggtcgacct aaaaatggtt
gcattgtcca tggcaaaaca ggacatctta 1680tggcctgctt tacatgtgca
aagaagctaa agaaaaggaa taagccctgc ccagtatgta 1740gacaaccaat
tcaaatgatt gtgctaactt atttccccta gttgacctgt ctataagaga
1800attatatatt tctaactata taaccctagg aatttagaca acctgaaatt
tattcacata 1860tatcaaagtg agaaaatgcc tcaattcaca tagatttctt
ctctttagta taattgacct 1920actttggtag tggaatagtg aatacttact
ataatttgac ttgaatatgt agctcatcct 1980ttacaccaac tcctaatttt
aaataatttc tactctgtct taaatgagaa gtacttggtt 2040tttttttttc
ttaaatatgt atatgacatt taaatgtaac ttattatttt ttttgagacc
2100gagtcttgct ctgttaccca ggctggagtg cagtggcgtg atcttggctc
actgcaagct 2160ctgcctcccg ggttcgcacc attctcctgc ctcagcctcc
caattagctt ggcctacagt 2220catctgccac cacacctggc taattttttg
tacttttagt agagacaggg tttcaccgtg 2280ttagccagga tggtctcgat
ctcctgacct cgtgatccgc ccacctcggc ctcccaaagt 2340gctgggatta
caggcatgag ccaccgcgtc cggcctaaat gtcacttagt acctttgata
2400taaagagaaa atgtgtgaaa gatttagttt tttgtttttt tgtttgtttg
tttgtttgtt 2460tgttttgaga tgagtctctc tgtcgcccag gctggagtgc
agtgtcatga tctagcagtc 2520tccgcttccc gggttcaagc cattctcctg
gctcagcctc tggagcagct gggattacag 2580gcatgcacca ccatgcccag
ctaatttttg tatttttagt agagataggg tttcaccatg 2640ttggccaggc
tggtcacgaa ctcctgacct caagtgaggt cacccgcctc ggcctcccga
2700agtgctggga ttgcagatgt gagccaccat gtccagccaa gaattagtat
ttaaatttta 2760gatactcttt tttttttttt tttttttttt ttttgagaca
gagtcttgct ccatcaccca 2820tgctagagtg cagtggagtg atctcggctc
actgcaactt ccgccttctg ggttcaagct 2880attctcctgc ctcagccttc
caagtaactg ggattacagg catgtaccac cataccagct 2940gatttttttg
tatttttagt aaagacaggg tttcaccatg ttagccaggc tgatcttgaa
3000ctcctaaact caagtgatct actcacctca gcctcccaaa atgctgggat
tacagatgtg 3060aggcacctgg cctcagattt ttgatactct taaaccttct
gatccttagt ttctctctcc 3120aaaatactct ttctaggtta aaaaaaaaaa
ggctcttata tttggtgcta tgtaaatgaa 3180aatgtttttt aggttttctt
gatttaacaa tagagacagg gtctccctgt gttgcccagg 3240ctggtctcga
actcctgggc tcaagagatc ctcctgtctt ggcctcgcaa agtgctaagt
3300aggattacag gcgttagcca ccacacccgg ctgtaaaaat gtacttattc
tccagcctct 3360tttgtataaa ccatagtaag ggatgggagt aatgatgtta
tctgtgaaaa tagccaccat 3420ttacccgtaa gacaaaactt gttaaagcct
cctgagtcta acctagatta catcaggccc 3480tttttcacac acaaaaaaat
cctttatggg atttaatgga atctgttgtt tccccctaag 3540ttgaaaaaca
actctaagac actttaaagt accttcttgg cctgggttac atggttccca
3600gcctaggttt cagacttttg cttaaggcca gttttagaaa cccgtgaatt
cagaaaagtt 3660aattcagaaa tttgataaac agaattgtta tttaaaaact
aactggaaag attgttaagt 3720tctttctgaa ttattcagaa attatgcatc
attttccttc aagaatgaca gggtcagcat 3780gtggaattcc aagatacctc
ttgacttcct ctcaagctcc gtgtttggtc agtggaggcc 3840catccgagct
cagcactgag aagtgttagt ttctttggga cccatctacc ctgaccacat
3900catgatgttc atctgcagct gttgcaaggt gttcagattg tataaacata
aatgtcacaa 3960aaactttaaa agaagtgcaa ttctcaaaag gttaggtgga
ctaaagcatt ctgtaaagca 4020actgctaata atgagcttac agtggatttg
aatttgaaaa atatagtaac aagcctgtca 4080aatatctgca agaactatgg
aataaaacta ctgatgcagt gaagacagtt gaaaagatca 4140aacaaatgcc
aagctatatt tataatgaac aaattcaaga aaaaggacta cggaaagttc
4200aggacatcaa agaagtcagg caaaactcat cttgacccct gttgcaggca
aaggaacgca 4260gctggaagaa aagatgatat aacagttaac aggatgcaga
catggcagag gtttcctaaa 4320aatctcatta tctataacca tttctatatt
tacatttgaa aatctccttt ggagacttag 4380aacctctaaa ttattgactt
attttttata taaggtcact ccgatgaaag gtgattacaa 4440aatcatctac
attgctgtct acaaaacaga taatatggat gtttgatcgc atctcattgt
4500taactcttta ctgatatgtt tgtaaataca gaagtgaaat gtggacataa
aatagttacg 4560ctatttggtt aatggtacta gacaacatgt aattaatgac
attcaaaaat ttatggctag 4620tgatatatat aaagtaaaat tttctttgca
gtaaaatatg ccctttatta tagaagggag 4680gatataagga accaacagtt
tgtatgaaaa tagctcaaat aatatctttt attttgattt 4740taatatttct
tattttggtt tattagtgtc ttagaacaaa atggccttat ataatgaagc
4800ctagttatgc tggactgttt tgatctcttt taattgttct gacagatagt
tggggatgag 4860agccgaataa ggtttgcctg aaataactga cactatataa
tttctgcttt ggcaaatact 4920aagttctaac ttgtcattcc tggtagaaca
agctttattt ttcgagccta gcaatgatct 4980agaagcagat gttatctcag
tgccttttgc aatttgttgt gtgggttttt ttttttttaa 5040agccacacaa
taattttgga aaacaatgta tgggtagaac atgtgtctgt taattgcaca
5100caaaaccact tttaatgggt acagagttaa atttgaagga ataagttcta
gctgaagtat 5160tatgaactcc aaataatgct ttgaggacct ccaaaggtaa
aagtactaat ccctttggcc 5220atttattgag agagagagag agagagagta
gggtgactat agttaatgta ttgaatgttc 5280ttgctacaaa taaatgatat
ttgagctgat gggtgtgcta attacactga tttgatcaat 5340acccattgta
tgtgaaacag tacatacacc atatttacaa ttatgtattt aacatttaaa
5400atttctaata taagtatctc tcaaactgtg gattaacttc ttgatttata
tttaaatatg 5460aatcttaagc aaaacagtga aaataaccat cttgatttag
tgtttttctc ccatatgtga 5520attgtatata cttaggtgaa gacaataaaa
tcaactgaac tgtaagctta gaataggact 5580gaggtaattc tgcacagcaa
ctttactaat ggtacattgt tgcttcaaaa ctctctctct 5640ctctctctgt
ctgtctcaat aaatggccaa agggattagt agtttacctg tggaggtcct
5700ccaagcatta tttggagttg ataatacttc agctacaacc aagcagaatc
tctttttttt 5760ggaggtcctc gaagcattat ttggagttga taatacttca
gcttcaattt ggagttgata 5820atatttcagc tagaacctag tagaatctgt
ttttttcctt tggaggtcct caaagcatta 5880ttggagttca taatactgaa
gctagaacca agcagaatct gtttttttct gaggagtatc 5940ggtagcataa
atgtgattat aaacatagta cacttgatat atggaggcag tgacagctat
6000ttttacaaaa tttaaatctg caaatggatt caacatgttt atgggttatt
aaaattgtct 6060gatttcttag gttctttata gtacacgtgt tgaaaataaa
tgattaagaa ttgtttcaag 6120aatgcaatta tttgatctta aatttttatg
agttgttaaa atagaaatta tttgaatatc 6180atatatttgg gtaacaaaag
gcacaagtct gaatgtgttt ctttttctgg aatggccatg 6240cctgcccact
ttagaaatac aaatatcact gggcagcttg aagcagttgg gagcctccaa
6300tgagagcaac ttgagagaat gatgttgcaa gttagtagga gtaagaaatg
ctgtgttctc 6360cctgtcttct cttaggtcac atggcagcct ggcctaagtg
atcgtgaatg gtctataagg 6420gaggtagctg ggacagggag gggagtttgg
gctagccacc gtaccacttg tcagcgtgaa 6480aagtaagatt gtaattgcct
gtttagtttt ctgcctcatc tttgaaagtt ccaccaagct 6540gggaacctct
tgattgtgag gcacaaatgt aagtacatca gaaaaaaaca aaaaaactgg
6600ctttaaagca ggagcttgtg ggcccctaag ccagacgggg actagctttt
ggcattatat 6660aattaagatt ttttaaatcc ttaataaggg ttttatttta
tttttattta ttttttgaga 6720cggagtcttg ctctgtggct caggctggag
tacagtggtg caatcttggc tcactgcaac 6780ctctgcctcc tggctgtgtt
caagtggttc tgcttcagcc tcccaagtag ctggggttag 6840agcaccctgt
caccacgccc cgctaatttt tgtatttcta gcagagatga agtttcacta
6900tgttggccag gctgggctca aactcctgac ctcaagtgat ctgcccgcct
tggcccccca 6960aagtgctgtg attacaggcg tgagccgcca cgcccagcct
aataagggtt ttaaagataa 7020ttagtgtgta ggtctgtagg cttatgatgg
taaccacaag ttgttaatgg cattgtgaaa 7080agtttttagt tgcgctttat
gggtggatgc tgaattacat tttgatttga tacttataaa 7140aagaaaaagt
atttcttcag cttaaaaaat tgtttaaaag tttgtgatca tattgtctac
7200catgtagcca gctttcaatt atatgtaaga gggacttttt gacatttaca
aataatactt 7260tgaggtagat atctgaaagc accagcactt ggaaggtgtt
cagaagtaac aaattataaa 7320atgagctaac aaacgaaagg caaaataaaa
ccgtaaagca agcagatggg aggcgtgttc 7380agtaacttat tcataatgca
tctgaaatga ttgctgtact caaatattta acgttagagt 7440aatagtattt
tgaatgaaaa ccatagttga tt 74722497PRTHomo sapiens 2Met Val Arg Ser
Arg Gln Met Cys Asn Thr Asn Met Ser Val Pro Thr 1 5 10 15 Asp Gly
Ala Val Thr Thr Ser Gln Ile Pro Ala Ser Glu Gln Glu Thr 20 25 30
Leu Val Arg Pro Lys Pro Leu Leu Leu Lys Leu Leu Lys Ser Val Gly 35
40 45 Ala Gln Lys Asp Thr Tyr Thr Met Lys Glu Val Leu Phe Tyr Leu
Gly 50 55 60 Gln Tyr Ile Met Thr Lys Arg Leu Tyr Asp Glu Lys Gln
Gln His Ile 65 70 75 80 Val Tyr Cys Ser Asn Asp Leu Leu Gly Asp Leu
Phe Gly Val Pro Ser 85 90 95 Phe Ser Val Lys Glu His Arg Lys Ile
Tyr Thr Met Ile Tyr Arg Asn 100 105 110 Leu Val Val Val Asn Gln Gln
Glu Ser Ser Asp Ser Gly Thr Ser Val 115 120 125 Ser Glu Asn Arg Cys
His Leu Glu Gly Gly Ser Asp Gln Lys Asp Leu 130 135 140 Val Gln Glu
Leu Gln Glu Glu Lys Pro Ser Ser Ser His Leu Val Ser 145 150 155 160
Arg Pro Ser Thr Ser Ser Arg Arg Arg Ala Ile Ser Glu Thr Glu Glu 165
170 175 Asn Ser Asp Glu Leu Ser Gly Glu Arg Gln Arg Lys Arg His Lys
Ser 180 185 190 Asp Ser Ile Ser Leu Ser Phe Asp Glu Ser Leu Ala Leu
Cys Val Ile 195 200 205 Arg Glu Ile Cys Cys Glu Arg Ser Ser Ser Ser
Glu Ser Thr Gly Thr 210 215 220 Pro Ser Asn Pro Asp Leu Asp Ala Gly
Val Ser Glu His Ser Gly Asp 225 230 235 240 Trp Leu Asp Gln Asp Ser
Val Ser Asp Gln Phe Ser Val Glu Phe Glu 245 250 255 Val Glu Ser Leu
Asp Ser Glu Asp Tyr Ser Leu Ser Glu Glu Gly Gln 260 265 270 Glu Leu
Ser Asp Glu Asp Asp Glu Val Tyr Gln Val Thr Val Tyr Gln 275 280 285
Ala Gly Glu Ser Asp Thr Asp Ser Phe Glu Glu Asp Pro Glu Ile Ser 290
295 300 Leu Ala Asp Tyr Trp Lys Cys Thr Ser Cys Asn Glu Met Asn Pro
Pro 305 310 315 320 Leu Pro Ser His Cys Asn Arg Cys Trp Ala Leu Arg
Glu Asn Trp Leu 325 330 335 Pro Glu Asp Lys Gly Lys Asp Lys Gly Glu
Ile Ser Glu Lys Ala Lys 340 345 350 Leu Glu Asn Ser Thr Gln Ala Glu
Glu Gly Phe Asp Val Pro Asp Cys 355 360 365 Lys Lys Thr Ile Val Asn
Asp Ser Arg Glu Ser Cys Val Glu Glu Asn 370 375 380 Asp Asp Lys Ile
Thr Gln Ala Ser Gln Ser Gln Glu Ser Glu Asp Tyr 385 390 395 400 Ser
Gln Pro Ser Thr Ser Ser Ser Ile Ile Tyr Ser Ser Gln Glu Asp 405 410
415 Val Lys Glu Phe Glu Arg Glu Glu Thr Gln Asp Lys Glu Glu Ser Val
420 425 430 Glu Ser Ser Leu Pro Leu Asn Ala Ile Glu Pro Cys Val Ile
Cys Gln 435 440 445 Gly Arg Pro Lys Asn Gly Cys Ile Val His Gly Lys
Thr Gly His Leu 450 455 460 Met Ala Cys Phe Thr Cys Ala Lys Lys Leu
Lys Lys Arg Asn Lys Pro 465 470 475 480 Cys Pro Val Cys Arg Gln Pro
Ile Gln Met Ile Val Leu Thr Tyr Phe 485 490 495 Pro 32175DNAHomo
sapiens 3gttgtatatc agggccgcgc tgagctgcgc cagctgaggt gtgagcagct
gccgaagtca 60gttccttgtg gagccggagc tgggcgcgga ttcgccgagg caccgaggca
ctcagaggag 120gcgccatgtc agaaccggct ggggatgtcc gtcagaaccc
atgcggcagc aaggcctgcc 180gccgcctctt cggcccagtg gacagcgagc
agctgagccg cgactgtgat gcgctaatgg 240cgggctgcat ccaggaggcc
cgtgagcgat ggaacttcga ctttgtcacc gagacaccac 300tggagggtga
cttcgcctgg gagcgtgtgc ggggccttgg cctgcccaag ctctaccttc
360ccacggggcc ccggcgaggc cgggatgagt tgggaggagg caggcggcct
ggcacctcac 420ctgctctgct gcaggggaca gcagaggaag accatgtgga
cctgtcactg tcttgtaccc 480ttgtgcctcg ctcaggggag caggctgaag
ggtccccagg tggacctgga gactctcagg 540gtcgaaaacg gcggcagacc
agcatgacag atttctacca ctccaaacgc cggctgatct 600tctccaagag
gaagccctaa tccgcccaca ggaagcctgc agtcctggaa gcgcgagggc
660ctcaaaggcc cgctctacat cttctgcctt agtctcagtt tgtgtgtctt
aattattatt 720tgtgttttaa tttaaacacc tcctcatgta cataccctgg
ccgccccctg ccccccagcc 780tctggcatta gaattattta aacaaaaact
aggcggttga atgagaggtt cctaagagtg 840ctgggcattt ttattttatg
aaatactatt taaagcctcc tcatcccgtg ttctcctttt 900cctctctccc
ggaggttggg tgggccggct tcatgccagc tacttcctcc tccccacttg
960tccgctgggt ggtaccctct ggaggggtgt ggctccttcc catcgctgtc
acaggcggtt 1020atgaaattca ccccctttcc tggacactca gacctgaatt
ctttttcatt tgagaagtaa 1080acagatggca ctttgaaggg gcctcaccga
gtgggggcat catcaaaaac tttggagtcc 1140cctcacctcc tctaaggttg
ggcagggtga ccctgaagtg agcacagcct agggctgagc 1200tggggacctg
gtaccctcct ggctcttgat acccccctct gtcttgtgaa ggcaggggga
1260aggtggggtc ctggagcaga ccaccccgcc tgccctcatg gcccctctga
cctgcactgg 1320ggagcccgtc tcagtgttga gccttttccc tctttggctc
ccctgtacct tttgaggagc 1380cccagctacc cttcttctcc agctgggctc
tgcaattccc ctctgctgct gtccctcccc 1440cttgtccttt cccttcagta
ccctctcagc tccaggtggc tctgaggtgc ctgtcccacc 1500cccaccccca
gctcaatgga ctggaagggg aagggacaca caagaagaag ggcaccctag
1560ttctacctca ggcagctcaa gcagcgaccg ccccctcctc tagctgtggg
ggtgagggtc 1620ccatgtggtg gcacaggccc ccttgagtgg ggttatctct
gtgttagggg tatatgatgg 1680gggagtagat ctttctagga gggagacact
ggcccctcaa atcgtccagc gaccttcctc 1740atccacccca tccctcccca
gttcattgca ctttgattag cagcggaaca aggagtcaga 1800cattttaaga
tggtggcagt agaggctatg gacagggcat gccacgtggg ctcatatggg
1860gctgggagta gttgtctttc ctggcactaa cgttgagccc ctggaggcac
tgaagtgctt 1920agtgtacttg gagtattggg gtctgacccc aaacaccttc
cagctcctgt aacatactgg 1980cctggactgt tttctctcgg ctccccatgt
gtcctggttc ccgtttctcc acctagactg 2040taaacctctc gagggcaggg
accacaccct gtactgttct gtgtctttca cagctcctcc 2100cacaatgctg
aatatacagc aggtgctcaa taaatgattc ttagtgactt tacttgtaaa
2160aaaaaaaaaa aaaaa 21754164PRTHomo sapiens 4Met Ser Glu Pro Ala
Gly Asp Val Arg Gln Asn Pro Cys Gly Ser Lys 1 5 10 15 Ala Cys Arg
Arg Leu Phe Gly Pro Val Asp Ser Glu Gln Leu Ser Arg 20 25 30 Asp
Cys Asp Ala Leu Met Ala Gly Cys Ile Gln Glu Ala Arg Glu Arg 35 40
45 Trp Asn Phe Asp Phe Val Thr Glu Thr Pro Leu Glu Gly Asp Phe Ala
50 55 60 Trp Glu Arg Val Arg Gly Leu Gly Leu Pro Lys Leu Tyr Leu
Pro Thr 65 70 75 80 Gly Pro Arg Arg Gly Arg Asp Glu Leu Gly Gly Gly
Arg Arg Pro Gly 85 90 95 Thr Ser Pro Ala Leu Leu Gln Gly Thr Ala
Glu Glu Asp His Val Asp 100 105 110 Leu Ser Leu Ser Cys Thr Leu Val
Pro Arg Ser Gly Glu Gln Ala Glu 115 120 125 Gly Ser Pro Gly Gly Pro
Gly Asp Ser Gln Gly Arg Lys Arg Arg Gln 130 135 140 Thr Ser Met Thr
Asp Phe Tyr His Ser Lys Arg Arg Leu Ile Phe Ser 145 150 155 160 Lys
Arg Lys Pro 58995DNAHomo sapiens 5gcagtggcga cgccgagccg gcgccctcag
tctcctcctc caccgcctcc cggttccgca 60gtcacttcct gcagctgttt ccctgtgggt
cgggttggac tgacttttga cagtcagcct 120tcggctgcgg agggggctcg
gcggcggccg gcggagaaag ttgctccgag aagaggctgg 180gtcgagctgg
gccgagccgg gcgcgcaggg cgggcgtcgc gggcgtcccg ggcggacgcg
240gcgcggagac tgccggcgcg tcccgggggt tccgatttga agaccttgct
tctcatcacc 300cactggatta tgccccaggc ttccctaccc aatgatcctc
ttgcaacacg ccgtgcttcc 360tccacctaag cagccctcac cctcgcctcc
tatgtcagtg gccaccaggt ctacaggaac 420cttgcagctt ccaccacaga
agccttttgg gcaggaggct tccttgcctc ttgcagggga 480agaagagtta
tcgaagggag gggagcaaga ctgtgccctg gaggagctat gtaagcccct
540gtactgcaaa ctctgcaatg tcaccttgaa ctctgcacag caagcccagg
ctcattatca 600gggtaaaaat catggtaaga aactccgaaa ttactatgca
gcaaatagct gtcctcctcc 660tgctagaatg agcaatgtgg tcgagcctgc
agctactcca gttgttccag tccctccgca 720gatgggctcc tttaagccag
gaggccgagt gatcctggcc acggagaatg attactgtaa 780gctctgtgat
gcctccttca gttccccagc tgtggctcag gctcactatc aagggaagaa
840tcatgccaag aggctgcggc tggcggaagc tcagagtaac tcattctcgg
aatcctcaga 900gctgggtcaa cggcgggcca ggaaagaagg gaatgagttt
aagatgatgc ctaacaggag 960aaatatgtat acagtacaga ataattcagc
aggtccttac ttcaatcccc gctctcggca 1020gagaattcca cgtgatctgg
ccatgtgtgt tactccaagt ggccagtttt actgctcaat 1080gtgtaatgtt
ggagctggcg aagagatgga attccggcag catttagaga gcaagcaaca
1140taagagcaag gtgtctgaac agcggtacag gaatgagatg gagaatctgg
gatatgtata 1200gtgattatca tattaagata gagcagcttt tcctgcctgt
tgtttgcctt ttgtcaactt 1260gccctgcttt gtggtctttt tgatatgagt
acattcctct gcttaatgtt aatacatgta 1320acccacagtg gtaccatgag
atgtcaaaac ctgggggccc gggggcgggg cggggggagg 1380tgggtgtgaa
gaacgtgctt cttaggtcat aacgcttttg cagggtcaat ggtgttgagc
1440cgctcatagc atgtgaccta cctaccccat cagaaataac tttttatctt
gctcaagttc 1500tggtcaacta gtagcctgac ggcttagaac tttgactatt
taaaagtttc attttctttt 1560gcaattttag ttttatgtac tgttaaagaa
ttgtactgaa ttctttttag atcacagtaa 1620aaataggttg gcagagattt
cagtttccca gggcttaacc agaaccgcca cctcaatgca 1680ttgtcagtag
aatacattat tagaaactgt taaggtcttt cccgggacat ttttttctgc
1740cattttcttt tgcaattgta gttttatgta ctgttaaaga attgtattga
attcttttta 1800gatcaaagta aaaataggtc agcagagatt tcagtttccc
agggcttaac cagaaccgcc 1860acctcaatgc attgtcagta ggatacatta
ttagaaactg ttagggtctt tcccaggaca 1920tttttttttc tgtatcatgt
ctccccatca ttgaagcgca aattttcttg aattcaaata 1980ctcccaatga
gcttgtatac ttccaaacag ctaaacttga tttccagttg tggatttcac
2040acatataatt gccgccttct tccctcctct tttttccccc ctagttgaat
cagcttgtct 2100aacaagccca ttttcatgcc ccagctgtgc tgtgggtttt
ccaagcctca tatttgaata 2160ttcaatgagt ttaagatgga tatgatttca
aaaaataggg ccgggcgcgg tggctcacgc 2220ctgtaatccc agcactttgg
gaggccgaag caggcggatc acgaggtcag gaggtcgaga 2280tcatcctggc
taacacagtg aaaccccatc tctactaaaa atacaaaaca ttagccgggc
2340gtggtggtgg gtgcctgtag tcccagctac tctggaggct gaggcaggag
aatggcgtga 2400acccgggagg cggagcttgc agtgagccga gatcgcgcca
ctgcactcca gcctgggtga 2460cagagcgaga ctccgtctca aaaaaaaaaa
aaaaaaaaaa aaaaaaatat atatatatat 2520agatatattt tccagcagtt
tttaggaaac aaaggtgtgt ttgattttcc aatttagagt 2580tacttcattg
atagtaacat gcgcttatat catgatctaa accataagtt cagattgctt
2640gatattttgt tttgccagac ttttttgata atctgattct tacggtttac
ttacattttc 2700ctctgtcttg ccagtctggt ggccatcctg aaaaatatca
ccacctgctg ttttatacac 2760agaggaattt tttaaaaagc aaataaagtt
tcactatctt cgtttccagt agaaatatac 2820acgaactatg gttttattct
ttgtaattcg gctttcttga agatactaac aagtatatga 2880tagatcactt
tggcatctga taattatatc agtattatta tttttgtttt tttgcgttta
2940aaataagaag ttgtatgaac ccaggaggtg gaggttgcag tcagccaaga
atcgtgccac 3000tgcactccag tctgggcgac agagcaatac tccgtctcca
aaaaaaaaaa aaaagaagct 3060ataatatata tctagattaa ctaatggagt
gctctgtgaa tattcattaa ctacatttta 3120tctatttact atattttata
tgggtaagac cagtggtcat ccgtatttct tttgaaagcc 3180cacttgatca
ggaagtttat attttaagca gtatgtttgc acaatggtca gttcacattt
3240gattgcttgt attactaatt agaggtaaaa cttctatttt ttcttgataa
ttctgtaggc 3300aaaaaaaatt ggggaaggca aattacaatc attcttcttc
tgtaatactt tgggacaatt 3360tttaaacaac tcagacccat gtttaaaaac
gagttttgtg tgattaaccc ttgtatagta 3420tccagttact gtcttctctt
gaagtggtgg ttctttgaga agtagaatta ttttgtaact 3480tttcttctcc
cagaaacaga agaatcaaat actattctgt taggattcta tctagacctg
3540tgactcttag tataataacc cttttattat tattattatt attatttttt
cagtaatcta 3600taaagtagag ttgcttagtt ttgagcaatt tagggctttt
cttattggcc agtaggttat 3660tcattttgct gctaaatata attttttggt
taattttaac attatagtgc tggccgcttg 3720gttctatgat tacctaaaaa
tctagttttt ttcctccata ggtagatgtg tgtgtatgca 3780tacccccaca
cacacacgta catatatgtt gtcatagaga ggtatttcaa cccttatttc
3840aaataacagt agaagatacg aacatgaatt tatattttgt aaaaatgtca
ttcatccact 3900ttgttttcca ttggaaatag ttttataaga agggttcccc
ttgctctctc cacttaacaa 3960tttcattata tacgtagaaa aagcagccga
cttaagggct tgatgttttt tcaggccttg 4020tggattcagg tttccagttt
cccagtgccc ttaatggatg ttatgaatgc ataagcacat 4080tttcttttaa
agaaagaagt tagatttata gtgttatttc ttacttgcta tatttctttg
4140cactaaaaaa gagctatgtg tttgttttat aggacacttt agtaccgtat
tgcctacaat 4200aactcagttt gctccttaaa ttccaaactc tgggaagttg
ataaataact tccatgatca 4260cttgtaaaag ttacatgcac atctgaaaaa
aaatcacaaa tctctatgac agtaggttat 4320gttttgagct tgttaccttg
cagtattctt ctctgttcca taggtgaaaa caaagggtga 4380cagaggttat
caggcaggaa atgcctaaat agatacatct ctgcatggta caatttctca
4440tattcatgta ttccataaac agtgtttttt ctctgtttaa gcagactgtt
gtttcttctg 4500agtcagtgat atgtgatctt cgttggtttc attttgtgaa
gctcagtctg tctctgtaac 4560atactttagg atttgcacct tgtgctcccc
aggaattatg ttagtgtcct tttctatgct 4620gtcttcaagg atggacagag
gcctaaacca caacaacaac aaaaattaga aaaaaaaata 4680cttagatttc
ggtaatcatc cataggaact catagcatca gtctcttttc tctgtgaata
4740atatctttgt gtaagttgtc ataaaaaatc aacgttagaa gatgacaatt
agaattcttc 4800ttaggtattg agggtaagaa gttgtaaaga aagaaaattc
gtgtttcaac taaaagattg 4860gattgcatat acctttgaag tggttttgta
aaaaaagttc agttactaaa ctgagtgtgc 4920cctgtaatcc ttttgagtgc
actgaagatg ctttgaaaat actttgttgg tcttcacatt 4980gtgcatcatg
tcctgcaact tgtaaatatg tgcatgttgt ttatgtttgt ctgcctgtct
5040cttattgcac taaattctgc aaggtgaata atttttttat accatttatt
tggaaaaagt 5100tcctcctcca actcttcttc actgaccttt taattagttg
gtaaacttag aaaaccaggt 5160aggatttttg aagccctgag tttaaaagaa
gaatcgtggc tatttgacat catccttaca 5220ttcccctgac ttaaaaagct
aacaagaagc acgagatctt ccacctcatt ttagaaagct 5280tttctacaga
actatatgct tgcttatagc tacctatcta cagtttgaac agggagaaag
5340ggagatatgt atgtctggtt acatcttcct tcactcttga attggctggg
acagcaagca 5400acaacagttt gaggtccagt gacctacgta aaatgagtgt
cgtttgtgtc aggggacaca 5460tgtaactgtg caacatggta ttttctacag
ggagggctag gaagggtggt tttggaacct 5520aacctacttt gtgtcttcat
tgtcagaact aaggttggaa atgcccttta aagaacttgg 5580tgaggcatat
gctaggacaa tagagctgct ttagaaagaa attgagacat gttttgtcag
5640gacagataaa agtttaatgc aggcttttga acagatgttt taaaacaaat
ttgaccttac 5700caactatttt tttcttctag ccaaatcatt gtacaggagt
ttcatatatg ataaaaagtg 5760ttttgttatt gtttttgctt tcttggcagg
ggagaacccc taccattgtg agcagttact 5820gtcactctgg ctgaatggac
aaatagctgt gtaaatagct tctcataaaa cgcttctact 5880gatagctgtt
tgactttttc ttcccgttat gaatgggagg aacatttgta aacttccttt
5940ctgggtagct accaaaaaac gtactggctt atggtcccat gtgaccttgt
ctccgttaag 6000cccagaatct gagtgccttt agcaagtgtt agcatttcac
agagagaaga gagacagaat 6060tattgctatt aatcaccatt cataaatagg
agcttggaat aacaaaggtc tgtgtgaatt 6120ctgttctacg tctttttttt
ccctttttta aataaatgtc aatttgatat caagtaaaac 6180tattgtcatt
attgatcaga aaccatacat tctgaaaatg aatccagttt tcccaagctg
6240gcagaagtca gagatcattt ttcaccttga tctgtgttgc gtttgtactt
agtgaatggc 6300agtgtggttg attggaagag cttgacactg atgtttggaa
aaattcttta ttctagtggt 6360cattttcaaa cttgtcttct gtagagaggg
gaaaaattat gtatttgcag ctaaagcgaa 6420gagactggca caataattat
taattgtgtt agttcatttc tatattaaat gaagcatctt 6480cacaaatcag
gtttgaagcc attaaaagca aaattttccc tagtttaatt aatttaaaat
6540tctaaattgc ctgactactt agaatcttag aaacgccctg ctagactgat
tttattatag 6600aaatgttaac atgttcctca acattttctc aagaaaattt
tcagacatat atcaaagttg 6660aaaaaacttt gcagtataac cactgctaga
ttctgccatc aacatttgac tatacttgta 6720ttgccatgta tctgttcata
ttctctatcc ctcttttcat ccatcgatcc atcagatttt 6780ttttttaaag
aacattccaa agtaaatttt aggcaataca ctgccctaaa ttcttagcat
6840gggtgtcatt aattaaggtt tagtattcgt ttaaatatct attttgaaag
tggtgtatga 6900agttgataat ctgagccaat taacatactt tttttttttt
cctcctgtgg acttttgtct 6960tccagtttct ctttttgtgt gtacttaggg
tgagggagga caattccttt caaacacaag 7020tttattttag aattggtcat
ttttaagtgc ttgtcataaa ttttaaagtt tcaatataat 7080ttttcttttc
cccacttctg ataatgtatt tttgccaaac tatgcagctt cttcaaaaaa
7140ctgtaaatta ctgattgggg tttatgaaat cagcgaatac ctcatttcaa
tctgttgctg 7200cttttctccc tcttgtcact tctcctttca ctactttcag
ctgctctacc agaaggtaga 7260ggggagtaaa gggtcaaacc cctatataat
tagctgtttt aaacaactct aggagagcag 7320attaagtagc ttagtaagtt
gaaactatta atttttctaa agaatttgat ttgaattcct 7380tgagaattgt
aattatccac acttcctcca gctataatta gcagaattaa aaatgattgt
7440actgtacaat gagttgttga aattgtaagc cttagtaacc atctttagct
ttattgtagt 7500catgtttaga aaaaattatt tttacatatg cctttatttt
tatgcccact ttttgtggat 7560aagattcttt agataaaatc taaagaattt
taagtgactt tctccaggtc atgaagattc 7620aatgggtaga attgaatcag
aattgaaatg ttccagattc atattcttgt gtgtgtttga 7680taaaattcat
ggcttccaaa gtaactgaac acttcctttg ggcccttgga gggaaaatcc
7740atatttttac taattacact ttttttttta gacatctggc agttctttga
acttaaacat 7800attctcatgg ccatagttcc aaattaagcc cgacgcagtt
gctaaaaatc ttgctgcact 7860gttgaatact aataatgcaa catttattgg
atgtttttgc attttgatga ccttcatgat 7920tcatttataa gtctttgtaa
gtgcttaagt gaccccctca ctagtgaaaa taataaatgt 7980tctatatcat
ttattattat ttgtgtattc tctacatgat atattttttt aaggaagagt
8040aactccacat gtcagaatga gtgatattat cctagggcaa agcgcaaata
gggcagtttg 8100tttctactct gcaaatatgg catgtatagg aacaaaactc
ttttggagtg gctggtcatt 8160gttctgccct cttttggtac ctgagtacct
ttctggggtt ttgtaaatcg tgtgtcattt 8220gtaagaattt cacgttaact
ctgcgttact tggtgttcac ctgtggtatc cttgactgac 8280cataatgatt
tagtttgggt atgatgtgtc tgctttgaaa tgccttactg gagtatgtca
8340gatcctgctt taaagcattc catatatctg ctgggacaat aagttgcttc
tccttggaaa 8400tatgctctag attcagaagc aaaaccgatt ttgctttcac
cattaaggtt gcattttaat 8460gcagttattg ttttaaatta gagaataaaa
tgtaaaacca agggaggctt tagaaccctt 8520tattgaatgg catggcaaac
ttttaaaact gcttttgcta tttcactaga actatctttg 8580ataaaggata
tagctaaaaa atgtcagccc aaactgtgtg taattagggt tgtttattaa
8640aattttctct aaatgtcata cagaggctta agatctgtgt atgctgttgg
gtcggagtgc 8700cagtcactgc tttggaagtc tgtgttctgg ggctgcagaa
tgacaaacgt gtcatgggat 8760taaaaccaat caactgtgaa ttgtgaaatt
gaaactactc tttcggtttt attttcttta 8820gcatattgag tatagaaatc
tgaaacttat ttaaaattta tactgctttt gttgatggct 8880cattttggct
gtgtatcctc acttatgtac tgatttctga taaaggcttg acattattat
8940aacacgcatt ttgtgttcca gtttaataaa acggtttctg agtcttgtct gaaaa
89956289PRTHomo sapiens 6Met Ile Leu Leu Gln His Ala Val Leu Pro
Pro Pro Lys Gln Pro Ser 1 5 10 15 Pro Ser Pro Pro Met Ser Val Ala
Thr Arg Ser Thr Gly Thr Leu Gln 20 25 30 Leu Pro Pro Gln Lys Pro
Phe Gly Gln Glu Ala Ser Leu Pro Leu Ala 35 40 45 Gly Glu Glu Glu
Leu Ser Lys Gly Gly Glu Gln Asp Cys Ala Leu Glu 50 55 60 Glu Leu
Cys Lys Pro Leu Tyr Cys Lys Leu Cys Asn Val Thr Leu Asn 65 70 75 80
Ser Ala Gln Gln Ala Gln Ala His Tyr Gln Gly Lys Asn His Gly Lys 85
90 95 Lys Leu Arg Asn Tyr Tyr Ala Ala Asn Ser Cys Pro Pro Pro Ala
Arg 100 105 110 Met Ser Asn Val Val Glu Pro Ala Ala Thr Pro Val Val
Pro Val Pro 115 120 125 Pro Gln Met Gly Ser Phe Lys Pro Gly Gly Arg
Val Ile Leu Ala Thr 130 135 140 Glu Asn Asp Tyr Cys Lys Leu Cys Asp
Ala Ser Phe Ser Ser Pro Ala 145 150 155 160 Val Ala Gln Ala His Tyr
Gln Gly Lys Asn His Ala Lys Arg Leu Arg 165 170 175 Leu Ala Glu Ala
Gln Ser Asn Ser Phe Ser Glu Ser Ser Glu Leu Gly 180 185 190 Gln Arg
Arg Ala Arg Lys Glu Gly Asn Glu Phe Lys Met Met Pro Asn 195 200 205
Arg Arg Asn Met Tyr Thr Val Gln Asn Asn Ser Ala Gly Pro Tyr Phe 210
215 220 Asn Pro Arg Ser Arg Gln Arg Ile Pro Arg Asp Leu Ala Met Cys
Val 225 230 235 240 Thr Pro Ser Gly Gln Phe Tyr Cys Ser Met Cys Asn
Val Gly Ala Gly 245 250 255 Glu Glu Met Glu Phe Arg Gln His Leu Glu
Ser Lys Gln His Lys Ser 260 265 270 Lys Val Ser Glu Gln Arg Tyr Arg
Asn Glu Met Glu Asn Leu Gly Tyr 275 280 285 Val 71870DNAHomo
sapiens 7ctccgagacg ggtggggccg gagctccaag ctggtttgaa caagccctgg
gcatgtttgg 60cgggaagttg gcttagctcg gctacctgtg gccccgcagt tttgtagtcc
ccgccttgtt 120tctccccaga ggcctctcaa tcctccctcc atgatcttcg
catagagcac agtacccctt 180cacacggagg acgcgatggc tcccaagaaa
cgcccagaaa cccagaagac ctccgagatt 240gtattacgcc ccaggaacaa
gaggagcagg agtcccctgg agctggagcc cgaggccaag 300aagctctgtg
cgaagggctc cggtcctagc agaagatgtg actcagactg cctctgggtg
360gggctggctg gcccacagat cctgccacca tgccgcagca tcgtcaggac
cctccaccag 420cataagctgg gcagagcttc ctggccatct gtccagcagg
ggctccagca gtcctttttg 480cacactctgg attcttaccg gatattacaa
aaggctgccc cctttgacag gagggctaca 540tccttggcgt ggcacccaac
tcaccccagc accgtggctg tgggttccaa agggggagat 600atcatgctct
ggaattttgg catcaaggac aaacccacct tcatcaaagg gattggagct
660ggagggagca tcactgggct gaagtttaac cctctcaata ccaaccagtt
ttacgcctcc 720tcaatggagg gaacaactag gctgcaagac tttaaaggca
acattctacg agtttttgcc 780agctcagaca ccatcaacat ctggttttgt
agcctggatg tgtctgctag tagccgaatg 840gtggtcacag gagacaacgt
ggggaacgtg atcctgctga acatggacgg caaagagctt 900tggaatctca
gaatgcacaa aaagaaagtg acgcatgtgg ccctgaaccc atgctgtgat
960tggttcctgg ccacagcctc cgtagatcaa acagtgaaaa tttgggacct
gcgccaggtt 1020agagggaaag ccagcttcct ctactcgctg ccgcacaggc
atcctgtcaa cgcagcttgt 1080ttcagtcccg atggagcccg gctcctgacc
acggaccaga agagcgagat ccgagtttac 1140tctgcttccc agtgggactg
ccccctgggc ctgatcccgc accctcaccg tcacttccag 1200cacctcacac
ccatcaaggc agcctggcat cctcgctaca acctcattgt tgtgggccga
1260tacccagatc ctaatttcaa aagttgtacc ccttatgaat tgaggacgat
cgacgtgttc 1320gatggaaact cagggaagat gatgtgtcag ctctatgacc
cagaatcttc tggcatcagt 1380tcgcttaatg aattcaatcc catgggggac
acgctggcct ctgcaatggg ttaccacatt 1440ctcatctgga gccaggagga
agccaggaca cggaagtgag agacactaaa gaaggtgtgg 1500gccagacaag
gccttggagc ccacacatgg gatcaagtcc tgcaagcaga ggtggcgatt
1560tgttaaaggg ccaaaagtat ccaaggttag ggttggagca ggggtgctgg
gacctggggc 1620actgtgggac tgggacactt ttatgttaat gctctggact
tgcctccaga gactgctcca 1680gagttggtga cacagctgtc ccaagggccc
ctctgtatct agcctggaac caaggttatc 1740ttggaactaa atgacttttc
tcctctcagt gggtggtagc agagggatca agcagttatt 1800tgatttgtgc
tcacttttga tatggccaat aaaaccatac cgactgagaa aaaaaaaaaa
1860aaaaaaaaaa 18708427PRTHomo sapiens 8Met Ala Pro Lys Lys Arg Pro
Glu Thr Gln Lys Thr Ser Glu Ile Val 1 5 10 15 Leu Arg Pro Arg Asn
Lys Arg Ser Arg Ser Pro Leu Glu Leu Glu Pro 20 25 30 Glu Ala Lys
Lys Leu Cys Ala Lys Gly Ser Gly Pro Ser Arg Arg Cys 35 40 45 Asp
Ser Asp Cys Leu Trp Val Gly Leu Ala Gly Pro Gln Ile Leu Pro 50 55
60 Pro Cys Arg Ser Ile Val Arg Thr Leu His Gln His Lys Leu Gly Arg
65 70 75 80 Ala Ser Trp Pro Ser Val Gln Gln Gly Leu Gln Gln Ser Phe
Leu His 85 90 95 Thr Leu Asp Ser Tyr Arg Ile Leu Gln Lys Ala Ala
Pro Phe Asp Arg 100 105 110 Arg Ala Thr Ser Leu Ala Trp His Pro Thr
His Pro Ser Thr Val Ala 115 120 125 Val Gly Ser Lys Gly Gly Asp Ile
Met Leu Trp Asn Phe Gly Ile Lys 130 135 140 Asp Lys Pro Thr Phe Ile
Lys Gly Ile Gly Ala Gly Gly Ser Ile Thr 145 150 155 160 Gly Leu Lys
Phe Asn Pro Leu Asn Thr Asn Gln Phe Tyr Ala Ser Ser 165 170 175 Met
Glu Gly Thr Thr Arg Leu Gln Asp Phe Lys Gly Asn Ile Leu Arg 180 185
190 Val Phe Ala Ser Ser Asp Thr Ile Asn Ile Trp Phe Cys Ser Leu Asp
195 200 205 Val Ser Ala Ser Ser Arg Met Val Val Thr Gly Asp Asn Val
Gly Asn 210 215 220 Val Ile Leu Leu Asn Met Asp Gly Lys Glu Leu Trp
Asn Leu Arg Met 225 230 235 240 His Lys Lys Lys Val Thr His Val Ala
Leu Asn Pro Cys Cys Asp Trp 245 250 255 Phe Leu Ala Thr Ala Ser Val
Asp Gln Thr Val Lys Ile Trp Asp Leu 260 265 270 Arg Gln Val Arg Gly
Lys Ala Ser Phe Leu Tyr Ser Leu Pro His Arg 275 280 285 His Pro Val
Asn Ala Ala Cys Phe Ser Pro Asp Gly Ala Arg Leu Leu 290 295 300 Thr
Thr Asp Gln Lys Ser Glu Ile Arg Val Tyr Ser Ala Ser Gln Trp 305 310
315 320 Asp Cys Pro Leu Gly Leu Ile Pro His Pro His Arg His Phe Gln
His 325 330 335 Leu Thr Pro Ile Lys Ala Ala Trp His Pro Arg Tyr Asn
Leu Ile Val 340 345 350 Val Gly Arg Tyr Pro Asp Pro Asn Phe Lys Ser
Cys Thr Pro Tyr Glu 355 360 365 Leu Arg Thr Ile Asp Val Phe Asp Gly
Asn Ser Gly Lys Met Met Cys 370 375 380 Gln Leu Tyr Asp Pro Glu Ser
Ser Gly Ile Ser Ser Leu Asn Glu Phe 385 390 395 400 Asn Pro Met Gly
Asp Thr Leu Ala Ser Ala Met Gly Tyr His Ile Leu 405 410 415 Ile Trp
Ser Gln Glu Glu Ala Arg Thr Arg Lys 420 425 91936DNAHomo sapiens
9gcttgtgggc gggcccgggc aggagcgggc ttgccctgcg gagcagtagc taggaacaga
60tccacttgca ggttgctgtt cccagccatg gcttcgcgct gctggcgctg gtggggctgg
120tcggcgtggc ctcggacccg gctgcctccc gccgggagca ccccgagctt
ctgccaccat 180ttctccacac aggagaagac cccccagatc tgtgtggtgg
gcagtggccc agctggcttc 240tacacggccc aacacctgct aaagcacccc
caggcccacg tggacatcta cgagaaacag 300cctgtgccct ttggcctggt
gcgctttggt gtggcgcctg
atcaccccga ggtgaagaat 360gtcatcaaca catttaccca gacggcccat
tctggccgct gtgccttctg gggcaacgtg 420gaggtgggca gggacgtgac
ggtgccggag ctgcgggagg cctaccacgc tgtggtgctg 480agctacgggg
cagaggacca tcgggccctg gaaattcctg gtgaggagct gccaggtgtg
540tgctccgccc gggccttcgt gggctggtac aacgggcttc ctgagaacca
ggagctggag 600ccagacctga gctgtgacac agccgtgatt ctggggcagg
ggaacgtggc tctggacgtg 660gcccgcatcc tactgacccc acctgagcac
ctggaggccc tccttttgtg ccagagaacg 720gacatcacga aggcagccct
gggtgtactg aggcagagtc gagtgaagac agtgtggcta 780gtgggccggc
gtggacccct gcaagtggcc ttcaccatta aggagcttcg ggagatgatt
840cagttaccgg gagcccggcc cattttggat cctgtggatt tcttgggtct
ccaggacaag 900atcaaggagg tcccccgccc gaggaagcgg ctgacggaac
tgctgcttcg aacggccaca 960gagaagccag ggccggcgga agctgcccgc
caggcatcgg cctcccgtgc ctggggcctc 1020cgctttttcc gaagccccca
gcaggtgctg ccctcaccag atgggcggcg ggcagcaggt 1080gtccgcctag
cagtcactag actggagggt gtcgatgagg ccacccgtgc agtgcccacg
1140ggagacatgg aagacctccc ttgtgggctg gtgctcagca gcattgggta
taagagccgc 1200cctgtcgacc caagcgtgcc ctttgactcc aagcttgggg
tcatccccaa tgtggagggc 1260cgggttatgg atgtgccagg cctctactgc
agcggctggg tgaagagagg acctacaggt 1320gtcatagcca caaccatgac
tgacagcttc ctcaccggcc agatgctgct gcaggacctg 1380aaggctgggt
tgctcccctc tggccccagg cctggctacg cagccatcca ggccctgctc
1440agcagccgag gggtccggcc agtctctttc tcagactggg agaagctgga
tgccgaggag 1500gtggcccggg gccagggcac ggggaagccc agggagaagc
tggtggatcc tcaggagatg 1560ctgcgcctcc tgggccactg agcccagccc
cagccccggc ccccagcagg gaagggatga 1620gtgttgggag gggaagggct
gggtccgtct gagtgggact ttgcacctct gctgatcccg 1680gccggccctg
gcttggaggc ttggctgctc ttccagcgtc tctcctccct cctggggaag
1740gtcgcccttg cgcgcaaggt tttagctttc agcaactgag gtaaccttag
ggacaggtgg 1800aggtgtgggc cgatctaacc ccttacccat ctctctactg
ctggactgtg gagggtcacc 1860aggttgggaa catgctggaa ataaaacagc
tgcaaccaag aaaaaaaaaa aaaaaaaaaa 1920aaaaaaaaaa aaaaaa
193610497PRTHomo sapiens 10Met Ala Ser Arg Cys Trp Arg Trp Trp Gly
Trp Ser Ala Trp Pro Arg 1 5 10 15 Thr Arg Leu Pro Pro Ala Gly Ser
Thr Pro Ser Phe Cys His His Phe 20 25 30 Ser Thr Gln Glu Lys Thr
Pro Gln Ile Cys Val Val Gly Ser Gly Pro 35 40 45 Ala Gly Phe Tyr
Thr Ala Gln His Leu Leu Lys His Pro Gln Ala His 50 55 60 Val Asp
Ile Tyr Glu Lys Gln Pro Val Pro Phe Gly Leu Val Arg Phe 65 70 75 80
Gly Val Ala Pro Asp His Pro Glu Val Lys Asn Val Ile Asn Thr Phe 85
90 95 Thr Gln Thr Ala His Ser Gly Arg Cys Ala Phe Trp Gly Asn Val
Glu 100 105 110 Val Gly Arg Asp Val Thr Val Pro Glu Leu Arg Glu Ala
Tyr His Ala 115 120 125 Val Val Leu Ser Tyr Gly Ala Glu Asp His Arg
Ala Leu Glu Ile Pro 130 135 140 Gly Glu Glu Leu Pro Gly Val Cys Ser
Ala Arg Ala Phe Val Gly Trp 145 150 155 160 Tyr Asn Gly Leu Pro Glu
Asn Gln Glu Leu Glu Pro Asp Leu Ser Cys 165 170 175 Asp Thr Ala Val
Ile Leu Gly Gln Gly Asn Val Ala Leu Asp Val Ala 180 185 190 Arg Ile
Leu Leu Thr Pro Pro Glu His Leu Glu Ala Leu Leu Leu Cys 195 200 205
Gln Arg Thr Asp Ile Thr Lys Ala Ala Leu Gly Val Leu Arg Gln Ser 210
215 220 Arg Val Lys Thr Val Trp Leu Val Gly Arg Arg Gly Pro Leu Gln
Val 225 230 235 240 Ala Phe Thr Ile Lys Glu Leu Arg Glu Met Ile Gln
Leu Pro Gly Ala 245 250 255 Arg Pro Ile Leu Asp Pro Val Asp Phe Leu
Gly Leu Gln Asp Lys Ile 260 265 270 Lys Glu Val Pro Arg Pro Arg Lys
Arg Leu Thr Glu Leu Leu Leu Arg 275 280 285 Thr Ala Thr Glu Lys Pro
Gly Pro Ala Glu Ala Ala Arg Gln Ala Ser 290 295 300 Ala Ser Arg Ala
Trp Gly Leu Arg Phe Phe Arg Ser Pro Gln Gln Val 305 310 315 320 Leu
Pro Ser Pro Asp Gly Arg Arg Ala Ala Gly Val Arg Leu Ala Val 325 330
335 Thr Arg Leu Glu Gly Val Asp Glu Ala Thr Arg Ala Val Pro Thr Gly
340 345 350 Asp Met Glu Asp Leu Pro Cys Gly Leu Val Leu Ser Ser Ile
Gly Tyr 355 360 365 Lys Ser Arg Pro Val Asp Pro Ser Val Pro Phe Asp
Ser Lys Leu Gly 370 375 380 Val Ile Pro Asn Val Glu Gly Arg Val Met
Asp Val Pro Gly Leu Tyr 385 390 395 400 Cys Ser Gly Trp Val Lys Arg
Gly Pro Thr Gly Val Ile Ala Thr Thr 405 410 415 Met Thr Asp Ser Phe
Leu Thr Gly Gln Met Leu Leu Gln Asp Leu Lys 420 425 430 Ala Gly Leu
Leu Pro Ser Gly Pro Arg Pro Gly Tyr Ala Ala Ile Gln 435 440 445 Ala
Leu Leu Ser Ser Arg Gly Val Arg Pro Val Ser Phe Ser Asp Trp 450 455
460 Glu Lys Leu Asp Ala Glu Glu Val Ala Arg Gly Gln Gly Thr Gly Lys
465 470 475 480 Pro Arg Glu Lys Leu Val Asp Pro Gln Glu Met Leu Arg
Leu Leu Gly 485 490 495 His 111084DNAHomo sapiens 11tagagcagac
aagcccgccc cgccgctcct cccagcagct tctatcccgg aagttgatgc 60cgagcgcaga
tcgcttgcag cttgctagct gtgtgggctg ggaggtctgg tagggctgag
120cttgcaagag gatcaacatg cctttggcta gagatttact acatccgtcc
ttggaagagg 180aaaagaaaaa acataaaaag aaacgcctag tacaaagtcc
aaattcttac tttatggatg 240taaaatgtcc aggttgctac aagatcacca
cggttttcag ccatgctcag acagtggttc 300tttgtgtagg ttgttcaaca
gtgttgtgcc agcctacagg aggaaaggcc agactcacag 360aagggtgttc
atttagaaga aagcaacact aatgattcaa acagcttcct gaattttaat
420tttgtgttgt ctcacagaaa gccttatcat aaattccata attctaatta
atttaccaag 480ataatgtaat tacatttggt tttgtaaggt atacagcagt
aatctcctat tttggtgtca 540gtttttcaat aaagttttga ttatgggcaa
atcccctctt tttctttttt taaaatatat 600ttgagtatgc catacattta
tatatatggt gtatatgaat ttggtttaaa cattttaaaa 660tttattctga
ttagtttgtg tctttttttt tttttttgag agagagagtc ctgctctgtc
720actcaagctg gagtgcagtg gtgcgatctc ggctcactgc aacctccgcc
tcccaggtcc 780aagcaattct cttgccttgt cctcccaagt agctgggatt
ataggcacac accaccatgc 840ctggctaatt tgtgtctcat tttcaagagt
agaaacccta aatattttat tttcattcct 900tttccaaatt gctatgaatg
ggattaaagg attacagatg taaagtctat tatttgtgaa 960ttctaaatgt
agttctgctg ttgtacctgt ggaaacatct taaagaagta catattttgc
1020acgtcctgca cgtgtacccc agaacttaaa ctataattaa aaagaatagt
ttcaaaaaaa 1080taca 10841284PRTHomo sapiens 12Met Pro Leu Ala Arg
Asp Leu Leu His Pro Ser Leu Glu Glu Glu Lys 1 5 10 15 Lys Lys His
Lys Lys Lys Arg Leu Val Gln Ser Pro Asn Ser Tyr Phe 20 25 30 Met
Asp Val Lys Cys Pro Gly Cys Tyr Lys Ile Thr Thr Val Phe Ser 35 40
45 His Ala Gln Thr Val Val Leu Cys Val Gly Cys Ser Thr Val Leu Cys
50 55 60 Gln Pro Thr Gly Gly Lys Ala Arg Leu Thr Glu Gly Cys Ser
Phe Arg 65 70 75 80 Arg Lys Gln His 13891DNAHomo sapiens
13tcacgtgacc cgggcgcgct gcggccgccc gcgcggaccc ggcgagaggc ggcggcggga
60gcggcggtga tggacgggtc cggggagcag cccagaggcg gggggcccac cagctctgag
120cagatcatga agacaggggc ccttttgctt cagggtttca tccaggatcg
agcagggcga 180atgggggggg aggcacccga gctggccctg gacccggtgc
ctcaggatgc gtccaccaag 240aagctgagcg agtgtctcaa gcgcatcggg
gacgaactgg acagtaacat ggagctgcag 300aggatgattg ccgccgtgga
cacagactcc ccccgagagg tctttttccg agtggcagct 360gacatgtttt
ctgacggcaa cttcaactgg ggccgggttg tcgccctttt ctactttgcc
420agcaaactgg tgctcaaggc cctgtgcacc aaggtgccgg aactgatcag
aaccatcatg 480ggctggacat tggacttcct ccgggagcgg ctgttgggct
ggatccaaga ccagggtggt 540tgggtgagac tcctcaagcc tcctcacccc
caccaccgcg ccctcaccac cgcccctgcc 600ccaccgtccc tgccccccgc
cactcctctg ggaccctggg ccttctggag caggtcacag 660tggtgccctc
tccccatctt cagatcatca gatgtggtct ataatgcgtt ttccttacgt
720gtctgatcaa tccccgattc atctaccctg ctgacctccc agtgacccct
gacctcactg 780tgaccttgac ttgattagtg ccttctgccc tccctggagc
ctccactgcc tctggaattg 840ctcaagttca ttgatgaccc tctgacccta
gctctttcct tttttttttt t 89114218PRTHomo sapiens 14Met Asp Gly Ser
Gly Glu Gln Pro Arg Gly Gly Gly Pro Thr Ser Ser 1 5 10 15 Glu Gln
Ile Met Lys Thr Gly Ala Leu Leu Leu Gln Gly Phe Ile Gln 20 25 30
Asp Arg Ala Gly Arg Met Gly Gly Glu Ala Pro Glu Leu Ala Leu Asp 35
40 45 Pro Val Pro Gln Asp Ala Ser Thr Lys Lys Leu Ser Glu Cys Leu
Lys 50 55 60 Arg Ile Gly Asp Glu Leu Asp Ser Asn Met Glu Leu Gln
Arg Met Ile 65 70 75 80 Ala Ala Val Asp Thr Asp Ser Pro Arg Glu Val
Phe Phe Arg Val Ala 85 90 95 Ala Asp Met Phe Ser Asp Gly Asn Phe
Asn Trp Gly Arg Val Val Ala 100 105 110 Leu Phe Tyr Phe Ala Ser Lys
Leu Val Leu Lys Ala Leu Cys Thr Lys 115 120 125 Val Pro Glu Leu Ile
Arg Thr Ile Met Gly Trp Thr Leu Asp Phe Leu 130 135 140 Arg Glu Arg
Leu Leu Gly Trp Ile Gln Asp Gln Gly Gly Trp Val Arg 145 150 155 160
Leu Leu Lys Pro Pro His Pro His His Arg Ala Leu Thr Thr Ala Pro 165
170 175 Ala Pro Pro Ser Leu Pro Pro Ala Thr Pro Leu Gly Pro Trp Ala
Phe 180 185 190 Trp Ser Arg Ser Gln Trp Cys Pro Leu Pro Ile Phe Arg
Ser Ser Asp 195 200 205 Val Val Tyr Asn Ala Phe Ser Leu Arg Val 210
215 154932DNAHomo sapiens 15ggctggccga agttaggcgg agccccgagg
cgggggaggc ggggccgggc cggcgcaggg 60agagtcactc aatggacagg cgagaaagca
ggaccggcgc ggcggggcgg ggccggccga 120gtccctagag ctgggggcgg
ggcggaccca gcggaccagc ggaccacctg ggtgctgtcg 180tagttggagg
tggcctgagg agctcagttc cctcagcgcc cgtagcttcg gcggagtctg
240cgcgatgggc gacccggaaa ggccggaagc ggccgggctg gatcaggatg
agagatcatc 300ttcagacacc aacgaaagtg aaataaagtc aaatgaagag
ccactcctaa gaaagagttc 360tcgccggttt gtcatctttc caatccagta
ccctgatatt tggaaaatgt ataaacaggc 420acaggcttcc ttctggacag
cagaagaggt cgacttatca aaggatctcc ctcactggaa 480caagcttaaa
gcagatgaga agtacttcat ctctcacatc ttagcctttt ttgcagccag
540tgatggaatt gtaaatgaaa atttggtgga gcgctttagt caggaggtgc
aggttccaga 600ggctcgctgt ttctatggct ttcaaattct catcgagaat
gttcactcag agatgtacag 660tttgctgata gacacttaca tcagagatcc
caagaaaagg gaatttttat ttaatgcaat 720tgaaaccatg ccctatgtta
agaaaaaagc agattgggcc ttgcgatgga tagcagatag 780aaaatctact
tttggggaaa gagtggtggc ctttgctgct gtagaaggag ttttcttctc
840aggatctttt gctgctatat tctggctaaa gaagagaggt cttatgccag
gactcacttt 900ttccaatgaa ctcatcagca gagatgaagg acttcactgt
gactttgctt gcctgatgtt 960ccaatactta gtaaataagc cttcagaaga
aagggtcagg gagatcattg ttgatgctgt 1020caaaattgag caggagtttt
taacagaagc cttgccagtt ggcctcattg gaatgaattg 1080cattttgatg
aaacagtaca ttgagtttgt agctgacaga ttacttgtgg aacttggatt
1140ctcaaaggtt tttcaggcag aaaatccttt tgattttatg gaaaacattt
ctttagaagg 1200aaaaacaaat ttctttgaga aacgagtttc agagtatcag
cgttttgcag ttatggcaga 1260aaccacagat aacgtcttca ccttggatgc
agatttttaa aaaacctctc gttttaaaac 1320tctataaact tgtcattggt
aaatagtagt ctattttcct ctgcttaaaa aaaattttaa 1380gtatatcctt
taaaggactg ggggtttgct caaaaggaaa tccaaaacct attctaaaca
1440atttgcattt atataatttt cctgtttaac aacaagagtg tgacctaaat
gcttttgtct 1500tgtcactgaa ataaaagatg gcattatgtg gttaagagca
tggggcgagg ggtcagacat 1560gagtctaagg ttctgccctt actccagtgt
gtgacccttg gcaagtcagt taatcttggt 1620aaacctcggt gtacttatct
ttaaaatggg agtaatagta ggtcctaaat tcatagagtg 1680gatattagga
ttaggatgca aaaataaatg cttaaccaac actactactg ttagcaccac
1740tactaattat cattcattga taatattaat tgcaatgatg ttgtaataaa
atactctcat 1800ttccttaaaa taattgtgat tctaggtcct aggatctaga
attagatctt tgtattttta 1860atgcttaggg gaagaatata agtatctcct
taaaaagaac ataattctca ttcacgcaag 1920aataagttct ttgaattcct
tagtatgtag tgaagaaaat ttagttgtta gttgctttgg 1980gaagcctact
tatggagtgg aaaccaggag gttatcatgg tagttgacct tataagaaaa
2040atgattcttc ttcagaaatt aaaaacataa ctattgccag atttagctct
ggaatgttta 2100gaatcaggct agaatagcat tttccaaaga atattctaag
agctattagc tcctctagat 2160atttttttgg gggaaaaagg ggattctgtg
gtcagatgag tttgggaaat gctgaacact 2220tcattcttct ttagcaagta
cagtcagtac atcaaagact gagcagttca gtggtacata 2280aatttatctc
gccctgcata ttcccaacat acttaacaca gatgtttttt acctgttaac
2340atctcaccca gctagtgttc ctcagaacaa agattggaaa aagctggccg
agaaccattt 2400atacatagag gaagggctta tggactgaga aagggagaac
atggtaggga ttattgaatc 2460atttcaaatt tataccagcc tgaatagtgt
accagcaatt gacttaggct gtgtttcttt 2520atggttttaa aactcttgag
ctgttataag agatagttct tttaatgtga ctatgcaaca 2580tgatagccaa
tggtgaggga aaaggaggtt tctctagaag agtctgatga aaggccggga
2640accaaggttt ttgagaagtc tgcccctatt tatttttagt aagtatcaag
aggtagcctg 2700agcctagtta gagttagacc tgtctttgga tgaagaagtc
ttaatactga aatactgaat 2760ttttaataca ttattatttg gtattctgta
taccccttca agcagttgtt tcccattccc 2820aacaaactgt actttataca
attctggatg ctaaaactta gagattttct ctttgcataa 2880attttggctc
cattctttcc ataacaatct aatcaaaact gggagttctc aagtgaatgc
2940aaaaggagca ggccataact ttatttgtta gatacactgt cagaaacttg
agatcttttg 3000gcctatgata ataccattaa tttttgcatt gcttcagttt
gccaagtgtt tttacatcat 3060ctcatttgat ctcaaaacag cttgacagag
caactgttat tgaaatatta cagatggaaa 3120gaatgaggct cagggaagtt
aaatgacttg gccaagatct gctcatcgtc actgtctgta 3180cagtattttt
ttttagaggt tgtaatgtct cagatttagt cctttaccat ctatgttgat
3240ttgcttttgt ctatttcctc attaattgaa tatactttaa atatatatat
taaagtatca 3300aaatatagag agacatttga actgtattca ggtaatatgt
ttaaagatat ttatatattg 3360ccatacaaaa acttaacatt taaaactgat
aatatctgta atgacatcag aatgaaagaa 3420aaaaaattgt acagtgtata
ttcctttgtt ttgaatccaa atctttttca taggtaatga 3480cagatgcctt
aatgtgaagc ttatttataa tagcaataaa cctaactgga tttggatgaa
3540gaagtcttaa tactgacata ctggattttt aatgcactgg tttgttattt
ggtattctat 3600ctctttttcc aggcctccag gttgcacatt tatttattat
gttcaatact ttggttctta 3660gttcttaaag aatcaagaag ttgtgtaatc
ttttaaaaat attatcttgc agataaagaa 3720aaaaattaag agtgtgttta
caactgtttt ctctttttta cagtacatgt atttaaatca 3780ttgctataat
aaagttaagt tcattaggaa tataaaaact tgcagttcta tgatagattg
3840catttattaa aaatgtttca ttgtatcaca tagaaatatg gccaggaagg
acttgagaag 3900acagtttgat ccattgcttt tagacaggac tgggttttgc
tgtccaatta tatacaataa 3960tagtttttct tacaactaag ctggccccag
ccttgtcttg atattaatac atgaaatttt 4020tataattgtc tcattgtctc
atttagaaac atccatattt ttctgctttt tctattgcca 4080ttttttattt
gtgcatgaat tgattattga gaaaatgtag cagtttgcat atttaaaaat
4140taatcatttt gcattttaca tttaaatatg ctaacatcac tgtcatagaa
ttcccaaatt 4200tcatttgtag atactgaact aagggctaat gtcaggagct
gatttttaat gataaagctg 4260cagatgggct aaataaaagc caaattaatc
ctacaatcag gtattatgtt tttaaaccaa 4320gttgagtgaa ttggtagtgg
acttgggaaa tcttccccag cagaatctgg atgaatggca 4380cagaattgaa
atctctttgt ttcccaccat ttccctttaa gtgctctgct cctttgtaaa
4440aagttaaaga tttgaaagag aatctcatat tcccgaggca ttaggaagaa
aggatttaat 4500cccttcaatt tggggcttaa tcttgtttaa aaaaatgtaa
gtgaagatgg aaggctggag 4560agaatgattg ctttttgtac agttaaataa
ggtcacaata ttcttacata ctttgtttta 4620caactgtgtt ttcatttttt
caaatgtctg gccatttagc aaagttattt actatttact 4680gtgtacatag
aaagctttat tatgtgtggt gtatctaaat tttttttgct gaaatacatt
4740atggtcaatc aagccaagcc tgcatgtaca gaatttgttt ttttttcaaa
taaattagtt 4800gttttcttat ttttttggct tagtatgttg aaataaacta
tggtatcttc atcattttgt 4860acatttcctt tttgaggaag gtttctttat
aagtgcaagg gctaccctaa taaaggaatg 4920tatatactta ct 493216351PRTHomo
sapiens 16Met Gly Asp Pro Glu Arg Pro Glu Ala Ala Gly Leu Asp Gln
Asp Glu 1 5 10 15 Arg Ser Ser Ser Asp Thr Asn Glu Ser Glu Ile Lys
Ser Asn Glu Glu 20 25 30 Pro Leu Leu Arg Lys Ser Ser Arg Arg Phe
Val Ile Phe Pro Ile Gln 35 40 45 Tyr Pro Asp Ile Trp Lys Met Tyr
Lys Gln Ala Gln Ala Ser Phe Trp 50 55 60 Thr Ala Glu Glu Val Asp
Leu Ser Lys Asp Leu Pro His Trp Asn Lys 65 70 75 80 Leu Lys Ala Asp
Glu Lys Tyr Phe Ile Ser His Ile Leu Ala Phe Phe 85 90 95 Ala Ala
Ser Asp Gly Ile Val Asn Glu Asn Leu Val Glu Arg Phe Ser 100 105 110
Gln Glu Val Gln Val Pro Glu Ala Arg Cys Phe Tyr Gly Phe Gln Ile 115
120 125 Leu Ile Glu Asn Val His Ser Glu Met Tyr Ser Leu Leu Ile Asp
Thr 130 135 140 Tyr Ile Arg Asp Pro Lys Lys Arg Glu Phe Leu Phe Asn
Ala Ile Glu 145 150 155 160 Thr Met Pro Tyr
Val Lys Lys Lys Ala Asp Trp Ala Leu Arg Trp Ile 165 170 175 Ala Asp
Arg Lys Ser Thr Phe Gly Glu Arg Val Val Ala Phe Ala Ala 180 185 190
Val Glu Gly Val Phe Phe Ser Gly Ser Phe Ala Ala Ile Phe Trp Leu 195
200 205 Lys Lys Arg Gly Leu Met Pro Gly Leu Thr Phe Ser Asn Glu Leu
Ile 210 215 220 Ser Arg Asp Glu Gly Leu His Cys Asp Phe Ala Cys Leu
Met Phe Gln 225 230 235 240 Tyr Leu Val Asn Lys Pro Ser Glu Glu Arg
Val Arg Glu Ile Ile Val 245 250 255 Asp Ala Val Lys Ile Glu Gln Glu
Phe Leu Thr Glu Ala Leu Pro Val 260 265 270 Gly Leu Ile Gly Met Asn
Cys Ile Leu Met Lys Gln Tyr Ile Glu Phe 275 280 285 Val Ala Asp Arg
Leu Leu Val Glu Leu Gly Phe Ser Lys Val Phe Gln 290 295 300 Ala Glu
Asn Pro Phe Asp Phe Met Glu Asn Ile Ser Leu Glu Gly Lys 305 310 315
320 Thr Asn Phe Phe Glu Lys Arg Val Ser Glu Tyr Gln Arg Phe Ala Val
325 330 335 Met Ala Glu Thr Thr Asp Asn Val Phe Thr Leu Asp Ala Asp
Phe 340 345 350 173212DNAHomo sapiens 17gaacccggtg gctgcacaga
caaaaaagcc ccgaatggct ggagggcgtt cagctgttaa 60cagccttttg gggcagagca
cggatttgac agctccacaa cgtgaggata tccactgacc 120ccgcgagacg
gaggagaacg cttccccgaa attctctgcc caccaaagcc agcgctgcaa
180ggttgcaact ttcaaacttt gtttttccag aaagaagact gccctttcgt
gtacaaggag 240agggtgagag ggtgacctag cttgtagatc ggctgaaggc
accagtggtt ccaaatgtca 300cccagatgtg tgttttcatg acgatttgat
ttctctgatt ttatttttac atttttcatt 360ttaaaaatac aaagcaattt
ttttggggca tgctgaaagg taactgaaga ccgcaaagga 420aaaactattg
tcatggctga aggagagaat gaagtgagat gggatggact ctgcagcaga
480gattcaacta ctagggagac agcattggaa aacattaggc aaaccatttt
gaggaaaacc 540gagtatcttc gttcggtgaa agaaacacct catcgtccat
cagacgggct ttcaaatacc 600gagtcttcgg atgggttgaa taagctactt
gctcatctgc ttatgctttc taagaggtgt 660cccttcaaag atgtgagaga
gaaaagtgag tttattctga agagcatcca ggaacttggc 720attagaattc
ctcgaccact aggacaggga ccaagcagat tcatcccaga aaaggagatc
780ctccaagtgg ggagtgaaga cgcacagatg catgctttat ttgcagattc
ttttgctgct 840ttgggccgtt tggataacat tacgttagtg atggttttcc
acccacaata tttagaaagt 900ttcttaaaaa ctcagcacta tctactgcaa
atggatgggc cgttacccct acattatcgt 960cactacattg gaataatggc
tgcggcaaga catcagtgct cctacttagt gaacctgcat 1020gtaaatgatt
tccttcatgt tggtggggac cccaagtggc tcaatggttt agagaatgct
1080cctcaaaaac tacagaattt aggagaactt aacaaagtgt tagcccatag
accttggctt 1140attaccaaag aacacattga gggactttta aaagctgaag
agcacagctg gtcccttgcg 1200gaattggtac atgcagtagt tttactcaca
cactatcatt ctcttgcctc attcacattc 1260ggctgtggaa tcagtccaga
aattcattgt gatggtggcc acacattcag acctccttct 1320gttagcaact
actgcatctg tgacattaca aatggcaatc acagtgtgga tgagatgccg
1380gtcaactcag cagaaaatgt ttctgtaagt gattctttct ttgaggttga
agccctcatg 1440gaaaagatga ggcagttaca ggaatgtcga gatgaagaag
aggcaagtca ggaagagatg 1500gcttcacgtt ttgaaataga aaaaagagag
agtatgtttg tcttctcttc agatgatgaa 1560gaagttacac cagcaagagc
tgtatctcgt cattttgagg atactagtta tggctataaa 1620gatttctcta
gacatgggat gcatgttcca acatttcgtg tccaggacta ttgctgggaa
1680gatcatggtt attctttggt aaatcgcctt tatccagatg tgggacagtt
gattgatgaa 1740aaatttcaca ttgcttacaa tcttacttat aatacaatgg
caatgcacaa agatgttgat 1800acctcaatgc ttagacgggc aatttggaac
tatattcact gcatgtttgg aataagatat 1860gatgattatg actatggtga
aattaaccag ctattggatc gtagctttaa agtttatatc 1920aaaactgttg
tttgcactcc tgaaaaggtt accaaaagaa tgtatgatag cttctggagg
1980cagttcaagc actctgagaa ggttcatgtt aatctgcttc ttatagaagc
taggatgcaa 2040gcagaactcc tttatgctct gagagccatt acccgctata
tgacctgatg cctttccttc 2100attaaagatg attctggaat gatcagcaga
tatagtctac aagggggaag gtactaagcc 2160ccaggaccaa tggtagacaa
aataattcag aaatccattg tgccatgatt cctttagttt 2220ctgctatttt
tctgtggaaa accactgctg gcacaagcag tgactgtttg gcagcttcaa
2280gtttagagct gtgaagacag gctgccattc acagtatttt gctttttgac
agtacaagat 2340gctgtgtaac tgttttaata cagcaaatag taactctcca
aatcctgttg cttttatgtt 2400aaataagata acaagaattg gagcatgcaa
agaatgggac ttggataatg acttaagctt 2460tatatgtaaa gaattttaga
agatcttggt gctgctattc ctgctggagg aatgaataga 2520tggctgtttc
agttaagcta ttagtaataa aagtgaacat tgctactatc tgagcctaca
2580tacataactt gtgtgatttc aaattaaact tgcattatgt gttaattttc
ttgcatctaa 2640aaaagcatag aattcctact cacacagctc agcaacaacc
attttgatgg taacagttaa 2700tttctttcat tagtttttta aattcagggt
tctggatatt aaattaaaat ggcattctta 2760aagattttct tcaaaaagca
atcctaaatg aaagtgtgta aattataaga agctggcgat 2820cttttgatat
gctgtttcac aggatcctga cactggaggg cagctgtctt gtgcattact
2880tgtgtttcca gcaccaaagt tgtgggacat gttgctgtag actgctgcgc
agtcctgggt 2940gcattcagtc tctctgcctc tgcctgcctc ctggtcccca
ctttaaaggc tgtgcagctc 3000cttaaataat aaagctggaa aatattttta
gtcgggttat caaatttgat ttacaaaaac 3060gctaactttg tttgaaatgc
aaacaggttt gaaaatatgt attaagtact ttgtattctg 3120gaagcgtgaa
ttgcttttga agtctgtcag tattactggt atttttaaat aaagaagaat
3180ttttctccaa ttttaaaaaa aaaaaaaaaa aa 321218551PRTHomo sapiens
18Met Ala Glu Gly Glu Asn Glu Val Arg Trp Asp Gly Leu Cys Ser Arg 1
5 10 15 Asp Ser Thr Thr Arg Glu Thr Ala Leu Glu Asn Ile Arg Gln Thr
Ile 20 25 30 Leu Arg Lys Thr Glu Tyr Leu Arg Ser Val Lys Glu Thr
Pro His Arg 35 40 45 Pro Ser Asp Gly Leu Ser Asn Thr Glu Ser Ser
Asp Gly Leu Asn Lys 50 55 60 Leu Leu Ala His Leu Leu Met Leu Ser
Lys Arg Cys Pro Phe Lys Asp 65 70 75 80 Val Arg Glu Lys Ser Glu Phe
Ile Leu Lys Ser Ile Gln Glu Leu Gly 85 90 95 Ile Arg Ile Pro Arg
Pro Leu Gly Gln Gly Pro Ser Arg Phe Ile Pro 100 105 110 Glu Lys Glu
Ile Leu Gln Val Gly Ser Glu Asp Ala Gln Met His Ala 115 120 125 Leu
Phe Ala Asp Ser Phe Ala Ala Leu Gly Arg Leu Asp Asn Ile Thr 130 135
140 Leu Val Met Val Phe His Pro Gln Tyr Leu Glu Ser Phe Leu Lys Thr
145 150 155 160 Gln His Tyr Leu Leu Gln Met Asp Gly Pro Leu Pro Leu
His Tyr Arg 165 170 175 His Tyr Ile Gly Ile Met Ala Ala Ala Arg His
Gln Cys Ser Tyr Leu 180 185 190 Val Asn Leu His Val Asn Asp Phe Leu
His Val Gly Gly Asp Pro Lys 195 200 205 Trp Leu Asn Gly Leu Glu Asn
Ala Pro Gln Lys Leu Gln Asn Leu Gly 210 215 220 Glu Leu Asn Lys Val
Leu Ala His Arg Pro Trp Leu Ile Thr Lys Glu 225 230 235 240 His Ile
Glu Gly Leu Leu Lys Ala Glu Glu His Ser Trp Ser Leu Ala 245 250 255
Glu Leu Val His Ala Val Val Leu Leu Thr His Tyr His Ser Leu Ala 260
265 270 Ser Phe Thr Phe Gly Cys Gly Ile Ser Pro Glu Ile His Cys Asp
Gly 275 280 285 Gly His Thr Phe Arg Pro Pro Ser Val Ser Asn Tyr Cys
Ile Cys Asp 290 295 300 Ile Thr Asn Gly Asn His Ser Val Asp Glu Met
Pro Val Asn Ser Ala 305 310 315 320 Glu Asn Val Ser Val Ser Asp Ser
Phe Phe Glu Val Glu Ala Leu Met 325 330 335 Glu Lys Met Arg Gln Leu
Gln Glu Cys Arg Asp Glu Glu Glu Ala Ser 340 345 350 Gln Glu Glu Met
Ala Ser Arg Phe Glu Ile Glu Lys Arg Glu Ser Met 355 360 365 Phe Val
Phe Ser Ser Asp Asp Glu Glu Val Thr Pro Ala Arg Ala Val 370 375 380
Ser Arg His Phe Glu Asp Thr Ser Tyr Gly Tyr Lys Asp Phe Ser Arg 385
390 395 400 His Gly Met His Val Pro Thr Phe Arg Val Gln Asp Tyr Cys
Trp Glu 405 410 415 Asp His Gly Tyr Ser Leu Val Asn Arg Leu Tyr Pro
Asp Val Gly Gln 420 425 430 Leu Ile Asp Glu Lys Phe His Ile Ala Tyr
Asn Leu Thr Tyr Asn Thr 435 440 445 Met Ala Met His Lys Asp Val Asp
Thr Ser Met Leu Arg Arg Ala Ile 450 455 460 Trp Asn Tyr Ile His Cys
Met Phe Gly Ile Arg Tyr Asp Asp Tyr Asp 465 470 475 480 Tyr Gly Glu
Ile Asn Gln Leu Leu Asp Arg Ser Phe Lys Val Tyr Ile 485 490 495 Lys
Thr Val Val Cys Thr Pro Glu Lys Val Thr Lys Arg Met Tyr Asp 500 505
510 Ser Phe Trp Arg Gln Phe Lys His Ser Glu Lys Val His Val Asn Leu
515 520 525 Leu Leu Ile Glu Ala Arg Met Gln Ala Glu Leu Leu Tyr Ala
Leu Arg 530 535 540 Ala Ile Thr Arg Tyr Met Thr 545 550
192484DNAHomo sapiens 19attcctcgtt agggcaggcg cggccccttc ggctccgagc
tgaccctgat cagggccgag 60ttgtctcggc ggcgctgccg aggcctccac ccaggacagt
ccccctcccc gggcctctct 120cctcttgcct acgagtcccc tctcctcgta
ggcctctcgg atctgatatc gtggggtgag 180gtgagcaggc ccggggaggg
tggttaccgc tgaggagctg cagtctctgt caagatgata 240gaggtactga
caacaactga ctctcagaaa ctgctacacc agctgaatgc cctgttggaa
300caggagtcta gatgtcagcc aaaggtctgt ggtttgagac taattgagtc
tgcacacgat 360aatggcctca gaatgactgc aagactaagg gactttgaag
taaaagatct tcttagtcta 420actcagttct ttggctttga cacagagaca
ttttctctag ctgtgaattt actggacaga 480ttcctgtcta aaatgaaggt
acagcccaag caccttgggt gtgttggact gagctgcttt 540tatttggctg
taaaatcaat agaagaggaa aggaatgtcc cattggcaac tgacttgatc
600cgaataagtc aatataggtt tacggtttca gacttgatga gaatggaaaa
gattgtattg 660gagaaggtgt gttggaaagt caaagctact actgcctttc
aatttctgca actgtattat 720tcactccttc aagagaactt gccacttgaa
aggagaaata gcattaattt tgaaagacta 780gaagctcaac tgaaggcatg
tcattgcagg atcatatttt ctaaagcaaa gccttctgtg 840ttggcattgt
ctatcattgc attagagatc caagcacaga agtgtgtaga gttaacagaa
900ggaatagaat gtcttcagaa acattccaag ataaatggca gagatctgac
cttctggcaa 960gagcttgtat ccaaatgttt aactgaatat tcatcaaata
agtgttccaa accaaatgtt 1020cagaagttga aatggattgt ttctgggcgt
actgcacggc aattgaagca tagctactac 1080agaataactc accttccaac
aattcctgaa atggtccctt aactggatta ttacagcacc 1140aaaaaacttc
tctgaagcct ttctccacaa ccttgttcta tggattccat aatgttacaa
1200tggatttaag ctatgaagcc tcaaaacatc acgagataag catgatggtc
tcagacttgg 1260gaaaactgcc taatattatg ctgtagtgga attatgttta
gatttgaatt catctgtgaa 1320gcattcaaat caaagctaaa agcctaaatg
tgaaatgcta atgacaagcc tgagaaggta 1380aactgtgaat cttcatttct
atcattgatc taactttaga tattggatca atatatttag 1440gtggtattga
aaatgctatt ggaggagtca cactaatact atcaactatc agtcttccca
1500cagcttcaat cactgtcatt attctaatcc tactcctact taaattttaa
gttatgaggt 1560ttatgtcaaa agcaacattt cacaaatgta cttttaaggc
ataataaggg ttaacattct 1620aggcagtata aacacacccc ataatgcaag
taataggtaa tctagagatg tggactttat 1680tgctatatgg gaattacatt
taaatttgag ggcattttat ataaagaaaa atacagacct 1740ataaagtttg
gcatattcat taagttatct tttaatattt ttttctagaa aacaggtgac
1800atttgtatct acgataaaaa tttttataca gaacctactg cctcaaactg
aatcccatca 1860agaaaactag tttctattgt attagtaact caaaataaat
tatcacttcg aaaacttgct 1920ttcccacact aaggtaagtt cagactagat
tgaacactcc agaatttttt actacagact 1980gtttttaagt tagaagtgat
ggcaatttta taaatagaga atatacttcc actgatgccc 2040ttactgtgcc
aaaacaaaaa tcttaagaaa agcaagtaga caccttcata actatgaatg
2100aagctgctga agtagtgttt aggatcctcc atggcagtta gtgaatgtaa
gaagtacagt 2160gttaaagtgt tgtaaacagt tactcagtgc aatgtatagc
ctgagtctat ccatgatggc 2220tatatccaat ttgacatcac gttatggatc
agtacacaat gaaaaaccaa agaaccacag 2280tatatcttat tcttaacttt
tgtaaaccat gttttatggg taacttttta gttttcccaa 2340aaggctgata
aatttcaata ttttgaatac atcattgtta attttgagtt ggcagaggta
2400aactaaccaa ctaccattat gttttagtac taagggatat acctttcaat
aaagttaatg 2460aaattcaaaa aaaaaaaaaa aaaa 248420295PRTHomo sapiens
20Met Ile Glu Val Leu Thr Thr Thr Asp Ser Gln Lys Leu Leu His Gln 1
5 10 15 Leu Asn Ala Leu Leu Glu Gln Glu Ser Arg Cys Gln Pro Lys Val
Cys 20 25 30 Gly Leu Arg Leu Ile Glu Ser Ala His Asp Asn Gly Leu
Arg Met Thr 35 40 45 Ala Arg Leu Arg Asp Phe Glu Val Lys Asp Leu
Leu Ser Leu Thr Gln 50 55 60 Phe Phe Gly Phe Asp Thr Glu Thr Phe
Ser Leu Ala Val Asn Leu Leu 65 70 75 80 Asp Arg Phe Leu Ser Lys Met
Lys Val Gln Pro Lys His Leu Gly Cys 85 90 95 Val Gly Leu Ser Cys
Phe Tyr Leu Ala Val Lys Ser Ile Glu Glu Glu 100 105 110 Arg Asn Val
Pro Leu Ala Thr Asp Leu Ile Arg Ile Ser Gln Tyr Arg 115 120 125 Phe
Thr Val Ser Asp Leu Met Arg Met Glu Lys Ile Val Leu Glu Lys 130 135
140 Val Cys Trp Lys Val Lys Ala Thr Thr Ala Phe Gln Phe Leu Gln Leu
145 150 155 160 Tyr Tyr Ser Leu Leu Gln Glu Asn Leu Pro Leu Glu Arg
Arg Asn Ser 165 170 175 Ile Asn Phe Glu Arg Leu Glu Ala Gln Leu Lys
Ala Cys His Cys Arg 180 185 190 Ile Ile Phe Ser Lys Ala Lys Pro Ser
Val Leu Ala Leu Ser Ile Ile 195 200 205 Ala Leu Glu Ile Gln Ala Gln
Lys Cys Val Glu Leu Thr Glu Gly Ile 210 215 220 Glu Cys Leu Gln Lys
His Ser Lys Ile Asn Gly Arg Asp Leu Thr Phe 225 230 235 240 Trp Gln
Glu Leu Val Ser Lys Cys Leu Thr Glu Tyr Ser Ser Asn Lys 245 250 255
Cys Ser Lys Pro Asn Val Gln Lys Leu Lys Trp Ile Val Ser Gly Arg 260
265 270 Thr Ala Arg Gln Leu Lys His Ser Tyr Tyr Arg Ile Thr His Leu
Pro 275 280 285 Thr Ile Pro Glu Met Val Pro 290 295 213729DNAHomo
sapiens 21cgaaggggcg tggccaagcg caccgcctcg gggcggggcc ggcgttctag
cgcatcgcgg 60ccgggtgcgt cactcgcgaa gtggaatttg cccagacaag caacatggct
cggaaacgcg 120cggccggcgg ggagccgcgg ggacgcgaac tgcgcagcca
gaaatccaag gccaagagca 180aggcccggcg tgaggaggag gaggaggatg
cctttgaaga tgagaaaccc ccaaagaaga 240gccttctctc caaagtttca
caaggaaaga ggaaaagagg ctgcagtcat cctgggggtt 300cagcagatgg
tccagcaaaa aagaaagtgg ccaaggtgac tgttaaatct gaaaacctca
360aggttataaa ggatgaagcc ctcagcgatg gggatgacct cagggacttt
ccaagtgacc 420tcaagaaggc acaccatctg aagagagggg ctaccatgaa
tgaagacagc aatgaagaag 480aggaagaaag tgaaaatgat tgggaagagg
ttgaagaact tagtgagcct gtgctgggtg 540acgtgagaga aagtacagcc
ttctctcgat ctcttctgcc tgtgaagcca gtggagatag 600agattgaaac
gccagagcag gcgaagacaa gagaaagaag tgaaaagata aaactggagt
660ttgagacata tcttcggagg gcgatgaaac gtttcaataa aggggtccat
gaggacacac 720acaaggttca ccttctctgc ctgctagcaa atggcttcta
tcgaaataac atctgcagcc 780agccagatct gcatgctatt ggcctgtcca
tcatcccagc ccgctttacc agagtgctgc 840ctcgagatgt ggacacctac
tacctctcaa acctggtgaa gtggttcatt ggaacattta 900cagttaatgc
agaactttca gccagtgaac aagataacct gcagactaca ttggaaagga
960gatttgctat ttactctgct cgagatgatg aggaattggt ccatatattc
ttactgattc 1020tccgggctct gcagctcttg acccggctgg tattgtctct
acagccaatt cctctgaagt 1080cagcaacagc aaagggaaag aaaccttcca
aggaaagatt gactgcggat ccaggaggct 1140cctcagaaac ttccagccaa
gttctagaaa accacaccaa accaaagacc agcaaaggaa 1200ccaaacaaga
ggaaaccttt gctaagggca cctgcaggcc aagtgccaaa gggaagagga
1260acaagggagg cagaaagaaa cggagcaagc cctcctccag cgaggaagat
gagggcccag 1320gagacaagca ggagaaggca acccagcgac gtccgcatgg
ccgggagcgg cgggtggcct 1380ccagggtgtc ttataaagag gagagtggga
gtgatgaggc tggcagcggc tctgattttg 1440agctctccag tggagaagcc
tctgatccct ctgatgagga ttccgaacct ggccctccaa 1500agcagaggaa
agcccccgct cctcagagga caaaggctgg gtccaagagt gcctccagga
1560cccatcgtgg gagccatcgt aaggacccaa gcttgccagc ggcatcctca
agctcttcaa 1620gcagtaaaag aggcaagaaa atgtgcagcg atggtgagaa
ggcagaaaaa agaagcatag 1680ctggtataga ccagtggcta gaggtgttct
gtgagcagga ggaaaagtgg gtatgtgtag 1740actgtgtgca cggtgtggtg
ggccagcctc tgacctgtta caagtacgcc accaagccca 1800tgacctatgt
ggtgggcatt gacagtgacg gctgggtccg agatgtcaca cagaggtacg
1860acccagtctg gatgacagtg acccgcaagt gccgggttga tgctgagtgg
tgggccgaga 1920ccttgagacc ataccagagc ccatttatgg acagggagaa
gaaagaagac ttggagtttc 1980aggcaaaaca catggaccag cctttgccca
ctgccattgg cttatataag aaccaccctc 2040tgtatgccct gaagcggcat
ctcctgaaat atgaggccat ctatcccgag acagctgcca 2100tccttgggta
ttgtcgtgga gaagcggtct actccaggga ttgtgtgcac actctgcatt
2160ccagggacac gtggctgaag aaagcaagag tggtgaggct tggagaagta
ccctacaaga 2220tggtgaaagg cttttctaac cgtgctcgga aagcccgact
tgctgagccc cagctgcggg 2280aagaaaatga cctgggcctg tttggctact
ggcagacaga ggagtatcag cccccagtgg 2340ccgtggacgg gaaggtgccc
cggaacgagt ttgggaatgt gtacctcttc ctgcccagca 2400tgatgcctat
tggctgtgtc cagctgaacc tgcccaatct
acaccgcgtg gcccgcaagc 2460tggacatcga ctgtgtccag gccatcactg
gctttgattt ccatggcggc tactcccatc 2520ccgtgactga tggatacatc
gtctgcgagg aattcaaaga cgtgctcctg actgcctggg 2580aaaatgagca
ggcagtcatt gaaaggaagg agaaggagaa aaaggagaag cgggctctag
2640ggaactggaa gttgctggcc aaaggtctgc tcatcaggga gaggctgaag
cgtcgctacg 2700ggcccaagag tgaggcagca gctccccaca cagatgcagg
aggtggactc tcttctgatg 2760aagaggaggg gaccagctct caagcagaag
cggccaggat actggctgcc tcctggcctc 2820aaaaccgaga agatgaagaa
aagcagaagc tgaagggtgg gcccaagaag accaaaaggg 2880aaaagaaagc
agcagcttcc cacctgttcc catttgagca gctgtgagct gagcgcccac
2940tagaggggca cccaccagtt gctgctgccc cactacaggc cccacacctg
ccctgggcat 3000gcccagcccc tggtggtggg ggcttctctg ctgagaaggc
aaactgaggc agcatgcacg 3060gaggcggggt caggggagac gaggccaagc
tgaggaggtg ctgcaggtcc cgtctggctc 3120cagcccttgt cagattcacc
cagggtgaag ccttcaaagc tttttgctac caaagcccac 3180tcaccctttg
agctacagaa cactttgcta ggagatactc ttctgcctcc tagacctgtt
3240ctttccatct ttagaaacat cagtttttgt atggaagcca ccgggagatt
tctggatggt 3300ggtgcatccg tgaatgcgct gatcgtttct tccagttaga
gtcttcatct gtccgacaag 3360ttcactcgcc tcggttgcgg acctaggacc
atttctctgc aggccactta ccttcccctg 3420agtcaggctt actaatgctg
ccctcactgc ctctttgcag taggggagag agcagagaag 3480tacaggtcat
ctgctgggat ctagttttcc aagtaacatt ttgtggtgac agaagcctaa
3540aaaaagctaa aatcaggaaa gaaaaggaaa aatacgaatt gaaaattaag
gaaatgttag 3600taaaatagat gagtgttaaa ctagattgta ttcattacta
gataaaatgt ataaagctct 3660ctgtactaag gagaaatgac ttttataaca
ttttgagaaa ataataaagc atttatctaa 3720aaaaaaaaa 372922940PRTHomo
sapiens 22Met Ala Arg Lys Arg Ala Ala Gly Gly Glu Pro Arg Gly Arg
Glu Leu 1 5 10 15 Arg Ser Gln Lys Ser Lys Ala Lys Ser Lys Ala Arg
Arg Glu Glu Glu 20 25 30 Glu Glu Asp Ala Phe Glu Asp Glu Lys Pro
Pro Lys Lys Ser Leu Leu 35 40 45 Ser Lys Val Ser Gln Gly Lys Arg
Lys Arg Gly Cys Ser His Pro Gly 50 55 60 Gly Ser Ala Asp Gly Pro
Ala Lys Lys Lys Val Ala Lys Val Thr Val 65 70 75 80 Lys Ser Glu Asn
Leu Lys Val Ile Lys Asp Glu Ala Leu Ser Asp Gly 85 90 95 Asp Asp
Leu Arg Asp Phe Pro Ser Asp Leu Lys Lys Ala His His Leu 100 105 110
Lys Arg Gly Ala Thr Met Asn Glu Asp Ser Asn Glu Glu Glu Glu Glu 115
120 125 Ser Glu Asn Asp Trp Glu Glu Val Glu Glu Leu Ser Glu Pro Val
Leu 130 135 140 Gly Asp Val Arg Glu Ser Thr Ala Phe Ser Arg Ser Leu
Leu Pro Val 145 150 155 160 Lys Pro Val Glu Ile Glu Ile Glu Thr Pro
Glu Gln Ala Lys Thr Arg 165 170 175 Glu Arg Ser Glu Lys Ile Lys Leu
Glu Phe Glu Thr Tyr Leu Arg Arg 180 185 190 Ala Met Lys Arg Phe Asn
Lys Gly Val His Glu Asp Thr His Lys Val 195 200 205 His Leu Leu Cys
Leu Leu Ala Asn Gly Phe Tyr Arg Asn Asn Ile Cys 210 215 220 Ser Gln
Pro Asp Leu His Ala Ile Gly Leu Ser Ile Ile Pro Ala Arg 225 230 235
240 Phe Thr Arg Val Leu Pro Arg Asp Val Asp Thr Tyr Tyr Leu Ser Asn
245 250 255 Leu Val Lys Trp Phe Ile Gly Thr Phe Thr Val Asn Ala Glu
Leu Ser 260 265 270 Ala Ser Glu Gln Asp Asn Leu Gln Thr Thr Leu Glu
Arg Arg Phe Ala 275 280 285 Ile Tyr Ser Ala Arg Asp Asp Glu Glu Leu
Val His Ile Phe Leu Leu 290 295 300 Ile Leu Arg Ala Leu Gln Leu Leu
Thr Arg Leu Val Leu Ser Leu Gln 305 310 315 320 Pro Ile Pro Leu Lys
Ser Ala Thr Ala Lys Gly Lys Lys Pro Ser Lys 325 330 335 Glu Arg Leu
Thr Ala Asp Pro Gly Gly Ser Ser Glu Thr Ser Ser Gln 340 345 350 Val
Leu Glu Asn His Thr Lys Pro Lys Thr Ser Lys Gly Thr Lys Gln 355 360
365 Glu Glu Thr Phe Ala Lys Gly Thr Cys Arg Pro Ser Ala Lys Gly Lys
370 375 380 Arg Asn Lys Gly Gly Arg Lys Lys Arg Ser Lys Pro Ser Ser
Ser Glu 385 390 395 400 Glu Asp Glu Gly Pro Gly Asp Lys Gln Glu Lys
Ala Thr Gln Arg Arg 405 410 415 Pro His Gly Arg Glu Arg Arg Val Ala
Ser Arg Val Ser Tyr Lys Glu 420 425 430 Glu Ser Gly Ser Asp Glu Ala
Gly Ser Gly Ser Asp Phe Glu Leu Ser 435 440 445 Ser Gly Glu Ala Ser
Asp Pro Ser Asp Glu Asp Ser Glu Pro Gly Pro 450 455 460 Pro Lys Gln
Arg Lys Ala Pro Ala Pro Gln Arg Thr Lys Ala Gly Ser 465 470 475 480
Lys Ser Ala Ser Arg Thr His Arg Gly Ser His Arg Lys Asp Pro Ser 485
490 495 Leu Pro Ala Ala Ser Ser Ser Ser Ser Ser Ser Lys Arg Gly Lys
Lys 500 505 510 Met Cys Ser Asp Gly Glu Lys Ala Glu Lys Arg Ser Ile
Ala Gly Ile 515 520 525 Asp Gln Trp Leu Glu Val Phe Cys Glu Gln Glu
Glu Lys Trp Val Cys 530 535 540 Val Asp Cys Val His Gly Val Val Gly
Gln Pro Leu Thr Cys Tyr Lys 545 550 555 560 Tyr Ala Thr Lys Pro Met
Thr Tyr Val Val Gly Ile Asp Ser Asp Gly 565 570 575 Trp Val Arg Asp
Val Thr Gln Arg Tyr Asp Pro Val Trp Met Thr Val 580 585 590 Thr Arg
Lys Cys Arg Val Asp Ala Glu Trp Trp Ala Glu Thr Leu Arg 595 600 605
Pro Tyr Gln Ser Pro Phe Met Asp Arg Glu Lys Lys Glu Asp Leu Glu 610
615 620 Phe Gln Ala Lys His Met Asp Gln Pro Leu Pro Thr Ala Ile Gly
Leu 625 630 635 640 Tyr Lys Asn His Pro Leu Tyr Ala Leu Lys Arg His
Leu Leu Lys Tyr 645 650 655 Glu Ala Ile Tyr Pro Glu Thr Ala Ala Ile
Leu Gly Tyr Cys Arg Gly 660 665 670 Glu Ala Val Tyr Ser Arg Asp Cys
Val His Thr Leu His Ser Arg Asp 675 680 685 Thr Trp Leu Lys Lys Ala
Arg Val Val Arg Leu Gly Glu Val Pro Tyr 690 695 700 Lys Met Val Lys
Gly Phe Ser Asn Arg Ala Arg Lys Ala Arg Leu Ala 705 710 715 720 Glu
Pro Gln Leu Arg Glu Glu Asn Asp Leu Gly Leu Phe Gly Tyr Trp 725 730
735 Gln Thr Glu Glu Tyr Gln Pro Pro Val Ala Val Asp Gly Lys Val Pro
740 745 750 Arg Asn Glu Phe Gly Asn Val Tyr Leu Phe Leu Pro Ser Met
Met Pro 755 760 765 Ile Gly Cys Val Gln Leu Asn Leu Pro Asn Leu His
Arg Val Ala Arg 770 775 780 Lys Leu Asp Ile Asp Cys Val Gln Ala Ile
Thr Gly Phe Asp Phe His 785 790 795 800 Gly Gly Tyr Ser His Pro Val
Thr Asp Gly Tyr Ile Val Cys Glu Glu 805 810 815 Phe Lys Asp Val Leu
Leu Thr Ala Trp Glu Asn Glu Gln Ala Val Ile 820 825 830 Glu Arg Lys
Glu Lys Glu Lys Lys Glu Lys Arg Ala Leu Gly Asn Trp 835 840 845 Lys
Leu Leu Ala Lys Gly Leu Leu Ile Arg Glu Arg Leu Lys Arg Arg 850 855
860 Tyr Gly Pro Lys Ser Glu Ala Ala Ala Pro His Thr Asp Ala Gly Gly
865 870 875 880 Gly Leu Ser Ser Asp Glu Glu Glu Gly Thr Ser Ser Gln
Ala Glu Ala 885 890 895 Ala Arg Ile Leu Ala Ala Ser Trp Pro Gln Asn
Arg Glu Asp Glu Glu 900 905 910 Lys Gln Lys Leu Lys Gly Gly Pro Lys
Lys Thr Lys Arg Glu Lys Lys 915 920 925 Ala Ala Ala Ser His Leu Phe
Pro Phe Glu Gln Leu 930 935 940 234154DNAHomo sapiens 23acttggacgc
gcttgcggag gattgcgttg acgagactct tatttattgt caccaacctg 60tggtggaatt
tgcagttgca cattggatct gattcgcccc gccccgaatg acgcctgccc
120ggaggcagtg aaagtacagc cgcgccgccc caagtcagcc tggacacata
aatcagcacg 180cggccggaga accccgcaat ctctgcgccc acaaaataca
ccgacgatgc ccgatctact 240ttaagggctg aaacccacgg gcctgagaga
ctataagagc gttccctacc gccatggaac 300aacggggaca gaacgccccg
gccgcttcgg gggcccggaa aaggcacggc ccaggaccca 360gggaggcgcg
gggagccagg cctgggcccc gggtccccaa gacccttgtg ctcgttgtcg
420ccgcggtcct gctgttggtc tcagctgagt ctgctctgat cacccaacaa
gacctagctc 480cccagcagag agcggcccca caacaaaaga ggtccagccc
ctcagaggga ttgtgtccac 540ctggacacca tatctcagaa gacggtagag
attgcatctc ctgcaaatat ggacaggact 600atagcactca ctggaatgac
ctccttttct gcttgcgctg caccaggtgt gattcaggtg 660aagtggagct
aagtccctgc accacgacca gaaacacagt gtgtcagtgc gaagaaggca
720ccttccggga agaagattct cctgagatgt gccggaagtg ccgcacaggg
tgtcccagag 780ggatggtcaa ggtcggtgat tgtacaccct ggagtgacat
cgaatgtgtc cacaaagaat 840caggtacaaa gcacagtggg gaagtcccag
ctgtggagga gacggtgacc tccagcccag 900ggactcctgc ctctccctgt
tctctctcag gcatcatcat aggagtcaca gttgcagccg 960tagtcttgat
tgtggctgtg tttgtttgca agtctttact gtggaagaaa gtccttcctt
1020acctgaaagg catctgctca ggtggtggtg gggaccctga gcgtgtggac
agaagctcac 1080aacgacctgg ggctgaggac aatgtcctca atgagatcgt
gagtatcttg cagcccaccc 1140aggtccctga gcaggaaatg gaagtccagg
agccagcaga gccaacaggt gtcaacatgt 1200tgtcccccgg ggagtcagag
catctgctgg aaccggcaga agctgaaagg tctcagagga 1260ggaggctgct
ggttccagca aatgaaggtg atcccactga gactctgaga cagtgcttcg
1320atgactttgc agacttggtg ccctttgact cctgggagcc gctcatgagg
aagttgggcc 1380tcatggacaa tgagataaag gtggctaaag ctgaggcagc
gggccacagg gacaccttgt 1440acacgatgct gataaagtgg gtcaacaaaa
ccgggcgaga tgcctctgtc cacaccctgc 1500tggatgcctt ggagacgctg
ggagagagac ttgccaagca gaagattgag gaccacttgt 1560tgagctctgg
aaagttcatg tatctagaag gtaatgcaga ctctgccatg tcctaagtgt
1620gattctcttc aggaagtcag accttccctg gtttaccttt tttctggaaa
aagcccaact 1680ggactccagt cagtaggaaa gtgccacaat tgtcacatga
ccggtactgg aagaaactct 1740cccatccaac atcacccagt ggatggaaca
tcctgtaact tttcactgca cttggcatta 1800tttttataag ctgaatgtga
taataaggac actatggaaa tgtctggatc attccgtttg 1860tgcgtacttt
gagatttggt ttgggatgtc attgttttca cagcactttt ttatcctaat
1920gtaaatgctt tatttattta tttgggctac attgtaagat ccatctacac
agtcgttgtc 1980cgacttcact tgatactata tgatatgaac cttttttggg
tggggggtgc ggggcagttc 2040actctgtctc ccaggctgga gtgcaatggt
gcaatcttgg ctcactatag ccttgacctc 2100tcaggctcaa gcgattctcc
cacctcagcc atccaaatag ctgggaccac aggtgtgcac 2160caccacgccc
ggctaatttt ttgtattttg tctagatata ggggctctct atgttgctca
2220gggtggtctc gaattcctgg actcaagcag tctgcccacc tcagactccc
aaagcggtgg 2280aattagaggc gtgagccccc atgcttggcc ttacctttct
acttttataa ttctgtatgt 2340tattatttta tgaacatgaa gaaactttag
taaatgtact tgtttacata gttatgtgaa 2400tagattagat aaacataaaa
ggaggagaca tacaatgggg gaagaagaag aagtcccctg 2460taagatgtca
ctgtctgggt tccagccctc cctcagatgt actttggctt caatgattgg
2520caacttctac aggggccagt cttttgaact ggacaacctt acaagtatat
gagtattatt 2580tataggtagt tgtttacata tgagtcggga ccaaagagaa
ctggatccac gtgaagtcct 2640gtgtgtggct ggtccctacc tgggcagtct
catttgcacc catagccccc atctatggac 2700aggctgggac agaggcagat
gggttagatc acacataaca atagggtcta tgtcatatcc 2760caagtgaact
tgagccctgt ttgggctcag gagatagaag acaaaatctg tctcccacgt
2820ctgccatggc atcaaggggg aagagtagat ggtgcttgag aatggtgtga
aatggttgcc 2880atctcaggag tagatggccc ggctcacttc tggttatctg
tcaccctgag cccatgagct 2940gccttttagg gtacagattg cctacttgag
gaccttggcc gctctgtaag catctgactc 3000atctcagaaa tgtcaattct
taaacactgt ggcaacagga cctagaatgg ctgacgcatt 3060aaggttttct
tcttgtgtcc tgttctatta ttgttttaag acctcagtaa ccatttcagc
3120ctctttccag caaacccttc tccatagtat ttcagtcatg gaaggatcat
ttatgcaggt 3180agtcattcca ggagtttttg gtcttttctg tctcaaggca
ttgtgtgttt tgttccggga 3240ctggtttggg tgggacaaag ttagaattgc
ctgaagatca cacattcaga ctgttgtgtc 3300tgtggagttt taggagtggg
gggtgacctt tctggtcttt gcacttccat cctctcccac 3360ttccatctgg
catcccacgc gttgtcccct gcacttctgg aaggcacagg gtgctgctgc
3420ctcctggtct ttgcctttgc tgggccttct gtgcaggacg ctcagcctca
gggctcagaa 3480ggtgccagtc cggtcccagg tcccttgtcc cttccacaga
ggccttccta gaagatgcat 3540ctagagtgtc agccttatca gtgtttaaga
tttttctttt atttttaatt tttttgagac 3600agaatctcac tctctcgccc
aggctggagt gcaacggtac gatcttggct cagtgcaacc 3660tccgcctcct
gggttcaagc gattctcgtg cctcagcctc cggagtagct gggattgcag
3720gcacccgcca ccacgcctgg ctaatttttg tatttttagt agagacgggg
tttcaccatg 3780ttggtcaggc tggtctcgaa ctcctgacct caggtgatcc
accttggcct ccgaaagtgc 3840tgggattaca ggcgtgagcc accagccagg
ccaagctatt cttttaaagt aagcttcctg 3900acgacatgaa ataattgggg
gttttgttgt ttagttacat taggctttgc tatatcccca 3960ggccaaatag
catgtgacac aggacagcca tagtatagtg tgtcactcgt ggttggtgtc
4020ctttcatgct tctgccctgt caaaggtccc tatttgaaat gtgttataat
acaaacaagg 4080aagcacattg tgtacaaaat acttatgtat ttatgaatcc
atgaccaaat taaatatgaa 4140accttatata aaaa 415424440PRTHomo sapiens
24Met Glu Gln Arg Gly Gln Asn Ala Pro Ala Ala Ser Gly Ala Arg Lys 1
5 10 15 Arg His Gly Pro Gly Pro Arg Glu Ala Arg Gly Ala Arg Pro Gly
Pro 20 25 30 Arg Val Pro Lys Thr Leu Val Leu Val Val Ala Ala Val
Leu Leu Leu 35 40 45 Val Ser Ala Glu Ser Ala Leu Ile Thr Gln Gln
Asp Leu Ala Pro Gln 50 55 60 Gln Arg Ala Ala Pro Gln Gln Lys Arg
Ser Ser Pro Ser Glu Gly Leu 65 70 75 80 Cys Pro Pro Gly His His Ile
Ser Glu Asp Gly Arg Asp Cys Ile Ser 85 90 95 Cys Lys Tyr Gly Gln
Asp Tyr Ser Thr His Trp Asn Asp Leu Leu Phe 100 105 110 Cys Leu Arg
Cys Thr Arg Cys Asp Ser Gly Glu Val Glu Leu Ser Pro 115 120 125 Cys
Thr Thr Thr Arg Asn Thr Val Cys Gln Cys Glu Glu Gly Thr Phe 130 135
140 Arg Glu Glu Asp Ser Pro Glu Met Cys Arg Lys Cys Arg Thr Gly Cys
145 150 155 160 Pro Arg Gly Met Val Lys Val Gly Asp Cys Thr Pro Trp
Ser Asp Ile 165 170 175 Glu Cys Val His Lys Glu Ser Gly Thr Lys His
Ser Gly Glu Val Pro 180 185 190 Ala Val Glu Glu Thr Val Thr Ser Ser
Pro Gly Thr Pro Ala Ser Pro 195 200 205 Cys Ser Leu Ser Gly Ile Ile
Ile Gly Val Thr Val Ala Ala Val Val 210 215 220 Leu Ile Val Ala Val
Phe Val Cys Lys Ser Leu Leu Trp Lys Lys Val 225 230 235 240 Leu Pro
Tyr Leu Lys Gly Ile Cys Ser Gly Gly Gly Gly Asp Pro Glu 245 250 255
Arg Val Asp Arg Ser Ser Gln Arg Pro Gly Ala Glu Asp Asn Val Leu 260
265 270 Asn Glu Ile Val Ser Ile Leu Gln Pro Thr Gln Val Pro Glu Gln
Glu 275 280 285 Met Glu Val Gln Glu Pro Ala Glu Pro Thr Gly Val Asn
Met Leu Ser 290 295 300 Pro Gly Glu Ser Glu His Leu Leu Glu Pro Ala
Glu Ala Glu Arg Ser 305 310 315 320 Gln Arg Arg Arg Leu Leu Val Pro
Ala Asn Glu Gly Asp Pro Thr Glu 325 330 335 Thr Leu Arg Gln Cys Phe
Asp Asp Phe Ala Asp Leu Val Pro Phe Asp 340 345 350 Ser Trp Glu Pro
Leu Met Arg Lys Leu Gly Leu Met Asp Asn Glu Ile 355 360 365 Lys Val
Ala Lys Ala Glu Ala Ala Gly His Arg Asp Thr Leu Tyr Thr 370 375 380
Met Leu Ile Lys Trp Val Asn Lys Thr Gly Arg Asp Ala Ser Val His 385
390 395 400 Thr Leu Leu Asp Ala Leu Glu Thr Leu Gly Glu Arg Leu Ala
Lys Gln 405 410 415 Lys Ile Glu Asp His Leu Leu Ser Ser Gly Lys Phe
Met Tyr Leu Glu 420 425 430 Gly Asn Ala Asp Ser Ala Met Ser 435 440
253134DNAHomo sapiens 25agtcggagcc gggcttgccc gggcatgtgg gagctgccgg
ctttccggac gccacgtgca 60gaccggaaga gacacgcggg gcttcaggct gctgccccat
tggaagatta ctccccaggc 120ttcccttgcc ccaagcagtg agctgactgg
aatggtaccc cgggaggccc ctgagtctgc 180tcagtgcctg tgcccttccc
tcaccatccc aaatgccaag gatgtgcttc ggaagaggca 240caagagaagg
agccgacagc accagcggtt catggcccgg aaggccttgc tgcaggagca
300ggggctgctg agcatgcctc cagaaccagg gtcctcccca ctgcccaccc
ctttcggggc 360agcgacagca actgaagctg ccagcagtgg gaagcagtgt
ctgagggctg gatctggcag 420tgccccatgc
agcagaaggc ctgctcccgg gaaagcctca gggcccttgc ccagcaagtg
480tgtggctatc gactgtgaga tggtgggcac gggaccccga gggcgggtaa
gcgagctggc 540ccgctgttcc attgtgagct accatggcaa tgtcctctat
gacaagtaca tcaggcctga 600gatgcccatc gctgactacc gtacccgctg
gagtggcatc actcggcagc acatgcgcaa 660ggctgtcccc ttccaggtgg
cccagaaaga gatccttaag ctcctgaagg gcaaggtggt 720ggtggggcac
gcgctgcaca acgacttcca ggcgctcaag tatgtccacc ctcggagcca
780gacccgggat acgacctatg tcccaaactt cctcagcgag cccggcctcc
acacccgggc 840ccgggtctct ctaaaggacc tggccctgca gctgctgcac
aagaagatcc aggtgggcca 900gcacgggcac tcatcagtag aagatgccac
gacagccatg gagctctacc ggctggtgga 960ggtgcagtgg gaacagcagg
aggcccgcag cctctggacc tgccccgagg acagagaacc 1020tgacagcagc
acagacatgg aacagtacat ggaggaccag tactggcccg atgacctggc
1080ccacggcagc agaggaggag ccagggaggc acaggacaga aggaattgag
aagggggcgg 1140ggctccctgg ctgggcttcc ggtgtggccg gtaggaagtg
ggggccagga gagcagcggg 1200cactccttcc tgggcagggt ggggcaggat
gcagtgagcc agccccaggg ccagaggagt 1260aggggtcatc tgttaccttg
acaccctctg cacacagcat agccctctct ctctccaggg 1320ctgttggttc
tttctcctga ctcctgtggt tttgctaatg gcactttaca gactccatgg
1380agatgtcagg tggaccatct tctagggccc agcaggagta gggaatgtgc
caacagactg 1440cccaggttgc cgtggccttc cccacccccc agatctcctg
agtcatcatg ctgtgctaat 1500gaaagggatc atatcatcct ctctggggat
ggtgggtggg ggtgtcaata tcctggagct 1560cccttacccc aactcaatga
cttgggggta aagttctctt ccttttgttg cctacctctt 1620cctccactca
tttgggttca gaataaacat gccctgaagt taaagaggag ttaagtccta
1680aaggaggcat ttcttcccca cctccctgac ctggaactct ggctacagcc
attgtaggaa 1740ctccgtgcct ggcctgtcag ctccctgcta ggctacagtg
gaatagcaga gcccacaggc 1800ttctcgtggg gagttggctc cttaacattt
cttggcaaca gaaagcccca ggcacagctc 1860agggaggagg gaaggcaggt
aagctttgga cgagaactgg catatttatt ttgacccaaa 1920tcagggattt
ccccagtcca cccagtactg ggctcttaag caaaagtctg agaaacaaga
1980cagtggtttg aattctgggg cctttgtgta ggattgtgcc tgacctttat
ttatttatta 2040acagcagggc cactcgtcta gggcagtgga gtctgcgtgt
ctcctggggc tggggcaggg 2100cattggcagt tacgcagtgg ccctgaacct
ggtctggtgc ccccgaacct ggtctgatgc 2160cccctcagct ctttgacaat
cactgtggct gttgggtttt ctcctatttc taaaaatgtt 2220ctcttctttc
ctaagtgaca gttttgaagt attggataac caagagctca ggtcacacag
2280accttggagc cccatctttg cttgcagctt agctttgaga tactaagcaa
gcgagggact 2340tcactcttga ggctgttttt tcctcatctg taaagtgggg
atagtggtac ggcctacctc 2400atagggttgt aatgagcact aaatgtgaag
tgcttggcac agtgcctggc acatggtgag 2460ccacagctac tgtgagtttc
tgtttatccc cctttttttt ttttaagccc attgtttatt 2520ctttgagaat
ttgttgtaac ttcttcagga taacacctga gtccacaggc tgagcagctg
2580tggcccagac agaactgctc cggcttggct gttccagcag gtggggcgct
ggcctcggtg 2640agggcacagc agcaaggttc acggatatcc gtgtgtcttg
tctgtggcca ccaggcacag 2700gtttggcttc cggtcagtgt cccgacactg
tgcgggaggt gacaacagag caaagcagcg 2760caggggtcag ggaggtacag
acactgctga aatcacacta ccccaccctc agctgaagcc 2820ccacgttcca
caaacttggg gtcatagatt gtccagtcac tggctccctc cctgtcagca
2880cagcacagag gaaggggcta actgaatctt ttaccacttc tggcctggct
ccagaacttt 2940gttctagatt ccttaaaagt cggtagctga tgtcaaactc
aattgagcag tagctttgat 3000cccttggtct gggggtcgaa ggaagatggt
gctgttatca gcggggaaat gtactattta 3060agatcagctt tgttgtaaaa
ccatttgttc tagaataaaa ctcaattgga aacgtgaaaa 3120aaaaaaaaaa aaaa
313426325PRTHomo sapiens 26Met Val Pro Arg Glu Ala Pro Glu Ser Ala
Gln Cys Leu Cys Pro Ser 1 5 10 15 Leu Thr Ile Pro Asn Ala Lys Asp
Val Leu Arg Lys Arg His Lys Arg 20 25 30 Arg Ser Arg Gln His Gln
Arg Phe Met Ala Arg Lys Ala Leu Leu Gln 35 40 45 Glu Gln Gly Leu
Leu Ser Met Pro Pro Glu Pro Gly Ser Ser Pro Leu 50 55 60 Pro Thr
Pro Phe Gly Ala Ala Thr Ala Thr Glu Ala Ala Ser Ser Gly 65 70 75 80
Lys Gln Cys Leu Arg Ala Gly Ser Gly Ser Ala Pro Cys Ser Arg Arg 85
90 95 Pro Ala Pro Gly Lys Ala Ser Gly Pro Leu Pro Ser Lys Cys Val
Ala 100 105 110 Ile Asp Cys Glu Met Val Gly Thr Gly Pro Arg Gly Arg
Val Ser Glu 115 120 125 Leu Ala Arg Cys Ser Ile Val Ser Tyr His Gly
Asn Val Leu Tyr Asp 130 135 140 Lys Tyr Ile Arg Pro Glu Met Pro Ile
Ala Asp Tyr Arg Thr Arg Trp 145 150 155 160 Ser Gly Ile Thr Arg Gln
His Met Arg Lys Ala Val Pro Phe Gln Val 165 170 175 Ala Gln Lys Glu
Ile Leu Lys Leu Leu Lys Gly Lys Val Val Val Gly 180 185 190 His Ala
Leu His Asn Asp Phe Gln Ala Leu Lys Tyr Val His Pro Arg 195 200 205
Ser Gln Thr Arg Asp Thr Thr Tyr Val Pro Asn Phe Leu Ser Glu Pro 210
215 220 Gly Leu His Thr Arg Ala Arg Val Ser Leu Lys Asp Leu Ala Leu
Gln 225 230 235 240 Leu Leu His Lys Lys Ile Gln Val Gly Gln His Gly
His Ser Ser Val 245 250 255 Glu Asp Ala Thr Thr Ala Met Glu Leu Tyr
Arg Leu Val Glu Val Gln 260 265 270 Trp Glu Gln Gln Glu Ala Arg Ser
Leu Trp Thr Cys Pro Glu Asp Arg 275 280 285 Glu Pro Asp Ser Ser Thr
Asp Met Glu Gln Tyr Met Glu Asp Gln Tyr 290 295 300 Trp Pro Asp Asp
Leu Ala His Gly Ser Arg Gly Gly Ala Arg Glu Ala 305 310 315 320 Gln
Asp Arg Arg Asn 325
* * * * *